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This thesis describes the development of chiral auxiliary based methodologies for the 
asymmetric synthesis of hydroxylated !-lactones and "-lactones containing multiple contiguous 
stereocentres. The first chapter introduces the concept of chirality and provides a general 
overview of the range of strategies available for the preparation of chiral molecules in 
enantiomerically pure forms. The second chapter critically reviews the range of synthetic 
methodology that is currently available for the asymmetric synthesis of chiral #-lactones that 
are either natural products or useful chiral building blocks for synthesis. The third chapter 
describes the development of novel methodology for the epoxidation/lactonisation of a range of 
$-vinyl-syn-aldols to directly afford !-lactones containing up to four contiguous stereocentres in 
high de. These reactions were shown to proceed via a mechanism whereby hydroxyl-directed 
diastereoselective epoxidation is followed by intramolecular attack of their !-acyl-oxazolidin-2-
one fragment, to directly afford the desired chiral !-lactone. The ‘self-cleavage’ aspect of these 
reactions was exploited to enable this methodology to be transferred to polymer-support using 


































Chapter 4 describes the development of a complementary methodology for the asymmetric 
synthesis of this type of hydroxylated !-lactone based on a strategy involving dihydroxylation of 
N-acyl-oxazolidin-2-one-$-vinyl-syn-aldols using catalytic amounts of osmium tetroxide. This 
methodology was developed as part of a reinvestigation of previously reported dihydroxylation 
reactions by Dias and coworkers, where we have clearly shown that the stereochemistry of the 
!# 
 
lactones reported in their paper have been incorrectly assigned. This diastereoselective 
dihydroxylation methodology has been successfully applied to the asymmetric synthesis of the 
































Finally, Chapter 5 describes the development of methodology for the asymmetric synthesis of 
chiral "-lactones containing four contiguous stereocentres of use as potential chiral building 
blocks for the synthesis of polyketide natural products. In this approach, cyclopropanation of  
N-acyl-oxazolidin-2-one-$-vinyl-syn-aldols occurs under the sterodirecting effect of the $-
hydroxyl group to afford cyclopropyl-aldols in very high de. These cyclopropyl-aldols are  then 
ring opened in the presence of mercuric ions, with their N-acyl-oxazolidin-2-one fragment 
acting as an internal nucleophile, to afford highly functionalised alkyl-mercury species that may 











































when R' = H and R'' = Alk/Ar
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This thesis deals with the development of methodology for the asymmetric synthesis of chiral 
lactones that contain multiple stereocentres as potentially useful chiral building blocks for 
natural product synthesis. Consequently, this introduction serves to introduce some of the 
fundamental concepts associated with the synthesis of chiral molecules as well as describing the 
different types of strategy that can be employed for their synthesis.  
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Chirality is an inherent property of a molecule that has no plane of symmetry, i.e. it is non-
superimposable upon its mirror image. These mirror images are known as enantiomers, and in 
the absence of a chiral environment, they display the same physical and chemical properties, 
only differing in the fact that they rotate the plane of polarised light in opposite directions. 
However, in a chiral environment, such as a biological receptor, or the active site of an enzyme, 
their ‘handedness’ becomes significant because of the potential to afford diastereoisomeric 
transition states (or complexes). Therefore, whilst there are examples of enantiomers or 
diastereoisomers of chiral molecules having the same biological activity, there are many other 



















One famous example from the pharmaceutical industry is the drug Thalidomide 1, which was 
sold during the 1960s as a racemate and marketed as an effective treatment for morning 
sickness. Tragically, it was later determined that its enantiomers displayed very different 
biological activity. Whilst (R)-Thalidomide was shown to be a potent anti-emetic and analgesic, 
(S)-Thalidomide displayed teratogenic properties. Consequently, prescription of this racemate to 
pregnant women led to the birth of many malformed children, clearly illustrating how important 




In recent years the development of enantioselective methodologies for the asymmetric synthesis 
of chiral molecules has been one of the main goals of organic chemistry, particularly in 
developing protocols that enable the rapid synthesis of molecules containing multiple 
stereocentres. There are many methods available within the organic chemistry arsenal for this 
purpose and I will now briefly describe the range of strategies that are available to synthetic 
chemists for the preparation of enantiopure compounds.  
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At the molecular level many of the compounds that Nature produces in large quantities are 
chiral and for many years the synthesis of enantiopure compounds on a large scale relied on 
access to this chiral pool.2 Indeed, Nature’s production of a wide range of amino acids, sugars 
and other natural products has enabled these chiral molecules to be used as useful chiral 
building blocks for asymmetric synthesis. 
 
For example, Lundt et al have recently demonstrated that 1,5-anhydro-D-fructose can be used as 
an effective chiral synthon for the synthesis of the glucosidase inhibitor 1-deoxymannojirimycin 
6 (See Scheme 1.1).3 Initially, lactone 2 was treated with O-benzylhydroxylamine to generate an 
oxime, which was selectively mono-tosylated to yield 6-O-tosylated-oxime 3.  Subsequent 
hydrogenation of 3 with H2 over Pd/C resulted in direct formation of the bicyclic imino-sugar 4. 
The final steps required cleavage of the ether bond, which was carried out by removal of the O-
tosyl-protecting group, subsequent pivaloylation of the free alcohol and amino functionality to 
yield 5, followed by treatment with BBr3, and addition of NaOMe in methanol to yield the 







































Although these types of chiral pool strategies have been shown to be highly effective at 
accessing specific enantiopure materials, the chiral pool approach is often limited in its scope. 
This is due to its dependence on the availability of enantiopure starting materials in large 
amounts, the fact that compounds are often limited to a single enantiomeric series, and the large 
number of synthetic steps that are often required to remove redundant functionality.  
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A catalyst is a substance that increases the rate of a reaction, which occurs via incorporation of 
the catalyst into the reaction transition state, but remains unchanged by the process. Introduction 
of chirality into the catalyst (present as a single enantiomer) allows for the potential formation 
of transient diastereomeric transition states (cat*-s, Figure 1.2), of different energies; thus 
favouring the formation of one enantiomer of a product over its antipode. There are three main 


















Chiral transition metal complexes have often been employed as asymmetric catalysts in organic 
transformations where efficient transfer of chirality from the catalyst results in the formation of 
chiral products in high ee. Many of the transition metal complexes that have been developed 
show very high activity. However, a number of chiral catalysts are often derived from 
expensive/toxic metals such as palladium or rhodium, although catalysts derived from more 
environmentally benign metals such as iron, zinc and copper have also been developed.4 For 
example, List has demonstrated the use of copper catalysts in the catalytic asymmetric transfer 
hydrogenation of #-keto-esters using Hantzsch esters as hydride donors (Scheme 1.2).5 
Treatment of ketone 7 under optimised reaction conditions of copper(II) triflate, bisoxazoline 
ligand 9 and Hantzsch ester 10 (which is the hydrogen source) resulted in an almost clean 
conversion to the alcohol 8 in 82% isolated yield and 94% de. The stereochemical outcome of 
this reaction is dictated by coordination of the chiral catalyst to the carbonyl of the prochiral 
ketone functionality, which results in formation of diastereotopic transition states that are 
different in energy, which results in a hydride equivalent being selectively delivered to one face 









































The wide-ranging effect that asymmetric catalysis has had in supplying new types of chiral 
building blocks for organic synthesis has been recognised by the joint award of the Nobel Prize 
to Noyori, Knowles and Sharpless in 2001. A representative series of popular catalytic 
transformations that are now widely used in organic synthesis are described in Scheme 1.3, with 
















































Organocatalysis utilises the chirality of small organic molecules that can catalyse reactions to 
relay stereocontrol for the formation of chiral products. In recent years, the field of 
organocatalysis has developed rapidly and a number of these catalysts can now compete with 
the more established fields of metal mediated and biocatalysis in terms of stereocontrol.9-11 
However, reaction times of >24 hrs using catalyst loadings of 20 mol% are often required for 
their reactions to proceed and as a consequence significant improvements in their catalytic 
activity, particularly reductions in catalyst loading, are still required in many cases.  
 
For example, Hiemstra and co-workers have demonstrated the application of a bifunctional 
thiourea catalyst in the asymmetric Henry reaction (Scheme 1.4).12 Treatment of 1-
naphthaldehyde with 10 mol% of chiral thiourea catalyst 13 and nitromethane resulted in 
63)7*('".8"9,*'+5:;*!+,"
Q"
formation of the aldol product 12 in 99% yield and 92% ee. It was postulated that asymmetric 
induction occurs via hydrogen bonding of the thiourea moiety to the aldehyde functionality, 
with the basic quinuclidine fragment catalysing formation of the nitromethane enolate that then 
undergoes nucleophilic attack via the postulated transition state 14.12 Despite the observed 
selectivity and excellent yields obtained for aromatic aldehydes, the scope of this reaction was 











































The origins of organocatalysis lie in the pioneering work of Hajos-Parrish in the 1970’s who 
first reported the development of intramolecular organocatalytic aldol chemistry for Robinson 
annulation reactions. However, the use of organocatalysis as a strategy for asymmetric synthesis 
remained relatively dormant until the recent explosion in activity in the late 1990’s that was 
triggered by the discovery that organocatalysts could be used to catalyse intermolecular 
reactions in high ee. Indeed, the rapid evolution of organocatalysis in recent times as a strategy 
for asymmetric synthesis has provided organic chemists with completely new types of chiral 
building blocks for natural product synthesis and drug-discovery applications. A representative 
range of popular organocatalytic transformations that are now widely employed in organic 
synthesis are described in Scheme 1.5,9 with well over 1000 reports of these methodologies 


































































Enzymes are Nature’s catalysts which can often catalyse highly stereoselective reactions, with 
the application of both whole cells and enzymes for organic synthesis continuing to increase.13 
This is because the use of biocatalysts provide an often clean and environmentally friendly 
methodology for transforming natural and non-natural substrates with high levels of 
stereocontrol.14  
 
Enzymes are polypeptides that adopt rigid three-dimensional structures with specific chiral 
environments/active sites where stereoselective reactions occur that allows for the reliable and 
dependable preparation of enantiopure materials. They offer an efficient strategy to resolve or 
produce products containing one or more chiral centres, under mild reaction conditions using 
protocols that often do not require the use of protection/deprotection strategies. On the other 
hand, they are often limited to specific compound types, can have poor substrate specificity 
profiles and suffer from the limited solubility of many organic compounds in water.14 However, 
in recent years there has been much interest in addressing these problems using molecular 
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biological techniques to modify the structures of enzymes to improve their specificity, stability 
and catalytic profile.15-17  
 
For example, Stewart and co-workers have demonstrated the power of whole cell strategies for 
the directed reduction of #-chloro-$-keto-ethyl ester 15.18 Treatment with engineered 
Escherichia coli (Over expressing YOR120w) under acidic conditions furnished the #-chloro-$-


















Philips has also described an enantioselective asymmetric reduction of prochiral ketones using 
W110A secondary alcohol dehydrogenase from Thermoanaerobacter ethanolicus in Tris buffer 
using propan-2-ol as co-solvent and a hydrogen source for cofactor regeneration (Scheme 1.7). 
The resulting secondary alcohol was obtained in 99% conversion and in >99% ee.19 These high 
levels of enantiocontrol under mild reaction conditions clearly show the potential for 

















Biotransformations are becoming increasingly important in the pharmaceutical industry, a 
representative series of popular enzymatic transformations that are now widely used ‘on-scale’ 





























up to 99 % ee
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An alternative strategy for accessing enantiomerically pure material is to carry out resolution of 
a racemic mixture. Chiral resolution is the separation of enantiomers by physical 
(chromatography or crystallisation) or chemical (reaction with a chiral catalyst) means.23 A 
simple example of a physical resolution has been demonstrated by Jacobsen (Scheme 1.9); 
whereby treatment of diamine 17 with a stoichiometric amount of  (2R,3R)-2,3-
dihydroxysuccinic acid 18 under acidic conditions generates the salt 19 which is readily 
recrystallised to afford a single diastereomer in approximately 42% yield. Subsequent treatment 
of the salt 19 under basic conditions releases the resolving agent thus allowing access to the 






















Classical kinetic resolution involves reaction of a racemate with a chiral reagent or catalyst 
under conditions whereby one enantiomer reacts faster than its corresponding antipode to 
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ideally generate a single enantiomer of a chiral product and an enantioenriched starting material 












For example, Sekar has demonstrated the use of oxidative kinetic resolution for the resolution of 
racemic secondary alcohols (See Scheme 1.11).27 Racemic benzoin 21 is treated with a chiral 
binaphthyl-Fe(OAc)2 complex (10 mol%), 2,2,6,6-tetramethylpiperidin-1-oxyl (TEMPO) (5 
mol%) in the presence of molecular oxygen, which oxidised 76% of the starting material to its 
corresponding achiral dione 22. This enabled separation by chromatography to allow access to 


























Another example is the copper catalysed resolution of azomethine imines described by Fu and 
co-workers.28 The racemate is resolved via a catalytic asymmetric [3+2] cycloaddition of 
azomethine imine 23 with terminal alkyne 24 using a chiral copper catalyst. Azomethine imine 
23 was treated with copper(I) iodide, chiral phosphaferrocene-oxazoline derivative 26 and a 
base at ambient temperature, with the bicyclic pyrazolidinone derivative 25  and 
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Enzymatic kinetic resolution can utilise the specific chiral environment of the chiral pocket of 
an enzyme active site to dynamically resolve a racemic substrate. For example, Feringa and co-
workers have demonstrated the use of haloalcohol dehalogenase HheC as an efficient 
biocatalyst for accessing enantiomerically enriched vicinal chloroalcohols by selectively 


















Despite being a practical method for the isolation of enantiopure materials, classical kinetic 
resolution strategies are limited, since the maximum theoretical yield from any racemate is 50 % 
and as such is inherently inefficient. Dynamic kinetic resolution protocols can address this 
problem, because resolution occurs under conditions where the starting material is being 
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There are also many methods reported in the literature of non-enzymatic dynamic kinetic 
resolutions of racemates. For example, Coldham and co-workers have demonstrated the 
resolution of 2-lithiopyrrolidine 30 (See Scheme 1.14).32 Initially pyrrolidine 29 is lithiated in 
the presence of a chiral bis-pyrrolidine-ligand, with the resultant diastereoisomeric 
intermediates (S)-30 and (R)-30 being rapidly racemised in situ. Treatment of this intermediate 
with excess n-butyllithium results in the (S)-2-lithiopyrrolidine enantiomer reacting faster with 
the electrophile TMSCl than its corresponding (R)-enantiomer, yielding (S)-silylated pyrrolidine 
































Both classical and dynamic kinetic resolutions are becoming increasingly popular and a 
representative series of popular resolutions that are now widely used in organic synthesis are 



















































A chiral auxiliary is an enantiopure compound that can be used to direct an organic reaction 
using a chiral controlling group to control the outcome of the reaction, which is achieved 
through the reversible attachment of the chiral auxiliary to a prochiral starting material. A 
general chiral auxiliary strategy is described in Figure 1.5; initially the chiral auxiliary (CA) is 
coupled to the starting material (s) to generate an intermediate (CA-s) that now contains a 
transformable functional group that has diastereotopic faces. Subsequent reaction of CA-s 
occurs under the control of the stereodirecting effect of the chiral auxiliary fragment to ideally 
afford CA-p with a new stereocentre in very high de. Purification of the major diastereomer to 
























The key requirements for a chiral auxiliary are that it can be easily attached to a prochiral 
substrate in quantitative yield, that it can direct reactions with high stereoselectivity and that it 
can be quantitatively removed and recycled without racemisation of the newly formed chiral 
centre.  
 
For example, Tadano has demonstrated the use of sugar derivatives as effective chiral 
auxiliaries for the enantioselective 1,4-addition of magnesium divinylcuprates to Michael 
acceptors (See Scheme 1.16).36 Initially, a crotonyl acceptor is added to the chiral auxiliary 33 
to yield O-crotonyl-34, which is followed by conjugate addition of magnesium divinylcuprate to 
yield the alkylated product 35 containing a new $-stereocentre in >95% de. The auxiliary 
fragment of 35 is then cleaved to yield the desired enantiopure chiral amide 36 in an overall 





























There are many types of chiral auxiliary that have been developed that enable the 
stereoselectivity of a wide range of transformations to be controlled. Popular examples include 
the use of chiral oxazolidin-2-ones, RAMP/SAMP-auxiliaries and sulphinamides that have been 





























































As we have seen, there are numerous strategies available for the synthesis of enantiomerically 
pure compounds; ranging from the chiral pool approach, through resolution to chiral catalysis 
and the use of chiral auxiliaries. However, it is worthy to note that there is generally no single 
approach that can be applied to obtain every class of chiral product currently required by 
academia and industry, with many of the developed methods often being applicable to defined 
classes of substrate. Therefore, whilst many chiral auxiliary approaches can often appear at first 
sight to be inferior to asymmetric catalyst approaches, their ability to reliably produce defined 
classes of enantiopure products in a predictable manner often means that they are employed as 





The majority of research described in this thesis deals with the development of novel chiral 
auxiliary methodology for the asymmetric synthesis of chiral !- lactones and as a consequence a 
brief review of existing methodology for their preparation in enantiopure form is now described. 
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Lactones are cyclic esters, where the ester bond is incorporated into the ring system. Under 
IUPAC convention, lactones are named as oxacycloalkanones. However, their names are more 
commonly derived from the acid that contains the same number of carbon atoms, e.g. 
butyrolactones contain four carbon atoms and propiolactones contain three carbon atoms. The 
size of the ring is designated by a Greek letter and refers to the number of carbon atoms 

























The !-lactone motif is ubiquitous in Nature and can be considered to be a privileged fragment 
that occurs in the structures of a wide range of natural product motifs (See Figure 2-2).  These 
products display a wide range of biological activity, displaying antimicrobial, antitumour and 






































































!-Butyrolactones have also been shown to be valuable synthetic precursors for the synthesis of a 
wide number of natural products.40,41 For example, trans-(+)-laurediol 50, was prepared from 
chiral $,!-disubstituted-!-butyrolactone 46, via oxidation with pyridinium chlorochromate to 
give its corresponding aldehyde, followed by subsequent stereoselective Wittig reaction to 
afford Z-alkene 47. The lactone functionality of 47 was next reduced to its corresponding lactol 
48 using DIBAL-H, which was subjected to a second Wittig olefination to afford trans-enyne 
49. Finally, removal of the silyl protecting group using tetra-butylamine fluoride gave the 

































The diverse range of biological activity and synthetic versatility observed for !-butyrolactones 
has resulted in much attention being directed towards the synthesis of these interesting 
frameworks.42-44 However, there are few general strategies available to access all of the different 
types of naturally occurring chiral !-butyrolactone, with most strategies being directed towards 
the synthesis of a specific class of !-butyrolactone natural product.42 Consequently, I shall now 
briefly describe some of the more popular and powerful methodologies that are currently 
available for the synthesis of chiral !-butyrolactone frameworks in enantiopure form. 
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One of the simplest strategies for accessing !-butyrolactones is via an oxidative ring expansion 
reaction. The conversion of ketones to esters via the Baeyer-Villiger reaction is well established 
in the literature, with the application of this oxidation reaction to the conversion of 
functionalised cyclobutanones to their corresponding chiral !-lactones having been widely 
investigated.45-48 For example, Malkov and co-workers have reported the palladium catalysed 
Baeyer-Villiger oxidative desymmeterisation of prochiral cyclobutanone 51 in the presence of a 
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chiral phosphine ligand 53, using urea-H2O2 complex as a stoichiometric oxidant,
49 which gave 


















Another simple strategy to access !-lactones is via regioselective oxidation of chiral 
tetrahydrofurans.50,51 Using modified Sharpless conditions, Nagaoka and co-workers showed 
that treatment of functionalised cyclic ether 54 with ruthenium tetroxide yielded !-butyrolactone 
55 in 66% yield via regioselective oxidation of its CH2-O methylene unit to its corresponding 














Another widely employed strategy to access !-butyrolactones, is to form the lactone ring via 
cyclisation of a chiral !-hydroxy-acid substrate that can be generated using either oxidative or 
reductive protocols.52-54 For example, Ikariya have demonstrated that the primary alcohol of 
triol 56 could be regioselectively oxidised to afford an unstable chiral !-hydroxy-acid 
intermediate that cyclised in-situ to afford its corresponding hydroxyl-lactone, (-)-muricatacin 
58 (Scheme 2.4).55 Therefore, treatment of 1,4,5-triol 56 with a Cp*Ru(II) catalyst 59 and 
potassium-tert-butoxide in acetone at 30 °C resulted in clean oxidative cyclisation to afford 





























Complementary to this approach, are strategies that rely on the stereoselective reduction of a 
substrate containing a !-ketone functionality to afford a chiral !-alcohol functionality that 
subsequently cyclises onto its ester functionality to afford its lactone ring.56-61 For example, 
Noyori and co-workers have reported that reduction of ethyl-o-acetyl-benzoate 60 with (S)-
BINAP (0.4 mol%) in ethanol under 100 atmospheres of hydrogen at 35 °C for 165 hrs, resulted  















As we will discuss later, chiral epoxides are powerful reaction precursors that can be readily 
ring-opened by nucleophiles in an intramolecular fashion to afford chiral. In this respect, Coates 
and co-workers have developed an efficient epoxidation carbonylation catalyst 
[(OEP)Cr(THF)2][Co(CO)4] that can ring open chiral epoxides with concomitant C1-
homologation to afford $-lactones which in the presence of an appropriate internal ester 
nucleophile can undergo further ring expansion to yield chiral !-butyrolactone skeletons 62.63 
Mechanistic studies revealed that the Lewis acid catalysed ring expansion of $-lactone 63 was 
occurring, whereby coordination of [(OEP)Cr(THF)2]
+ to the carbonyl of $-lactone (R)-63 
resulted in intramolecular nucleophilic attack of its ester group at its $-position to afford a 
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dioxycarbenium ion intermediate 66, that then undergoes a further ring opening reaction at its !-





























































This type of carbonylation reaction is not simply limited to ring expansion strategies, since it 
can also be employed as a key reaction to catalytically introduce the carbonyl group of a lactone 
ring.64 For example, Tamaru have reported an elegant palladium(II)-catalysed bis carbonylation 
of 3-butenol 67, which upon treatment with palladium(II) chloride in methanol and 
dichloromethane under 1 atmosphere of carbon monoxide generates the spiro-!-lactone 68 in 















Chiral epoxides can also be used as substrates in ‘formal’ carbonylation reactions to directly 
afford chiral !-butyrolactones.66,67 Therefore, Jacobsen and co-workers have shown that 
treatment of terminal epoxide (S)-2-(phenoxymethyl)oxirane 69 with a Lewis acid and ynamine 
73 results in clean conversion to !-butyrolactone 72 with complete retention of configuration.67 
Initially, epoxide 69 is ring opened via Lewis acid mediated nucleophilic attack of C1 of  
ynamine 73 at its methylene centre to generate an unstable intermediate 70 whose hydroxyl 
group cyclises back onto its imminium group to generate cyclic keteneaminal 71. Subsequent 
hydrolysis and protodesilylation of 71 furnishes the !-butyrolactone 72 in 92% yield with 


































Electrophilic cyclisation reactions that employ carboxylic acid equivalents as intramolecular 
nucleophiles to cyclise onto appended alkene functionalities represent a particularly useful 
method for constructing !-butyrolactone ring systems.68-70 These reactions proceed similarly to 
the Lewis acid mediated ring opening of epoxide systems discussed previously as demonstrated 
for the stereoselective iodocyclisation reactions of (S)-allyalanine derivatives shown in Scheme 
2.9.71 Initially, N-Iodo-Succinimide acts as a source of I+ which adds across the alkene double 
bond to reversibly generate diastereoisomeric cyclic iodonium intermediates (75), that are 
intercepted by intramolecular nucleophilic attack of its carboxylic acid functionality at the !-























It has been observed that treatment of unsaturated #-hydroxy-$-vinyl-carboxylic acid 77 with 
phenyl selenyl bromide selectively generates a seliniranium ion intermediate 79, which is ring-
opened by attack by its remote carboxylic acid in a 5-endo cyclisation ring opening reaction to 
yield selenyl-!-lactone 78a as the major diastereomer in a 9:1 ratio (See Scheme 2.10). The high 
levels of diastereoselectivity observed for formation of 79 occurs because of selective 
coordination of the phenyl selenyl bromide to the #-hydroxyl functionality, which results in 

































Further to this, Reiser has utilised cyclopropanes for the synthesis of $,!-disubstituted-!-
butyrolactones (Scheme 2.11).42,75,76 Copper(I) catalysed cyclopropanation of furan 80 with 
diazoester 88 was shown to proceed in 81% ee using bisoxazoline 87 as a chiral ligand to 
induce stereocontrol, with recrystallisation of the crude reaction mixture allowing for access to 
cyclopropane furan 81 in 35% yield and >99% ee. Ozonolysis of cyclopropyl-furan 81 readily 
furnishes the cyclopropane carboxaldehyde 82, with subsequent Lewis acid catalysed addition 
of allyltrimethylsilane yielding allylalcohol 83 in >95% de and was carried forward without the 
need for further purification. Treatment of 83 with barium hydroxide resulted in ester hydrolysis 
to afford an alkoxide (84) that underwent a clean retro-aldol reaction that resulted in cleavage of 
the strained cyclopropane ring to afford an unstable open chain derivative (85) that cyclised to 















































A number of protocols for the synthesis of !-lactones have been developed which rely on the 
intramolecular addition of a carboxylic acid nucleophile onto an activated alkyne 
functionality.77-80 This type of cyclisation reaction is normally carried out using gold 
catalysis,81,82,83-85 with Genêt having shown that treatment of acetylenic acid 89 with gold(I) 
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chloride results in a clean cycloisomerisation to afford its corresponding the !-butyrolactone 90 
















Gold has a particularly high affinity for the pi-systems of alkynes and initially it is postulated 
that gold(I) coordinates to the alkynyl functionality of alkyne 89 to generate the activated 
intermediate 90. Subsequent nucleophilic attack of the carbonyl group of the carboxylate 
generates an unstable gold alkylidene-!-lactone 91, which is protonated to afford the !-





























Intramolecular reactions of alkynes and alkenes have been demonstrated as effective methods of 
carbon-carbon bond formation for the generation of !-butyrolactones.40,88,89 For example, the 
intramolecular Alder-ene reaction has been demonstrated as a strategy to access a range of 
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alkylidene-!-lactones (Scheme 2.13). Zhang and co-workers demonstrated an effective catalytic 
kinetic resolution system for the rhodium catalysed Alder-ene reaction of enyn-ester 93 using 
[RhCOCCl]2/BINAP/AgSbF6 as a catalytic system to enable access to the desired enantiopure 












47 %, >99 % ee
(R)-93





It is postulated that the rhodium complex coordinates to the alkene ( system, with subsequent $-
hydride elimination to afford an allylic-metal-hydride species 96 that results in concomitant 
intramolecular attack of the alkynyl system to generate the new C-C bond yielding of rhodium-
diene 97. Subsequent hydride shift generates the alkylidene-!-lactone 94 with regeneration of 




























Olefin metathesis reactions are one of the most powerful tools for organic synthesis and the 
application of this strategy for ring formation is now a well-established protocol for 
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constructing 5-membered rings of !-lactone frameworks.90-94 For example, Quinn and co-
workers have demonstrated the power of Grubbs’ second generation catalyst in tandem ring-
closing/cross metathesis reactions (See Scheme 2.14).94 Initially, monoester 98 was prepared via 
a two-step mono-silylation/ acryloyl chloride esterification protocol to afford triene 99, which 

























Initial intramolecular ring closing metathesis between the alkene of the acryloyl fragment and 
the proximal alkene occurs to cleanly afford #,$-unsaturated-!-butyrolactone 102, with none of 
the corresponding "-lactone being formed. Subsequent intermolecular cross metathesis between 
the terminal alkene functionality of lactone 102 and alkene 103 then results in formation of !-







































There are many examples in the literature where radicals have been used to construct lactone 
functionalities via intramolecular cyclisation onto unsaturated functionalities.95-97,98,99 For 
example, Naito has described free radical-mediated methodology for cyclisation of oxime ether 























Therefore, refluxing triethylborane in toluene generates an ethyl radical, which undergoes 
conjugate addition to the acrylate functionality of 104 to a carbonyl stabilised #-radical 107, 
that then undergoes intramolecular 5-exo-trig intramolecular cyclisation onto its oxime 
functionality. The resulting oxime radical 108 is trapped via reaction with a further equivalent 
of triethylborane to generate an ethyl radical and borane-!-lactone 109 which on aqueous 

































Another, interesting reaction for the generation of carbon-carbon bonds involves ring formation 
via carbene insertion into an unactivated C-H bond.101 For example, Doyle et al have reported 
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the synthesis of $,!-disubstituted-!-butyrolactone 111 via rhodium catalysed intramolecular C-H 






















The reaction is envisaged to proceed via generation of a rhodium carbenoid species 113 whose 
p-orbital of overlaps with the !-orbital of a suitably orientated C-H bond to initiate C-C bond 
formation via intermediate 114 (Figure 2.8), with hydrogen atom migration to the original 























Strategies that utilise carbon-carbon bond forming reactions to access chiral-!-butyrolactones 
are not simply limited to intramolecular reactions, with protocols based on Baylis-Hillman and 
aldol reactions having been used to access chiral starting materials for iterative synthesise of !-
butyrolactones. Therefore, a number of ‘one-pot’ C-C bond formation/lactonisation reactions 
have been developed for this purpose, with boron-mediated allylation reactions of aldehydes 
representing an impressive route to alkylidene-!-butyrolactones.103,104 For example, 
Ramachandran has shown that treatment of Z-crotylboronate 115 with cyclohexane 
carboxaldehyde with ytterbium(III) triflate as a Lewis acid resulted in cis-$,!-disubstituted-#-





















In recent years there has been an ever-increasing interest in organocatalysis and it applications 
for organic synthesis,9,105 with its use for the asymmetric synthesis of lactone moieties having 
attracted much interest.106 The application of nucleophilic heterocyclic carbenes (NHC) for 
reaction catalysis has been widely investigated.107-109 Suresh and co-workers demonstrated the 
application of the NHC catalysed reaction of enals and 1,2-dicarbonyl species for the synthesis 






















Initially the carbene is generated by treatment of IMes'HCl with a base (DBU) to generate 
catalytic species 121 in-situ, with subsequent nucleophilic attack at the carbonyl of aldehyde 
119 to generate alkoxide intermediate 122 that then tautomerises to afford diene 123, which 
undergoes nucleophilic attack at the carbonyl of acetone to generate a !-hydroxy-carbonyl 125, 






















































Clearly, there are a wide range of synthetic strategies available to construct a range of different 
!-butyrolactone frameworks; utilising a range of reactions from organocatalysis, 
electrocyclisation to reduction/oxidation to name but a few. However the synthesis of three or 
more contiguous stereocentres in a single !-butyrolactone still remains a challenge with most 
strategies being target driven aiming at a particular class of !-butyrolactone natural products. 
Here in we shall discuss our attempts to access highly functionalised #,$,-substituted-!-








Chiral trisubstituted !-butyrolactones are of particular synthetic and biological interest. They are 
known to display a wide range of biological activity with the !-butyrolactone moiety being 
found in a wide range of natural products. For example, Crassalactone C (130) isolated from 
Asian trees is known to display cytotoxic activity against human tumour cells;110 ent-
Clavilactone B (131) isolated from the Clitocybe clavipes fungus demonstrates antibacterial 
activity;111 and peroxylactone Plakortolide 132 (isolated from a Jamaican sponge) has been 

























Moreover, trisubstituted !-butyrolactones have proven to be powerful synthetic precursors, and 
have been used in many natural product syntheses. 40,113 One such example is in the synthesis of 
cryptophycin A (Scheme 3.1).114 Initially (R)-#-methyl lactone 133 is esterified and acetal 
protected using 2,2-dimethoxypropane, methanol and Amberlyst 15 in a one pot procedure. The 
resulting open chain methyl ester-acetonide 134 is subsequently reduced to the corresponding 
aldehyde derivative with concomitant Mukaiyama aldol addition/dehydration giving the 









































As a consequence of their diverse applications, a wide range of methods have been developed 
for the synthesis of enantiopure trisubstituted !-butyrolactones.115,116 One such example is the 
synthesis of (-)-epi-blastmycinolactol 141; where Schobert utilised a one-pot Wittig 
alkenylation/Claisen rearrangement for construction of the lactone moiety.117 Treatment of 
methallyl-(S)-lactate 138 with (triphenylphosphoranylidene) ketene 139 in toluene under 
microwave irradiation (sealed vial, 180 °C, 10 min) generated the unsaturated !-lactone 140 in 
65% yield. Subsequent hydrogenation of the alkenyl bonds utilising a rhodium/alumina catalyst 





















Given their potential importance, I now report the development of highly efficient methodology 
for the asymmetric synthesis of trisubstituted hydroxylated !-butyrolactones via hydroxyl 
directed epoxidation reactions of $-hydroxy-$-vinyl-N-acyl-oxazolidin-2-ones. 
 
C6? S$*7#1(+'91$8'
Aldehydes are important building blocks in organic chemistry, with the range of high yielding 
one-step transformations that the aldehyde synthon can undergo making them highly desirable 
precursors for organic synthesis. As such, chiral aldehydes (or their equivalents) containing #-
stereocentres are widely employed as versatile chiral building blocks for the asymmetric 
synthesis of complex natural products and drug like molecules.  
 
As a consequence, a wide range of methodology has been developed for their asymmetric 
synthesis. These include reduction of corresponding chiral amides,118 Weinreb amides,119 
thioesters and oxazolines that allow direct access to chiral aldehyde motifs.120,121 Oxidations 
from chiral primary alcohols are also viable, although often limited by the potential of 
racemisation of the #-stereocentre.122 Alternatively, oxidative cleavage of chiral diols and 
ozonolysis of chiral alkenes or hydrazones have also been widely reported.123 Further to this, 
methodologies have also been developed that do not require oxidative or reductive steps to 
generate the aldehyde functionality, including hydroformylation of alkenes,124 rearrangement 
reactions,125 conjugate addition reactions, cycloadditions, and kinetic resolution of racemic 
substrates. 
 
A number of chiral auxiliary approaches have been developed for the asymmetric synthesis of 
chiral aldehydes.126-128 In these protocols, chiral aldehyde equivalents are stereoselectively 
transformed into a chiral intermediate containing a new stereocentre in high de, with 
diastereocontrol being controlled by the attached chiral auxiliary fragment. Subsequent cleavage 
of the chiral auxiliary fragment from each chiral intermediate then generates a chiral aldehyde 
product containing an #-stereocentre in high ee.  
 
Previous work in the SDB group has focused around the use of $-hydroxy-$-vinyl-N-acyl-
oxazolidin-2-one substrates as novel synthons for the asymmetric synthesis of chiral 
aldehydes.129,130 In these methodologies, a novel ‘temporary stereocentre’ strategy is employed 
to relay stereocontrol which enables a chiral auxiliary fragment to be used to create remote 




One such example utilises a three-step strategy of stereoselective aldol/directed 
cyclopropanation/retro-aldol reactions for the synthesis of enantiopure cyclopropane 
carboxaldehydes (See Scheme 3.3). Initially, N-acyl-oxazolidin-2-one 142a was treated under 
boron mediated aldol conditions to generate a syn-aldol product in high de. Treatment of syn-
aldol 143 with diethyl zinc and diiodomethane in dichloromethane at –10 °C resulted in a highly 
diastereoselective cyclopropanation reaction to yield cyclopropyl aldol 144 in 99% yield and > 
95% de. Subsequent treatment of cyclopropyl-syn-aldol 144 with LHMDS in toluene at 0 °C 
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The overall outcome of this three-step protocol was the stereoselective transformation of an 
achiral #,$-unsaturated aldehyde into chiral cyclopropane carboxaldehyde 145 in high ee, using 
reversible formation of the temporary $-hydroxyl stereocentre of syn-aldol 143 to control the 
facial selectivity of the cyclopropanation reaction. Further to this the SDB group has also 
demonstrated that this three-step ‘temporary stereocentre’ approach is not simply limited to the 
hydroxyl-directed-cyclopropanation reaction. One example is the asymmetric synthesis of (S)-
#-methyl octanal, with anti-aldol 146 being generated via use of the magnesium enolate of 142a 
in high levels of diastereocontrol (See Scheme 3.4). Hydrogenation of anti-aldol 146 with 
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Wilkinson’s catalyst in dichloromethane generated the saturated (2R,3R,4S)-anti-aldol 147 in 
96% de. Subsequent treatment of (2R,3R,4S)-anti-aldol 147 with LHMDS at 0 °C, resulted in a 




































!,"-Unsaturated-N-acyl-oxazolidin-2-ones have previously been shown to undergo epoxidation 
reactions. For example, Trova et al previously demonstrated that epoxidation of !,"-unsaturated 
N-acyl-oxazolidin-2-one 149 with mCPBA and NaHCO3 in dichloromethane yielded a 50:50 
































With this precedent in mind, it was decided to investigate the hydroxyl-directed epoxidation 
reactions of $-hydroxy-$-vinyl-N-acyl-oxazolidin-2-ones, with the aim of developing a 
‘temporary stereocentre’ methodology for the synthesis of chiral #,$-epoxy aldehydes.  
 
Initially, an asymmetric aldol reaction would be used to generate the directing hydroxyl 
functionality of 151 with high levels of stereocontrol; subsequent reaction of the aldol product 
151 under hydroxyl-directed epoxidation conditions would generate the chiral epoxide 152 with 






































The initial target was therefore the synthesis of gram quantities of SuperQuat auxiliary 157, the 




The synthesis of the SuperQuat auxiliary was adapted from the original methodology reported 






























(S)-Phenylalanine was esterified using thionyl chloride at room temperature. Initially, the 
thionyl chloride reacts with methanol to generate dry HCl which catalyses the esterification 
reaction with methanol to yield the HCl salt of methyl ester 154 in 98% yield, which was used 





























































The next stage was protection of the primary amine of L-phenylalanine methyl ester 154 with a 
tert-butoxycarbonyl (Boc) moiety, which was achieved by reaction with Boc-anhydride and 
sodium hydrogencarbonate in tetrahydrofuran, affording N-Boc-ester 155 in 96% yield without 
the need for purification.  
 
Reaction of 155 with excess methyl magnesium iodide (generated in situ from Mg turnings and 
methyl iodide) resulted in formation of the gem-dimethyl alcohol 156 in 74% yield without the 
need for further purification. The acidic proton of the N-Boc functionality is also deprotonated 
in this reaction, which prevents racemisation of the #-stereocentre of the ketone intermediate 



























Treatment of the gem-dimethyl alcohol 156 with potassium tert-butoxide in tetrahydrofuran 
generated a potassium alkoxide intermediate, which underwent intramolecular cyclisation 
elimination to yield the desired SuperQuat auxiliary 157 in overall 65% yield. Therefore, the N-
Boc functionality not only serves as a protecting group but also acts as a sacrificial carbonyl 



























A range of N- acylated oxazolidin-2-ones were then synthesised (See Table 3-1). The parent 
oxazolidin-2-one 157 was treated with n-butyllithium (2.5M in hexanes) at –78 oC, followed by 
addition of the appropriate acid-chloride and the resulting reaction mixture allowed to warm to 
room temperature over 2 hours. The reaction was quenched with saturated ammonium chloride 





































































The aldol reaction is one of the most powerful and widely documented methodology for 
stereoselective carbon-carbon bond formation, which involves reaction of an enol/enolate with 
an aldehyde to generate a $-hydroxy-carbonyl compound.  
 
It is important to note that this reaction, can potentially afford four diastereomeric products, and 
as a consequence it is necessary to control both the diastereoselectivity (S1 and S2 vs. A1 and A2) 









































The diastereoselectivity of the aldol reaction is dependent on the geometry (cis or trans) of the 
enol or enolate generated. Lewis acid mediated enantioselective aldol reactions proceed via a 
concerted pericyclic process, that can generate two diastereotopic transition states for each 
enolate geometry (See Figure 3.6).135 The resultant rigid Zimmerman-Traxler transition states 












No choice over orientation:





















































R' group is arranged pseudo-
equatorial - Favoured configuration
R' group is arranged pseudo-
axial - Disfavoured configuration
R' group is arranged pseudo-
equatorial - Favoured configuration
R' group is arranged pseudo-






No choice over orientation:






For lithium enolates the geometry of the enolate is solely dependent on the size of the non-
enolisable group, with large groups forcing the enolate to adopt a cis-geometry and smaller 
groups allowing for a trans-geometry. However, softer boron enolisation allows for greater 
stereocontrol with the groups attached to the boron serving to control the geometry of the 
enolate. The boron atom of 9-BBN-OTf is relatively unhindered, allowing the R group to 










The previous models allow us to predict the relative stereochemistry of the aldol reaction, with 
the stereochemical outcome being dependent on the enolate geometry. Unhindered boron Lewis 
acids generate cis-enolates and the above models predict that potentially two syn diastereomers 
could be formed.136 However, using a chiral auxiliary it is possible to access a single 
diastereomer, since the stereogenic centre located on the auxiliary introduces a steric bias 
between the two faces of the cis-enolate (See Figure 3.7).  Upon addition of an aldehyde to a 
cis-boron enolate, the boron centre coordinates to the carbonyl of the aldehyde. In the absence 
of chelation, the auxiliary is free to rotate about the carbon-nitrogen bond and arranges itself so 
that the oxazolidin-2-one carbonyl is positioned syn-periplanar to the alkene functionality of the 
cis-enolate. In this conformation the bulky R group of the oxazolidin-2-one projects downward 
(according to Scheme 3.7) and the aldehyde is delivered preferentially from the opposite face to 
















































non-Evans' syn-aldol 158a Evans' syn-aldol 158b "
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The SDB group has previously optimised Caddick’s conditions for the synthesis of racemic 
Evans’ syn-aldol products.130,137-140 For example generation of the boron enolate of 160 via 
treatment with 9-BBNOTf and DIPEA in dichloromethane, followed by reaction with an 





















As such, it was decided to apply these conditions to the synthesis of unsaturated syn-aldol 
products.141 N-propionyl-‘SuperQuat’ oxazolidin-2-one 157 was initially treated with 9-BBN-
OTf (1.1 equiv) and DIPEA (1.3 equiv) to generate the cis-boron enolate. Subsequent addition 
of the appropriate aldehyde (1.3 equiv) yielded the desired syn-aldol products in >95% de. This 
methodology has been applied to a range of #,$-unsaturated aldehydes for the synthesis of 
unsaturated syn-aldol products 163a-i (See Scheme 3.10), with the syn stereochemistry of the 


















































































































%p is equivalent to the SuperQuat auxiliary; 
a Isolated yield after column chromatography eluting with CH2Cl2; 
b de 





The syn-aldol products (Entries 1 to 3 and 6 to 9) were all synthesised from their commercially 
available aldehydes in greater than 95% de and good to excellent yields. Entries 4 and 5, were 
synthesised using a non-commercially available aldehydes 164 and 165 respectively, whose 



















Therefore, aldehydes 164 and 165 were prepared via Mannich-type reactions involving 
treatment of iso-valeroaldehyde or octanal with formaldehyde (37% solution in water) and 
dimethylamine over a 24 hour period. Initially formaldehyde reacts with dimethylamine to 
generate a reactive imminium species 166, with a second equivalent of dimethylamine 
generating an enolate 167 (or enamine equivalent) of the aldehyde. Subsequent reaction of the 
enolate 167 and imminium species 166 generates the tertiary amine 167. This is concomitantly 
enolised (168) and dimethylamine eliminated to generate the desired 1,1-disubstituted aldehyde 
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The cis-octenal aldol derivative (163j) had to be indirectly synthesised via its corresponding 
alkyne derivative 170, because cis-alkenes are known to be notoriously unstable under Lewis 
acidic conditions and readily isomerise to generate inseparable mixtures of cis and trans 



























As a result, aldol 163j was synthesised by treatment of octynal under the standard aldol 
conditions to yield the alkynyl-aldol derivative 170 (See Scheme 3.13). Subsequent reduction 
under hydrogen over Lindlar’s catalyst gave the desired cis-#,$-unsaturated aldol 170 in 79% 






























The cis-stereochemistry was confirmed from its 1H NMR spectrum, the vicinal coupling (Ja,b) of 
the alkenyl protons was shown to be 11.0 Hz which is consistent with literature precedent, 
where small coupling constants between 7-11 Hz are indicative of a small dihedral angle found 




For completeness, an anti-aldol substrate was synthesised to investigate the effect of the #-
stereocentre upon diastereoselectivity in the future epoxidation reactions.  
 
Therefore, non-Evans’ anti-aldol 146 was prepared via treatment of N-acylated oxazolidin-2-
one 142a with 1,1-disubstituted aldehyde 165, magnesium chloride (10 mol%), triethylamine (2 
equiv), chlorotrimethylsilane (1.5 equiv) and sodium hexafluoroantimonate (30 mol%) in ethyl 
















In this reaction there appears to be a delicate balance between metal mediated silylation and 
reversible retro-aldol fragmentation, with silylation trapping the “unstable” trans-aldolate, thus 
preventing epimerization to a mixture of syn- and anti-products.  Clearly, this aldol reaction 
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does not follow the “traditional” auxiliary mediated process (vide supra); since the alpha 
substituent is syn to the chiral auxiliary’s R group in the final product. This unexpected anti-
aldol product can be rationalized by consideration of the transition state of this reaction. In this 
case the previous Zimmerman-Traxler models are precluded with a 6-coordinate magnesium 
species being invoked, that results in a twisted boat transition state for the carbon-carbon bond 
forming step.143 This results in coordination of the oxazolidin-2-one carbonyl to the magnesium 
counterion throughout the course of the reaction, with the aldehyde approaching the trans-















R' group is arranged pseudo-
equatorial - Disfavoured configuration
R' group is arranged pseudo-




No choice over orientation:
 R must be pseudo-axial
Coordination of magnesium gives






























In the epoxidation reactions of allylic alcohols the oxidant can deliver oxygen to either of the 
two diastereotopic faces of the alkene functionality, generating either threo- or erythro-epoxy 
alcohols (See Figure 3.10). The terms threo and erythro are used in acyclic systems as 
descriptors for relative stereochemistry and are specifically used to describe two contiguous 
stereocentres where two of the groups on the asymmetric carbons are the same and one is 
different.144 Erythro describes how the identical groups are on the same side (when drawn in the 
Fischer convention), i.e. in the case of erythro-171a the two oxygen atoms are on identical 
faces. In the case of threo, the two identical groups are on opposite sides, for example, in threo-




















Epoxidation of allylic alcohols has been widely reported in the literature, and methodologies 
available to exist to access both the threo- and erythro-epoxy products in high levels of 
diastereocontrol. These include the use of metal catalysed approaches such as VO(acac)2, 
Ti(OiPr)4 or Mo(CO)6 activation of tert-butylhydroperoxide, MTO/UHP (Methyl trioxo-
rhenium/Urea hydrogen peroxide) and non metal peroxides such as mCPBA and DMD 
(Dimethyl-dioxirane).145 
 
The stereoselectivity of these epoxidations relies on a delicate balance between conformational 
control and substrate-reagent interactions. Of these interactions, there are two distinct 
mechanisms or intermediates that must be considered, involving either alkoxide coordination 
and/or hydrogen bonding. This area has been widely investigated by Adam et al who have 
experimentally investigated the selectivity of a range of epoxidation methods and the 
relationship of their epoxidation diastereoselectivity to their transition states (See Figure 3.11 


























! ca. 60° 70° < ! > 60° 120° < ! > 130°
Alkoxide binding for VO(acac)2, 
Ti(OiPr)4 and Mo(CO)6 epoxidations
Hydrogen bonding for peracids, 






    Erythro/Threo diastereoselectivity 




















CH2Cl2 Alkoxide 78:22 09:91 76:24 05:95 
4 mCPBA CH2Cl2 H-bonding 55:45 05:95 52:48 05:95 




CHCl3 H-bonding 50:50 18:82 44:56 17:83 
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Adam demonstrated that the facial selectivity for epoxidation is generally the same for both 
metal alkoxide or hydrogen bond coordinated intermediates. However, alkoxide intermediates 
gave an overall higher level of stereocontrol, with vanadium-mediated epoxidations (Entry 1) 





Consequently, it was decided to attempt epoxidation reactions on our $-vinyl-aldol substrates 
utilising the homogenous vanadium oxidation system that employs vanadyl acetylacetonate and 
tert-butyl hydroperoxide. Mechanistically, tert-butyl hydroperoxide oxidises the vanadyl 
acetylacetonate from the inactive d1 complex 172 to the catalytically active d0 vanadate ester 
173.149 Rapid ligand exchange generates alkoxy-intermediate 174, which rearranges to activate 
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the alkyl peroxide by bidentate coordination to the vanadium centre generating species 175. 
Subsequent intramolecular nucleophilic attack on the allylic functionality yields the epoxy-













































Both Sharpless and Adam have investigated the stereoselectivity of the homogenous vanadium 
catalysed epoxidation of allylic alcohols.146,147 They have shown that provided efficient 
coordination operates between the reagent and the substrate, high diastereoselectivity can be 
observed, whose final selectivity can be rationalised by consideration of allylic strain. 
 
Experimental observations by Adam et al have shown that the presence of an #-substituent 
favours an erythro-epoxy alcohol, whilst the presence of a cis-$-substituent results in a threo-
































































This stereochemical outcome can be rationalised by consideration of the allylic strain of the 
intermediate transition state. For 3-methylbut-3-en-2-ol (Entry 2), the oxidant is delivered to the 
one face of the alkene due to minimisation of A1,2 strain. In this example there is no sterically 
demanding group in the cis-$-position and as a consequence A1,3 strain is negligible. Thus, for 
1,1-disubstituted alkenes A1,2 strain is dominant and an erythro-epoxy alcohol 177a is favoured.  
Conversely, for the case of 4-methyl-pent-3-en-2-ol (Entry 5) the lack of a sterically demanding 
group at its #-position means that A1,2 strain can be considered negligible, and as a consequence 
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A1,3 becomes dominant due to the presence of its cis-$-substituent, with a threo-epoxy alcohol 































A1,2 strain is minimised
Favoured conformation


































A1,3 strain is maximised
Disfavoured conformation
A1,3 strain is minimised
Favoured conformation
Threo-178b "
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Adam observed that cis-$-functionalities are more sterically dominant than trans-$-substituents. 
This can be observed by comparison of the epoxidation selectivities of trans- and cis-3-methyl-
pent-3-en-2-ol (Entries 6 and 7 respectively), with a cis-substituent decreasing selectivity to 
33% de due to increased A1,3 strain. This is further supported by consideration of the geometric 
isomers of pent-3-en-2-ol  (Entries 3 and 4). Here the stereochemical outcome is fully inverted, 
with epoxidation of cis-pent-3-en-2-ol being dominated by A1,3 strain to favour the threo-epoxy 
alcohol, and trans-pent-3-en-2-ol being dominated by A1,2 strain to favour the erythro-epoxy 
alcohol. Furthermore, the poor levels of diastereocontrol for epoxidation of simple trans-$-



































A1,3 strain is relieved 
because the trans-methyl 
group points away from the 
demanding methyl of the 
carbinol.
A1,2 strain is maximised
Threo-179b
H
A1,2 strain is minimised
A1,2 strain between 
carbinol and vinylic 
proton is still small which 







Considering this literature precedent, it was decided to attempt the directed epoxidation of 1,1-
disubstituted unsaturated aldol 163c, which we expected to proceed in very high de. Aldol 163c 
was dissolved in benzene and vanadyl acetylacetonate (10 mol%) added, with tert-butyl 
hydroperoxide (1.1 equiv.) after 5 minutes added in one portion and the reaction was stirred for 
24 hours. 1H NMR spectroscopic analysis of the crude reaction mixture revealed that the 
starting material had been consumed, however none of the desired epoxide 180 was present in 



















The 1H NMR spectrum indicated that only N-H oxazolidin-2-one 157 was present in the organic 
layer, with no product derived from the aldol side chain present. However, saturation of the 
aqueous layer with sodium chloride and extraction with ethyl acetate yielded a "-butyrolactone 
181c, in high de. The gross structure of this !-butyrolactone was determined using several 
analytical techniques. Firstly, FTIR indicated a compound with a single carbonyl group at 1740 
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cm-1, which is consistent for a cyclic ester, a broad signal was observed at 3504 cm-1 which 
represents the presence of hydroxyl functionality. The 1H NMR spectra indicated a dq at 2.79 
ppm that integrated to one proton, this is indicative of a CH adjacent to an ester functionality 
with a methyl group attached. The 13C NMR spectra indicated the presence of 3 carbon centres 
attached to oxygen centres, as such it was inferred that a !-lactone was generated which is 
derived form the aldol side chain. This was further confirmed by HRMS, which confirmed the 
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The stereochemical determination of five-membered cyclic systems is more complicated than 
their six-membered counterparts. Normally, 1H NMR spectroscopy can be used to assign 
relative stereochemistry to vicinal chiral centres because of the correlation of coupling constants 
to the dihedral angle.151 However, in five membered lactones this is known to be difficult, the 
ring system is puckered, not flat, and two potential conformers exist for the ‘envelope’ 
structure. The ring system rapidly interconverts between the two conformers with similar 
energies (pseudorotation), which makes structural elucidation limited (See Figure 3.17).152 
Addition of functionality to the ring system alters the puckering of the ring, and leads to some 

























The more functionalised the ring system then the more favoured one conformer becomes, as 
such it was hoped that use of NOE spectroscopy could help to assign the relative 
stereochemistry of our tetra-substituted lactone 181c.  
 
To define the stereochemical outcome, the key interactions to consider are those about the 
newly formed stereocentre at the C5 position.  The C3 hydrogen is shown to strongly interact 
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with the CH2OH hydrogens (Figure 3.15), which indicates a syn relationship for these 
substituents. Further to this the C3 methyl group was shown to be close in space to the C4 
hydrogen, which in turn strongly interacts with the C6 hydrogens indicating that these 
functionalities are all on the same face of the ring system. Given the known 2S,3S configuration 
of the precursor syn-aldol 163c that was epoxidised this is indicative of an S geometry at the 























Lactone 181c was recrystallised from diethyl ether and petroleum ether, X-ray crystallography 












Therefore, when all this spectroscopic information is considered, it is clear that treatment of 1,1-
disubstituted unsaturated aldol 163c under vanadium mediated epoxidation conditions yields the 

























Before we can rationalise the stereochemical outcome for this epoxidation/lactonisation reaction 
we must consider the potential mechanism that is operating under these epoxidation conditions. 
There are many examples of stable epoxides of 1,1-disubstituted allylic alcohols having been 
reported in the literature. Therefore, if the observed lactonisation of unsaturated-syn-aldol 163c 
proceeds via epoxidation, then there must be something about the epoxide intermediate that 
makes it so reactive. A review of the literature revealed that similar !,"-epoxy-amides had been 
reported previously to be unstable, also ring opening to afford !-butyrolactones.153,154 For 
example, Jenkins et al showed that treatment of amide-diene 182 with meta-chloroperbenzoic 
acid in acetonitrile and water yielded a mixture of both the epoxide 183 and hydroxy lactone 
184. The yield of the hydroxy lactone 184 could be further improved by treatment of the 
epoxide 183 under either acidic (H2SO4) or basic (NaOH) conditions according to the 















































Applying this mechanistic rationale to our substrate, it is proposed that aldol 163c is 
stereoselectively epoxidised to generate an unstable (2S,3S,4R)-!,"-erythro-epoxy-N-acyl-
oxazolidin-2-one 180 in high de as predicted for directed epoxidation of this class of 1,1-
disubstituted alkene. Concomitant nucleophilic ring opening of the epoxide at its !-centre via a 
neighbouring group participation mechanism involving intramolecular nucleophilic attack of the 
exo-cyclic carbonyl of its N-acyl fragment, would result in inversion of the stereocentre at the 
C5 position, affords the unstable imminium intermediate 187. It is proposed that this imminium 
species may be potentially stabilised by the reversible formation of NOO-intermediate 188. The 
imminium intermediate is then hydrolysed on workup to yield the parent N-H auxiliary 157 and 
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A similar mechanism has been proposed for the iodolactonisation of !,"-unsaturated oxazolidin-
2-one functionalities which aldol afforded !-butyrolactones.155 Shibuya et al showed that 
treatment of bis-!,"-unsaturated oxazolidin-2-one 189 with N-iodo-succinimide in 
tetrahydrofuran and water, generated a key iodonium intermediate 192 that underwent a 
neighbouring group ring opening where by its exo-cyclic carbonyl also acts as an internal 
































It was considered that an alternative mechanism might be operating in which an external water 
nucleophile was responsible for hydrolysing the unstable epoxide followed by cyclisation of the 









































M0"*:*' C6??=' %4*(',)*!#(" 0(;3),!-0" 1+'" *3(" (7+$!5)*!+,S4);*+,!-)*!+," +1"$O3N5'+$NO$O#!,N4O1O);N4O+$)`+4!5!,O<O
+,("<GC0D"'
 
Although this mechanism seemed unlikely, since numerous stable epoxides of this type had 
been isolated previously from these types of epoxidation reactions, it was decided to investigate 
whether the epoxide intermediate 180 could be intercepted by powerful nucleophiles such as 
ethane thiol or azide. Therefore, unsaturated aldol 163c, was treated under standard epoxidation 
conditions, with the reaction being subsequently quenched with ethanethiol or a solution of 
aqueous sodium azide. Subsequent inspection of the resultant crude 1H NMR spectra indicated 
that none of the lactone derivatives 194/195 or 196/197 were present in the crude reaction 
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A second consideration was that peroxide mediated exo-cyclic cleavage of the oxazolidin-2-one 
fragment of the intermediate epoxide 180 had occurred, since lithium alkyl-hydroperoxides 
63)7*('"=8"%,"(11!;!(,*")-N00(*'!;"-N,*3(-!-"+1"3N5'+$NO!O&:*N'+4);*+,(-"
UZ"
were known to cleave N-acyl-oxazolidin-2-ones to afford their corresponding carboxylic acid 
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It was proposed that vanadium peroxides could potentially act in a similar fashion, with the 
resulting carboxylic acid derivative acting as a nucleophile in the intramolecular cyclisation 
reaction. To further investigate whether this potential cleavage mechanism could occur, a 
saturated syn-aldol 198 was prepared via reaction of the boron enolate of N-propionyl 
oxazolidin-2-one 142a with iso-valeroaldehyde in 81% yield and >95% de. Subsequent 
treatment of aldol 198 with vanadyl acetylacetonate and tert-butyl hydroperoxide resulted in 
>90% starting material being recovered, with 10% of the N-acylated auxiliary 142a being 
observed. This indicates that N-acyl-oxazolidin-2-one derived aldol products do not undergo 
exo-cyclic cleavage of their oxazolidin-2-one fragments under these epoxidation conditions, 
however their vanadium alkoxides do appear to have a slight propensity to undergo retro-aldol 

































To further confirm our mechanism, it was decided to attempt the epoxidation of syn-aldol esters, 
which should allow access to a stable epoxy-aldol product so that we could confirm the 
stereochemical outcome of the epoxidation reaction. Lactonisation of related syn-aldol esters via 
an epoxide intermediate has been reported previously in the literature.157,158 For example, 
Nakata had reported that epoxidation of syn-aldol benzyl ester 200 gave an epoxide intermediate 
that was stable, with subsequent hydrogenation of the benzyl group yielding a carboxylic acid 
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that immediately underwent intramolecular cyclisation ring-opening onto the epoxide to yield a 



















Unsaturated syn-aldol 163b was treated with sodium methoxide solution for five minutes and 
the resulting methyl ester isolated in quantitative yield with no racemisation of the #-
stereocentre being observed in the crude 1H NMR spectra. Methyl ester 202 was subsequently 
treated with vanadyl acetylacentonate and tert-butyl hydroperoxide in benzene, which after one 
hour resulted in complete consumption of the starting material as observed by thin layer 
chromatography. The resulting reaction mixture was concentrated under reduced pressure and 
the crude 1H NMR spectra indicated complete consumption of the starting material and the 
presence of two distinct doublets observed at 2.92 and 2.59 ppm, which were indicative of the 
chemical shifts expected for epoxide protons. However, attempts to purify this unstable epoxide 
proved unsuccessful, with chromatography and distillation both resulting in conversion to the 




























With this in mind, it is inferred that the lactonisation reaction proceeds via the predicted 5-exo 
reaction, where a neighbouring group participation mechanism operates with inversion of 







In an attempt to decrease the reaction time, it was initially decided to consider the effect of 
temperature upon reaction rate. The reaction was repeated at room temperature, 25 °C, 30 °C 
and 40 °C. Increases in temperature were found to have no effect on the consumption of starting 
material, according to thin layer chromatography, which indicated the presence of epoxide 180, 
some of the desired lactone 181c and N-H oxazolidin-2-one 157. After 24 hours, thin layer 
chromatography indicated the reactions had reached completion, with complete consumption of 
the epoxide intermediate having occured. Increases in temperature were shown to have a limited 
effect on the rate of lactonisation, however the diastereocontrol of 181c was shown to decrease 





















de at RT     = > 95%
de at 30 °C = > 95%





It was subsequently decided to investigate the effect of catalyst loading upon the 
epoxidation/lactonisation reactions. Increases in the loading of VO(acac)2 did not affect the 
overall rate of reaction, with comparable rates of consumption of the starting material observed 
by thin layer chromatography analysis. However, decreasing the loading to 1 mol% did effect 
the epoxidation reaction significantly, with some starting material still present in the reaction 
mixture. Use of 5 mol% vanadyl acetylacetonate also showed a decrease in the rate of 
































The reaction work-up was then modified to maximise the yield of !-butyrolactone 181c from the 
yield of epoxidation/lactonisation reaction. It was found that !-butyrolactone 181c was readily 
soluble in water, which resulted in it being partitioned between the organic/aqueous layers 
during work-up. Therefore, the reaction work-up was modified to limit the amount of water 
added to the reaction media. Therefore, 0.1 mL of water was added to an 
epoxidation/lactonisation reaction after 24 hours and the solvent was removed in vacuo to 
afford the crude product that was analysed by 1H NMR spectroscopy, which indicated the 
presence of the N-H oxazolidin-2-one 157 and the !-lactone 181c in a 1:1 ratio. This crude 
mixture was purified by chromatography over silica eluting with a mixture of ethyl acetate and 


















 VO(acac)2 Conversion 
(i) 1 mol% 95% 
(ii) 5 mol% 100% 
(iii) 10 mol% 100% 






It was then decided to investigate the scope and limitation of the developed methodology for the 
epoxidation of a range of syn-aldol products, which were predicted to be epoxidised with 











































































































Epoxidation of syn-aldol 163b-e,i  under optimal epoxidation-lactonisation conditions resulted 
in the formation of !-butyrolactones 181b-e,i (via the erythro-epoxy aldols 180b-e,i) in good to 
excellent yields and >95% diastereoselectivity (Entries 2-6). The configuration of the C5 
stereocentres of the !-butyrolactones 181b-e,i were assigned according to the proposed 
neighbouring group participation mechanism with (S)-configuration of the C6-hydroxy 
following from the stereochemistry of the erythro-epoxide intermediate 180b-e,i. 
 
It was then decided to investigate the effect of the #-stereocentre on the diastereocontrol of 
these tandem epoxidation/lactonisation reactions. Consequently, non-Evans’ anti-aldol was 
treated under standard epoxidation/lactonisation conditions (See Scheme 3.29), which gave the 
desired lactone with equally high diastereoselectivity to that observed for the corresponding 























The (S)-configuration of the C5 position was confirmed from examination of its NOESY 
spectra. A favoured conformation is shown in Figure 3.28, which positions the vicinal C4OH 
and C5-alkyl groups in axial positions on opposite faces of the lactone ring.. With this in mind, 
the C3 proton gave a strong correlation to the proton on C4, which in turn gave a strong 
interaction with the protons on C6. Further to this, the C3 proton and the C5 hexyl-substituent are 



















The success of the epoxidation/lactonisation upon 1,1-disubstituted allylic alcohols then led us 




The next study was focussed around the lactonisation of various unsaturated aldols containing 
$-cis substituents that were predicted to proceed with threo selectivity. Initially, unsaturated 
aldol 163h was treated under the optimised oxidation conditions to yield a !-butyrolactone in 
>95% de, which from literature precedent was predicted to derived from the threo-epoxy aldol 




















Analysis of the crude 1H NMR spectra indicated a high level of diastereo-control, however, in 
the absence of a crystal structure we needed to confirm the configuration of its C5-stereocentre. 
This was complicated by the fact that Baltas et al had previously reported the potential for 2,2-
disubstituted-epoxy-$-hydroxy-tert-butyl esters to undergo a competitive endo-cyclisation 
mechanism during the formation of !-lactones.159,160 They reported that treatment of epoxy ester 
206 with a Lewis acid resulted in a neighbouring group participation mechanism occurring via a 
competing endocyclic cyclisation manifold to yield a "-lactone 207. This "-lactone was shown 
to be unstable and readily rearranged under mild conditions, to its more stable !-lactone 208 
































We reasoned that unsaturated aldol 180h might have an increased potential to undergo this type 
of competitive 6-endo-cyclisation rearrangement pathway, because the 2,2-disubstituted methyl 
groups would stabilise a carbocation at its C5 position thus potentially favouring endocyclic 
attack. This raised concerns over the stereochemical outcome of lactonisation since 6-endo 
lactonisation would not result in inversion of the C5 stereocentre, whereas 5-exo cyclisation 


































NOE spectroscopy of the purified !-lactone 181h showed a strong interaction between the C3 
methyl group interacting with the C6-dimethyl functionality, and further strong interactions 
between the C3 and C5 hydrogens (vide infra). These strong interactions were indicative of the 
stereochemistry assigned for the 5-exo cyclisation of the threo-epoxy aldol 180h and that the 
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potential 6-endo lactonisation pathway was not occurring. This was confirmed by comparison 
with the NOESY of the diastereomeric 5R lactone 210, which will be discussed in the following 
chapter (See Section 4.5.6). 







































Further to this stereochemical analysis, cis-octene aldol derivative 163j was treated with 
vanadyl acetylacetonate and tert-butyl hydroperoxide, with the !-butyrolactone 181j being 
generated in 84% yield and in >95% de. Once again, the stereochemistry of the lactone was 
inferred from the predicted threo-epoxide intermediate with inversion occurring at the C5 






























It was then decided for completeness to investigate epoxidation/lactonisation of trans-allylic-
syn-aldol 163f, which, if our epoxidation/lactonisation mechanism was correct, would be 
predicted to proceed with poor levels of erythro-diastereocontrol. Initially, aldol 163f was 
treated under the standard epoxidation conditions, with the analysis showing that all of the 
starting material had been consumed after 24 hours. 1H NMR spectroscopic analysis of the 
crude reaction product revealed that two diastereoisomeric !-butyrolactones 181fa and 181fb in 
33% de. These diastereoisomeric lactones were then separated by chromatography to afford 


































The configuration of the (3S,4S,5S,6S)-!-butyrolactone 181fa and (3S,4S,5R,6R)-!-
butyrolactone 181fb were assigned from comparison of their 1H NMR and NOESY spectra. 
One key difference in the 1H NMR spectra was the C3 proton signal, which in the erythro-
product 181fa was observed as a quartet of doublets, however in the threo-product 181fb a 
quartet of doublets is observed. Distinguishing between the two diastereomers was achieved 
using NOE spectroscopy, which could clearly differentiate between the interactions of the C3 































In recent years, the use of solid supported reagents, catalysts and scavengers for synthesis has 
increased widely. This is particularly true within the pharmaceutical industry where there is a 
need to synthesise focussed libraries of compounds in >90% purity, for high throughput 
screening against different biological targets. 161 
 
The use of solid supported reagents has many advantages over their homogeneous equivalents. 
Excess reagents can be employed to drive reactions to completion, with simplified purification 
procedures involving washing of the solid phase, thus allowing for removal of impurities or 
excess reagents. This allows solid phase synthesis to be used to rapidly prepare libraries of 
compounds in high yields and purities, without the need for complicated work-ups or 
purification.  
 
However, solid phase synthesis does have its limitations, with extra steps required to attach 
starting materials and remove products from solid support. Also monitoring reactions on solid 
support is difficult, because the range of available analytical techniques is often limited. This 
often results in existing solution phase reactions needing to be reoptimised for use with solid 
supported systems, with rates of reaction often much slower on polymer support. 
 
Previously, polymer-supported chiral auxiliaries have been used for the asymmetric synthesis of 
chiral !-lactones on solid supports. Procter et al reported the use of a solid supported chiral 
ephedrine 211 for use in asymmetric radical reactions of alkenes with aldehydes using 
samarium iodide as a reductive catalyst.161,162 In this case, the chiral ephedrine resin was readily 
esterified with crotonyl chloride and the resultant unsaturated O-acyl resin 212 was treated with 
samarium iodide and cyclohexanecarboxaldehyde, resulting in an asymmetric radical reaction 
with self-cleavage to afford the disubstituted !-lactone 214 in 66% yield and 96% ee. 
                                                      
* This work was carried out in collaboration with Rachel Green, whose PhD focussed around novel 
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Schore et al reported that iodolactonisation of polymer supported !,"-unsaturated chiral 
pyrrolidine derivative 215.163,164 Initially, polymer supported pyrrolidine derivative 215 was 
treated with pentenyl chloride to afford N-acyl-polymer 216 whose lithium enolate was 
alkylated by methyl iodide to afford a chiral #-methyl-!,"-unsaturated pyrrolidine derivative 
217. Subsequent treatment with iodine generates an iodonium ion, with concomitant 
nucleophilic attack by the amide moiety which results in cleavage to afford the monosubstituted 































The high levels of diastereocontrol observed for our solution phase epoxidation/lactonisation 
protocol, and the successful literature applications of solid supports to the synthesis of chiral 
lactones, led us to consider transferring our methodology to polymer support.  
 
Previously, the SDB group has developed conditions for the solid supported synthesis of syn-
aldol products using an L-tyrosine derived oxazolidn-2-one.165 Initially, L-tyrosine derived 
oxazolidin-2one 220 is coupled to a Merrifield resin through its phenolic oxygen, followed by 
N-propionylation to afford polymer-supported N-acyl-oxazolidin-2-one 222. Subsequent 
treatment of this polymer with 9-BBN-OTf under our modified aldol conditions enabled a small 
series of polymer supported syn-aldol products to be formed.166 These polymers were then 











































It was proposed that this methodology could be applied to the synthesis of $-vinyl-aldols, which 
could then be subjected to our epoxidation/lactonisation conditions. The advantage of applying 
our strategy to solid support was that the methodology would incorporate a self-cleaving 
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auxiliary fragment that could be removed by filtration at the end of the reaction, thus 
simplifying the purification process.  
 
However, to confirm that polymer-supported Evans’ type oxazolidin-2-one auxiliary 220 would 
perform correctly under our epoxidation lactonisation conditions it was decided to repeat our 
epoxidation/lactonisation methodology using an Evans’ auxiliary in solution phase. Initially, 
oxazolidin-2-one 225 was acylated to afford N-propionyl oxazolidin-2-one which was 
subsequently treated under syn-aldol conditions (9-BBN-OTf, DIPEA, isopropyl acrolein) to 
yield Evans’ unsaturated-syn-aldol 226 in 79% yield and >95% de. Treatment of syn-aldol 226 
with vanadyl acetylacetonate and tert-butylhydroperoxide using our optimised 
epoxidation/lactonisation conditions yielded the desired lactone 163d in a comparative 79% 


























Initially, Merrifield resin 219 was treated with 3 equivalents of L-tyrosine derived oxazolidin-2-
one 220, potassium carbonate and 18-crown-6 in dimethylformamide at 60 °C for 18 hours, 
with Merrifield resin being chosen for its stability under Lewis acid conditions. The resulting 
polymer-supported auxiliary 221 was then treated with an excess of propionic anhydride, 
triethylamine and lithium chloride in refluxing THF. After 3 hours the reaction was filtered and 
the resin dried in an oven, with gravimetric analysis indicating that the key N-propionyl 
polymer had been formed with a loading of approximately 0.79 mmol g-1.  IR analysis of the 
resin in a KBr disk indicated the presence of two carbonyl functionalities at 1705 cm-1 and 1783 

























N-propionyl polymer 222 was subsequently treated with 5 equivalents of 9-BBN-OTf in CH2Cl2 
and agitated at 0 °C for 1 hour. The resulting reaction mixture was filtered under nitrogen and 
the polymer beads treated with 5 equivalents of N,N-diisopropylethylamine at 0 °C to generate a 
polymer-supported-(Z)-boron-enolate intermediate. Excess solvents and reagents were then 
filtered off and the polymer beads resuspended in fresh CH2Cl2 before being cooled to -78 °C. 
2-Ethyacrolein was then added and the reactions slowly allowed to warm to 0 °C overnight. The 
resulting polymer-supported-syn-aldol 227 was isolated by filtration of the reaction mixture and 
a small portion characterised by subsequent reduction of the resultant resin with sodium 
borohydride in THF/H2O to afford a clean sample of chiral diol 228 in >95% de whose structure 






























The remaining syn-aldol-functionalised resin 227 was then treated with 0.5 equivalents of 
vanadyl acetylacetonate and 5 equivalents of tert-butyl hydroperoxide for 24 hours before the 
reaction mixture was filtered to remove the polymer and the filtrate concentrated under reduced 
























As such it can be considered that this solid supported strategy may represent a highly practical 





It has been demonstrated that chiral N-propionyl-oxazolidin-2-ones may be used in a highly 
efficient aldol/epoxidation/lactonisation protocol to afford a highly functionalised !-lactones 










































In the previous chapter we demonstrated that $-vinyl-oxazolidin-2-one derived aldol products 
undergo an efficient epoxidation/lactonisation reaction with catalytic vanadyl acetylacetonate 
and a stoichiometric equivalent of tert-butylhydroperoxide to afford chiral !-lactones. Initially, a 
chiral epoxide is generated in high levels of diastereocontrol; concomitant nucleophilic attack of 
the exo-cyclic carbonyl (via neighbouring group participation) then results in opening of the 
epoxide intermediate with a clean inversion of stereochemistry at the C5 position. Subsequent 
hydrolysis results in clean conversion to a highly functionalised hydroxy-!-butyrolactone 
containing three or more contiguous stereocentres (See previous page).  
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Concurrent to our investigation into this epoxidation/lactonisation strategy (vide supra), Dias 
and co-workers published a paper on the dihydroxylation of unsaturated aldol products 228a-e 
as effective precursors to produce chiral trisubstituted !-butyrolactone derivatives with good 
levels of diastereocontrol (See Table 4.1).167 They reported that treatment of a series of 
structurally related Evans’ derived $-vinyl-O-silyl-aldol adducts 228a-e with a catalytic amount 
of osmium tetroxide and a stoichiometric amount of N-methylmorpholine-N-oxide in 
acetone/water (8:1) yielded the free N-H oxazolidin-2-one 225 and a series of !-butyrolactones 













































































































In the same paper, Dias reported application of the same osmylation/lactonisation strategy to a 
non-silylated acrolein-derived aldol 230, which yielded lactone 232 in 40 % yield and 80% de 
that was reported to be its (5S) derivative. The reported (5S)-configuration of 232 was identical 
to that described for the OTBS protective aldol derivatives 228a-e, which were also described to 































These reaction clearly proceed via a dihydroxylation/lactonisation mechanism however the 
results reported in this paper revealed several concerns regarding the reported stereochemical 
outcome of these osmylation/lactonisation reactions. These were: 
 
(a) The relative stereochemistry of the C4/C5 positions of lactones 229b and 229c (Entries 2 and 
3) were assigned from their (J4,5) coupling constants, which as previously discussed is not 
reliable for five membered lactone systems. The conformational fluxionality of the “envelope” 
structure renders the elucidation of the stereochemical relationship of vicinal chiral centres from 



































(b) The NOE spectrum used to assign the stereochemistry of lactone 229b (Entry 2) reported 
NOE interactions of a conformationally mobile TBS protecting group. If we consider the two 
potential diastereomers, (5S)-229b and (5R)-229f, it can be seen that interactions between the 
TBS group with the newly formed exo-cyclic C5 substituents of both diastereomers can occur. 
As such, the NOE cross peaks observed for the TBS group do not enable unequivocal 

















































































Although, the stereochemical outcomes of the dihydroxylation reactions reported were inferred 
from 1H NMR and NOE spectroscopy, no consideration of the literature precedent for facial 
selectivity of these dihydroxylation reactions were considered. Dias proposed a two-step 
reaction mechanism where the alkenyl system was initially dihydroxylated followed by a 
concomitant cyclisation-elimination reaction to give the desired !-butyrolactone and N-H 
oxazolidin-2-one 225. However, close examination of literature precedent (vide infra) revealed 
that the facial selectivity of a number of the proposed dihydroxylation reactions appeared to be 
incorrect.168 
 
(c) Examination of the structures of lactones 229b and 229d (Entries 2 and 4) revealed that they 
could not possibly have been accessed from a conventional syn-dihydroxylation reaction of 
trans-alkenyl systems. Indeed, their formation would require either an anti-dihydroxylation of a 











































Given the aldol chemistry used to prepare the aldol precursors used as substrates for 
dihydroxylation, it is unlikely that Dias’ reaction proceeded from a cis-alkenyl system. 
However, it was possible that an anti-dihydroxylation product could potentially have been 
accessed via a neighbouring group participation mechanism similar to that proposed for the 
epoxidation/lactonisation reaction discussed in Chapter 3 of this thesis.  
 
In this case, osmium tetroxide would add across the alkenyl functionality of aldol 228b to 
stereoselectively generate a (cis)-osmate ester 235. Subsequent nucleophilic ring opening at C4 
of the osmate ester by intramolecular nucleophilic attack of the exo-cyclic carbonyl of the N-
acyl fragment could potentially occur with resultant inversion of the C4 stereocentre. The 
resultant imminium intermediate 236 would then be hydrolysed on workup to yield the parent 
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However, a comprehensive examination of the literature revealed that there was no precedent 
whatsoever for this type of mechanism, with no neighbouring group participation effect having 
been reported to afford anti-diol products.  
 
(d) Dias reported that treatment of Evans syn-aldol 228a (Entry 1) and the non-Evans anti-aldol 
228e (Entry 5) under the osmylation/lactonisation conditions proceeded with the same facial 
selectivity, despite the fact that they have opposing configurations at their C4 stereocentres. This 
was surprising because it would be expected that their stereogenic C4 hydroxyl-substituents 
would be likely to control the facial selectivity of these dihydroxylation reactions in a similar 
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(e) Finally, there were concerns over the spectroscopic data reported for O-TMS-lactone 229a 
(Entry 1). Dias reported that dihydroxylation/lactonisation of 1,1-disubstituted-unsaturated-
aldol  proceeds with the same selectivity as that established for our epoxidation/lactonisation 
reaction of aldol 163b generating (5S)-lactone 181b (See Chapter 3). However, even allowing 
for the presence of its O-TBS protecting group, it was clear that our spectroscopic data for 
lactone 181b was significantly different to that reported by Dias for their O-TBS-lactone 228a, 





















Since we had unequivocally proven by X-ray analysis that treatment of SuperQuat derived syn-
aldol 163c under our epoxidation/lactonisation conditions gave lactone (5S)-181c (See Chapter 
3), it was decided to dihydroxylate this syn-aldol 163c to directly compare the spectroscopic 
data of the resultant !-lactone.  
 
Treatment of unsaturated aldol 163c with osmium tetroxide (10 mol%) and N-
methylmorpholine-N-oxide under Dias’ conditions gave a new !-lactone , whose spectroscopic 
63)7*('"Z8"%,")4*(',)*!#("5!3N5'+$N4)*!+,"7'+*+;+4"1+'"*3(")-N00(*'!;"-N,*3(-!-"+1";3!')4"!O&:*N'+4);*+,(-"
\\"
data was clearly different to that of the lactone (3S,4S,5S)-181c produced in our previous 
epoxidation reaction. Therefore it follows that its newly formed C5 stereochemistry must in fact 














































In order to confirm that an Evans’ derived syn-oxazolidin-2-one auxiliary 157 would perform in 
a similar manner under these osmylation/lactonisation conditions, it was decided to 
dihydroxylate syn-aldol 163c. Towards this end, N-propionyl-oxazolidin-2-one 241 was treated 
under syn-aldol conditions (9-BBN-OTf, DIPEA, ethacrolein) to yield Evans’ $-vinyl-syn-aldol 
242 in 82% yield and >95 % de. Subsequent treatment of syn-aldol 242 with osmium tetroxide 
and N-methylmorpholine-N-oxide in acetone/water (8:1) once again resulted in (3S,4S,5R)-
lactone 240c in a comparative 78 % yield and >95% de to that obtained previously using 



































The dihydroxylation of simple 1,1-disubtituted-allylic alcohols with osmium tetroxide has been 
widely reported in the literature, with both free hydroxyl and O-silyl-protected systems 
proceeding with good levels of (anti)-diastereoselectivity (See Section 4.3 for further 
discussion).169,170 However, application of osmium catalysed dihydroxylation reaction to 
oxazolidin-2-one derived aldol products had not been reported previously prior to Dias’ paper. 
As such it was decided to investigate what effect the presence of the silyl-protecting group 
would have on the facial selectivity of the dihydroxylation reaction of this type of $-vinyl-aldol 
substrate. 
 
Therefore, $-vinyl-syn-aldol 163c was treated with TBSOTf, 2,6-lutidine in dichloromethane at 
0 °C for three hours to afford O-TBS protected aldol 243 in 85 % yield. Subsequent treatment 
under UpJohn dihydroxylation conditions gave N-H oxazolidin-2-one (225) and hydroxy-
butyrolactone (3S,4S,5R)-(244) in 65 % yield and a much reduced 50 % de when compared to 
the previous >95 % de obtained for dihydroxylation/lactonisation of unprotected O-H $-vinyl-


















































The ratio of diastereomers obtained was similar to that published by Dias for dihydroxylation of 
$-vinyl-syn-aldol 228a, however our results suggest that the configuration at the newly formed 
stereocentre was (5R), which is opposite to the (5S)-configuration that they reported. For direct 
comparison, the major diastereomer O-silyl-lactone 244 was deprotected using TBAF to access 
the O-H hydroxy-!-butyrolactone 240c. As expected 1H NMR spectroscopic analysis indicated 
that the major diastereomer was identical to that obtained previously for 
dihydroxylation/lactonisation of the free O-H unsaturated aldol 163c. Based upon these results, 
it appears that dihydroxylation of 1,1-disubstituted unsaturated aldols (O-H-aldol 163c and O-
silyl-aldol 243) proceed with an overall anti-addition to its alkene functionality to generate a 





































Given our discovery of this incorrect stereochemical assignment, it was decided to investigate 
Dias’ dihydroxylation results more fully in order to identify any further discrepancies in their 
assigned lactone structures. However, before we can rationalise the stereochemical outcome of 
these dihydroxylation reactions it is necessary to consider the potential transition states that 
operate to control the facial selectivity of dihydroxylation reactions of allylic alcohols with 
different alkene substitution patterns. 
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The direct conversion of alkenes to cis-vicinal diols using catalytic amounts of osmium 
tetroxide is one of the most powerful and widely utilised reactions in synthesis. Despite the cost 
and toxicity of osmium tetroxide, its mildness, generality, chemoselectivity and low catalyst 
loading makes it a versatile strategy to access cis-vicinal diols.168 
 
The mechanism of the catalytic osmium tetroxide dihydroxylation reaction has been widely 
investigated. Initially, osmium tetroxide adds across the alkene bond, generating an osmate ester 
249 that is subsequently hydrolysed to generate a cis-vicinal diol (248) and reduced osmium 
oxide  (Figure 4.7).171 The catalyst is subsequently regenerated in the presence of a 






































Until recently, the mechanism of the initial osmium addition across the alkene functionality was 
much debated. Originally, a concerted [3+2] cycloaddition pathway was proposed, where 
addition of O=Os=O across the carbon-carbon double bond generates a metallacycle 
intermediate (osmate ester, 249).173 In 1977, Sharpless challenged this concerted mechanism in 
favour of a step-wise process.174,175 He proposed that Os=O adds across the alkene functionality 
via a [2+2] cycloaddition with the resulting four membered metallacycle 254 undergoing 






















The debate over the mechanism of the addition pathway was subsequently solved by 
computational studies and detailed experimental investigation.176-178 Comparison of activation 
energies indicated that the concerted [3+2] cycloaddition was the favoured reaction pathway, 
with a calculated activation energy of <10 kcal mol-1, whereas the activation energy for the 
[2+2] cycloaddition was calculated as >39 kcal mol-1. Houk and Sharpless corroborated the 
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concerted [3+2] cycloaddition pathway with comparison of computed transition states, as well 
as by measuring kinetic isotope effects.179 
  
The stereoselectivity of catalytic dihydroxylation reactions of chiral allylic alcohols systems has 
also been widely investigated, although it is worthy to note that, until recently, the majority of 
the research has focussed on O-protected allylic systems. Unlike the epoxidation reaction, 
where a chelation effect predictably and reliably controls the stereochemical outcome, 
dihydroxylation of allylic alcohols does not appear to proceed with such clear predictability. 
Therefore, it is clear that the facial selectivity of these types of dihydroxylation reactions is 
dependent on many factors, with the steric demand of their allylic substituents and their alkene 




1,1-Disubstituted, 1-substituted and (E)-1,2-disubstituted allylic alcohols have been shown to 
undergo dihydroxylation with high levels of anti-diastereocontrol in catalytic osmylation 
reactions.  
 
For example, Chakraborty has previously reported the dihydroxylation of O-silyl-protected 1,1-
disubstituted allylic alcohol 255 with anti-selectivity to generate the diol 256 in 91% yield and 
















Similarly, Donohoe described that dihydroxylation of O-H allylic alcohol 257 occurs with good 
















There are several examples in the literature of the dihydroxylation of acrolein derived allylic 
systems.169,181 Blechert has demonstrated the osmium catalysed dihydroxylation reaction of the 
free allylic alcohol 259 was shown to proceed in 70% de in favour of the anti-addition product, 

































Surprisingly there are no reports in the literature on the dihydroxylation of O-silyl protected 
trans-allylic alcohols, however there are numerous publications focussed around the osmylation 
of their corresponding free allylic alcohols.169,183,184 For example, Solladié et al have previously 
reported the dihydroxylation of a chiral allylic-$-hydroxysulphoxide 263 which gave 
































Several models have been proposed to rationalise the observed anti-diastereoselectivity for both 
O-silyl-protected and free O-H allylic systems, most notable being the models described by 


































The Kishi empirical rule is based on minimisation of 1,3-allylic strain. By positioning the 
hydrogen atom HA syn-periplanar to the alkenyl functionality then A
1,3 strain is minimised 
(Figure 4.10).185,186 It is proposed that the oxidant then approaches from the opposite face to the 
electron rich oxygen group (i.e. minimising the electrostatic repulsions between the oxygen 
functionality of the allylic alcohol and osmium reagent). As such TS1 is the favoured transition 










































A1,3 strain is minimised
Favoured Transition State
A1,3 strain is maximised
Disfavoured Transition State
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However, Kishi’s model does not always corroborate experimental data. Evans described the 
dihydroxylation of several allylic systems, where increasing the size of the R-alcohol 
substituent resulted in an increase in stereocontrol rather than a decrease as Kishi’s model 
would infer.170   
 
Evans observed that his results better fitted the Houk and Vedej models. The Houk model is an 
extension of his work on the “inside alkoxy effect,” which was developed to rationalise the 
stereochemical outcome of nitrile oxide cycloaddition reactions of related allylic alcohol 
systems.187 Houk used ab initio calculations to show that TS3 which positions the hydroxyl 
functionality in an inside conformation (Figure 4.11), was lower in energy than the alternative 

























































The Vedejs model rationalises the observed stereochemical outcome by considering the steric 
implications of the positions of the alkenyl and allylic substituents that are propagated into the 
osmate ester transition state. 190,191 As such, the smallest hydrogen substituent is arranged 
parallel to the region of greatest congestion in the transition state, i.e. the hydrogen is on the 
same face as the direction of attack of the osmium tetroxide, thus minimising steric hindrance 
with the remaining groups positioned on the opposing side. The C-O bond is directed towards 
the ‘inside position’ of the double bond as in the Houk model. Consequently, the Vedejs model 












































Both Evans and Donohoe have shown that both the Vedejs and Houk models are consistent with 
the observed stereochemical trends for anti-dihydroxylation of O-H 1,1-disubstituted and trans-
1,2-allylic systems.169,170  
 
However, Donohoe has shown that this is not the case for allylic alcohol systems containing cis-
allylic substituents. For example, treatment of 2,2-disubstituted allylic system 266 under 













All of the previous examples in Section 4.4.3 have shown that both the Vedejs and Houk 
models can be used to explain the observed stereochemical trends for the dihydroxylation of O-
H 1,1-disubstituted, monosubstituted and trans-1,2-allylic systems.169,170 However, these models 
fail when considering cis-substituent. A modification of Kishi’s model can be used to rationalise 
the observed inversion in stereoselectivity for alkenes containing cis substituents, although it 
requires that the oxidant must now add from the same face as the free hydroxyl group (Figure 
Figure 4.13).169,170,189 The stereoselectivity of cis-systems is further enhanced when R is 
particularly bulky and when the alcohol is unprotected, because steric effects now dominate 








































A1,3 strain is minimised
Favoured Transition State







The literature precedent for dihydroxylation of 1,1,2-trisubtituted allylic alcohols is limited, 
Chakraborty reported that dihydroxylation of allylic alcohol 268 proceeds with syn-selectivity 






















However, Evans has shown that treatment of the trisubstituted allylic alcohol methyl ester 270 













The previously discussed 1,1-disubstituted and (E)-1,2-disubstituted systems were shown to 
proceed with an overall anti-selectivity. From these observations (Section 4.4.1), it would be 
expected that (E)-1,1,2-trisubstituted systems would also proceed with an overall anti- 
dihydroxylation, and this would indeed fit with the previously discussed Houk model. However, 
the report of syn-selectivity by Chakraborty did leave some doubts about the stereochemical 




With the selectivity of each allylic system established it is now time to return to the 
stereochemical assignments of the lactones reported by Dias and co-workers. As we have 
established, it should be noted that selectivity of dihydroxylation is not significantly altered by 
the presence of an O-silyl protecting group, and that unprotected allylic alcohols generally 
afford higher levels of diastereocontrol. Therefore, it was decided to run all subsequent 
dihydroxylation reactions upon the free allylic alcohols systems, thus limiting the need to carry 







Dias reported that methacrolein derived O-silyl-syn-aldol 228a undergoes catalytic 
dihydroxylation/lactonisation reaction to yield !-lactone 229a in 43% yield and 56% de. As 
already discussed, they implied that the dihydroxylation proceeds with syn-selectivity 




















We had already demonstrated that dihydroxylation of ethacrolein derived aldol 163c afforded a 
(5R)-lactone 240c, and as a consequence were certain that Dias’ (5S)-stereochemical assignment 
of O-silyl-lactone 229b was incorrect. In order to verify this, it was decided to apply the 
dihydroxylation reaction to the unprotected methacrolein derived syn-aldol 163b. Therefore, 
treatment of methacrolein derived syn-aldol 163b with 10 mol% osmium tetroxide and N-































Comparison of the 1H NMR spectra of the previously prepared (5S)-lactone 181b (See Chapter 
3) indicated that the dihydroxylation/lactonisation reaction does not yield the same lactone as 
generated in our epoxidation/lactonisation protocol, and consequently must have a (5R)-
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configuration.  As such the lactone generated in the dihydroxylation procedure was assigned as 
(3S,4S,5R)-240b, which was confirmed by examination of its NOE spectra. This showed a 
strong interaction between the methyl substituent of C5 interacting with the C3 proton, with the 
C5 CH2OH methylene resonance interacting strongly with the C3 methyl functionality and the C4 
hydrogen. This confirms the syn relationship of these functionalities, thus providing further 

























Dias reported that acrolein derived O-silyl-syn-aldol 228c undergoes a catalytic 
dihydroxylation/lactonisation reaction to yield !-lactone 229c in 42 % yield and 80 % de 
(Scheme 4.14). As already discussed, Dias inferred that the dihydroxylation proceeds with a 
syn-selectivity generating an (S) geometry at C5, which is opposite to the (anti)-stereoselectivity 


























Unsaturated aldol product 163a was treated with osmium tetroxide (10 mol%), N-
methylmorpholine-N-oxide with 8:1 mixture of acetone/H2O, and left to stir for forty-eight 
hours. 1H NMR spectroscopic analysis showed that the desired !-lactone had been formed as a 


































Attempts to purify the diastereomers proved unsuccessful; as such the structures and 
diastereoselectivity were assigned from the mixture of diastereomers using 1H NMR, 13C NMR, 
COSY spectroscopy and NOE spectroscopy, which allowed for complete elucidation of their 
stereochemistry. 
 
The (anti)-diastereoselectivity reported for this class of allylic alcohol predicts that the major 
diastereomer should be (3S,4S,5R)-240a1, which was confirmed from our NOE analysis. 
Therefore, the C3-proton of the major lactone 240a1 was shown to strongly interact with the C5 
proton, whilst its C4 proton, was found to strongly interact with the C5 CH2OH methylene 
protons. In turn, the minor diastereomer was assigned as (3S,4S,5S)-240a2 which was 






















As such this confirms that although this dihydroxylation reaction proceeds with a limited 
stereocontrol, the predominant facial selectivity is consistent with literature precedent, showing 
that dihydroxylation proceeds with anti-selectivity and not with syn-selectivity as reported by 






We then considered the facial selectivity of the dihydroxylation reaction of aldol 228b, which 
Dias had reported proceeds to afford lactone 229b, whose formation would have required a 






























In order to investigate the diastereoselectivity of this substitution pattern, cinnamaldehyde 
derived aldol product 163g was treated under the catalytic dihydroxylation/lactonisation 


































The major diastereomer was isolated using column chromatography and the stereochemistry 
was assigned from the ‘anti’-stereoselectivity predicted for this class of substrate and confirmed 
via NOE spectroscopy. Its NOE spectra indicated that the C3-proton interacts strongly with the 
C5-proton, whilst the C4 proton interacts strongly with both the C3 methyl group and the C5 
HC(OH)Ph, thus indicating a syn relationship between these substituents. The stereochemistry 
of the major diastereomeric lactone was therefore inferred as (3S,4S,5S)-240g1, which is 
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consistent with the osmylation reaction proceeding with anti-selectivity to the hydroxyl 





















In relation to this, a trans-crotonaldehyde derived aldol 163f was also treated under catalytic 
UpJohn dihydroxylation conditions. The resulting lactone products were inseparable from one 
another, however analysis of the 1H NMR and COSY spectra of the resultant diastereoisomers 
allowed for a complete analysis and determination of their structure. Once again, NOE 
spectroscopic analysis indicated that anti-dihydroxylation had occurred to afford (3S,4S,5S)-





































We then investigated the diastereoselectivity of dihydroxylation of O-TBS-aldol 228d, which 




























Unsaturated aldol 163i was treated with osmium tetroxide, N-methylmorpholine-N-oxide in 





















The observed high diastereoselectivity is consistent with that previously discussed for (anti)-
dihydroxylation reactions of similar 1,1-disubstituted alkene systems (Figure 4.19). NOE 
spectroscopy indicated that the proton on C3 strongly interacts with both the C5 methyl group 
and the C3 hydroxy functionality, whilst the C3 methyl group was shown to interact with the C5 
CH-OH substituent, thus confirming the (5R) stereochemistry. Therefore, given the syn-
dihydroxylation mechanisms we are able to infer that the configuration of the newly formed C6 




























Although Dias had not reported dihydroxylation of an aldol substrate with a cis-alkene 
substituent, it was decided to investigate dihydroxylation of 2,2-disubstituted aldol 163h, which 
generated a 2:1 mixture of lactones 240h1 and 240h2 under standard dihydroxylation 
conditions. This observation was consistent with the poor selectivity previously observed by 
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The two diastereomers were readily separated via column chromatography. Analysis of the 
NOE spectra indicated that the major diastereomer was the product of a syn dihydroxylation 
reaction, which is consistent with Donohoe’s observations on simple allylic systems (See 
Scheme 4.9). This was confirmed from the strong NOE between its C3 methyl group and the C5 
hydrogen indicating the syn relationship of these functionalities, which implies a (5R) 
configuration. Minor diastereomer 240h2 was also isolated; with analysis of its NOE spectra 
indicating a large interaction between its C3 hydrogen and C5 hydrogen indicating a syn 




Furthermore, comparison of the 3J coupling constants of the vicinal C4 and C5 protons of these 
lactones is consistent with their stereochemical assignments; the 3J4,5 = 7.4 Hz observed for the 
major (3S,4S,5R)-diastereomer 240h1 is consistent with a syn relationship, whereas a smaller 
3
J4,5  = 4.0Hz was observed for the minor product (3S,4S,5S)-240h2 and indicative of an anti 
configuration.  
 
It is worthy to note that the minor diastereomer (3S,4S,5S)-240h2 is equivalent to the lactone 
product generated from our epoxidation/lactonisation protocol (See Chapter 3) as confirmed 

































3Jab = 7.4 Hz







Since it was known that the selectivity of osmylation/lactonisation reaction was not only 
affected by the substitution pattern of its alkene, but also affected by the steric demand of its 
allylic substituents, it was decided to investigate what effect varying the nature of the #-
substituent might have on the dihydroxylation reaction. As such a range of methacrolein derived 
aldol products 163b and 163k-n containing different #-substituents were synthesised in >70 % 








































































































a Percentage yield after column chromatography; b Stereochemistry of lactone structures was confirmed by NOESY 
analysis and used to infer the facial selectivity of the dihydroxylation reaction; c Determined from 1H NMR spectra of 
crude reaction product; d Prepared using standard boron mediated aldol conditions (General Procedure 2); e Prepared 
using a modified boron mediated aldol (General Procedure 3); f Prepared using Magnesium catalysed non-Evans’ anti-
aldol conditions (General Procedure 4). 
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Each aldol substrate was then subjected to our standard osmylation/lactonisation conditions 
over 48 hours. It is worthy to note for the #-methyl derivative 163b a slight decrease in reaction 
selectivity is observed when compared to the ethacrolein equivalent 163c, which further 





Syn-Aldols 163b, 163k-l and anti-aldol 164n were shown to consistently generate the predicted 
anti-dihydroxylation products in reasonable diastereocontrol with only slight variations in the 
diastereoisomeric excesses observed. Therefore, it is interesting to note that for these cases 
inversion of the configuration of the #-stereocentre appears to have little effect on the 
diastereoselectivity of the dihydroxylation/lactonisation reaction. 
 
However, the diastereoselectivity of the dihydroxylation/lactonisation reaction of #-isopropyl-
derivative 163 was vastly inferior to that observed previously, proceeding in only 8% de. It is 
clear that the increased steric bulk of the #-isopropyl substituent is responsible for this reduced 
diastereoselectivity, which may be rationalised by consideration of the Houk model (Figure 
4.21). Therefore, in this case the methyl substituent of the #-isopropyl-substituent can arrange 
itself in close proximity to either face of the alkene, thus equally hindering attack to the (Re)- 






















Increased bulk under the 
site of addition increases 






Hydroxy-!-butyrolactones are widely observed in Nature and are often derived from the 
corresponding sugars. One such example is 2-deoxyribonolactone 272, which is a by-product of 
oxidatively damaged DNA.  DNA damage can be readily induced by a number of exogenous 
agents, including free radicals, UV light, and ionizing radiations and can lead to cellular death 
by apoptosis.193 In the case of oxidatively damaged DNA, reactions involving reactive oxygen 










Specifically, reactive oxygen species lead to oxidative damage of the nucleobase and 
deoxyribose moieties of nucleotides in the DNA helix. A 2-deoxyribonolactone 272 lesion is 
























2-Deoxyribonolactone 272 is also a practical synthetic precursor. Woski demonstrated that 2-
deoxyribonolactone derivative 273 can be readily converted in two steps to 1,2-dideoxy-1-$-
aryl-D-ribanose derivatives 275 (Scheme 4.21).195 These nucleoside derivatives are also of 
structural interest because they can potentially act as universal bases and as non-hydrogen 































The range of biological application and synthetic versatility make deoxysugar-derived lactones 
of particular interest as synthetic targets. Therefore, it was decided to apply our 
osmylation/lactonisation strategy to the synthesis of 2-deoxy-D-ribonolactone. It was proposed 
that deoxyribonolactone 272 could be readily accessed via osmylation/lactonisation of the 
simple acrolein derived unsaturated aldol 273 (Figure 4.23). The direct synthesis of Evans’ 
oxazolidin-2-one derived aldol products with no #-substituent is problematic, because the 
diastereoselectivity of their aldol reactions are much reduced. However, compounds of this type 
can be readily accessed from aldol reactions of the corresponding 2-chloroacetyl derived aldol 
274. Treatment of 241b under modified aldol conditions was predicted to afford an #-chloro-
syn-aldol 274 with good diastereoselectivity. Subsequent dechlorination would result in 
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reductive elimination of the chlorine atom to yield the desired aldol 275, which would then be 
















































Treatment of 2-chloroacetylated oxazolidin-2-one 241b under our modified boron mediated 
aldol conditions generated the syn-aldol 274 in 57% yield and >95% de. Subsequent treatment 
of the #-chloro-$-vinyl-aldol 274 with zinc dust and ammonium chloride in methanol readily 
eliminated the chlorine to generate the corresponding unsubstituted aldol product 275.  
 
Treatment of unsaturated aldol 275 under UpJohn conditions (Osmium tetroxide, N-
methylmorpholine-N-oxide, acetone/water (8:1)) resulted in the expected 
dihydroxylation/lactonisation reaction to afford a mixture of 2-deoxy-!-lactones 272a and 172b 
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in 50% de with no enrichment of either diastereomer in any eluted fractions. However, repeated 
separation of the diastereomers using column chromatography proved unsuccessful. 
Nevertheless, full analysis of the purified lactone mixture using 1H NMR, 13C NMR, COSY and 




















This mixture of diastereomeric !-lactones is currently being subjected to preparative HPLC 
chromatography to obtain a pure sample of 2-deoxyribinlactone. 
 
D6B !1,0&(+#1,+'
In conclusion, we have demonstrated the use of an osmylation/lactonisation strategy to access 
complimentary hydroxy-butyrolactones to those generated by epoxidation/lactonisation of 
unsaturated aldol products. It has been shown that, for 1,1-disubstituted, monosubstituted and 
1,2-disubstituted-trans-alkenyl systems, that the osmylation/lactonisation reaction proceeds 
with anti-selectivity. This is consistent with the literature for simple allylic alcohol systems 
which have been shown to proceed with comparable levels of stereocontrol.169,170 We have 
shown that Dias’ literature precedent for osmylation/lactonisation of related $-vinyl-syn-aldol 
systems was flawed; however, in their defence it should be noted that assignment of 
stereochemistry for #-lactone systems is notoriously problematic.152 This dihydroxylation 
methodology was subsequently applied to the synthesis of 2-deoxyribonolactone 272 in 
moderate de. 
..= 




Polypropionate chains are structural motifs that often contain a large number of alternating 
vicinal stereogenic methyl and hydroxy groups that decorate an aliphatic backbone.197 This 
important class of compounds form the skeleton of a wide range of important pharmaceutical 
compounds that can exhibit a wide range of chemotherapeutic activity. For example, 
erythronolide B 276 (antibacterial),198 (-)-baconipyrone 277 (antimicrobial and cytotoxicity)199 
and (+)-superstolide A 278 (cytotoxic against several cancer cell lines) all represent potentially 
































Since their discovery, the development of synthetic methodology for the asymmetric synthesis 
of polypropionates has attracted the interests of numerous synthetic organic chemists. These 
stereochemically complex targets contain multiple contiguous stereocentres, often with different 
relative configurations, and as a consequence they represent a demanding synthetic challenge to 
even the most skilled synthetic practitioner. There are many strategies that have been developed 
to access the wide range of polypropionate motifs that exist,197,200-202 with many approaches 
being based on the use of iterative aldol methodology. Whilst this approach is often successful 
in affording stereochemically complex polypropionates it is not particularly efficient since its 
success often requires a lot of redox manipulation of functional groups and the copious use of 
protection/deprotection strategies. A representative example of this approach is Guindon’s 
synthesis of a polypropionate stereopentad shown in Scheme 5.1.202-204 Initially, a Mukaiyama 
aldolisation reaction of aldehyde 279 and silyl-ketene acetal 287 in the presence of dibutylboron 
triflate generates 280, which readily undergoes a free radical hydrogen transfer reaction in the 
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presence of the Lewis acid (triethyl borane) to generate the anti-aldol 281. Subsequent 
reduction/oxidation steps generate the chiral aldehyde 284, which undergoes a further 













































Cossy has developed an alternative strategy to access polypropionates from 
cyclopropanealkanols using highly regio- and stereo-selective oxymercuration ring-opening 
reactions of hydroxy-cyclopropanes.205 Treatment of cyclopropanealkanols with mercuric 
trifluoroacetate results in coordination of a mercuric species to the hydroxyl functionality and 
electrophilic coordination to the cyclopropane with concomitant anti nucleophilic attack of a 
trifluroacetate counter-anion at the most electron-rich carbon centre of the cyclopropane ring to 
generate an organomercurial species. Subsequent hydrolysis in the presence of halide ions 
followed by radical mediated demercuration reaction results in the formation of a stereodefined 
























The application of Cossy’s oxymercuration/demercuration strategy has been extended to more 
complex systems, with stereotriads, stereotetrads and stereopentads having been accessed 
(Scheme 5.2).  For example, hydroboration of 1,1-disubstituted alkene 288 yields the primary 
alcohol 289 as a diastereomeric mixture, which can be readily purified via column 
chromatography. Subsequent oxidation of its oxygen functionality using TPAP generates an 
aldehyde, which is immediately treated with ethylmagnesium bromide to furnish a secondary 
alcohol 290 in 77:23 dr. Acetyl protection of the hydroxyl functionality proceeds in excellent 
yield with subsequent oxymercuration/demercuration/reduction to furnish the stereotetrad 292 






























Previous work in the Bull group has focussed on using temporary stereocentre methodology for 
the asymmetric synthesis of chiral cyclopropane carboxaldehydes with high levels of 
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diastereocontrol. Initially, N-acyl-oxazolidin-2-one 142a was treated under standard boron 
mediated aldol conditions to generate a syn-aldol product in high de. Treatment of syn-aldol 143 
with diethyl zinc and diiodomethane in dichloromethane at –10 °C resulted in a highly 
diastereoselective cyclopropanation reaction to yield cyclopropyl aldol 144 in 99% yield and > 
95% de. Subsequent treatment of cyclopropyl-syn-aldol 144 with LHMDS at 0 °C resulted in a 
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Since this methodology had established that a wide range of $-vinyl-syn-aldols 143 could be 
cyclopropanated cleanly with high levels of diastereocontrol,129 it was proposed that application 
of Cossy’s oxymercuration ring-opening methodology to these substrates could afford 
organomercurial lactones 294 containing three or more contiguous stereocentres with high 
levels of diastereocontrol. Subsequent reduction of the organomercurial species would then 











































Cyclopropanes have been widely reported in the literature as compounds that can readily 
undergo ring opening reactions of use in organic synthesis.206 The cyclopropane moiety is found 
in numerous natural products,207,208 a number of which display interesting properties when 
compared to conventional aliphatic systems with their ring strain energy having been calculated 
to be almost identical to that of cyclobutanes.209 As such their synthesis has attracted a great 
deal of interest, with a major breakthrough coming in 1958 when Simmons and Smith 
discovered that treatment of alkenes with diiodomethane and an activated zinc species afforded 
cyclopropanes in high yield.210,211 Since these initial studies, several modifications have been 
made to this cyclopropanation protocol,212-214 with application of these conditions to allylic 
systems having been widely investigated.215 For example, Charette has studied the directed 
cyclopropanation of numerous allylic alcohols under modified Furukawa’s conditions (diethyl 
zinc and diiodomethane), resulting in methodology that affords cyclopropyl-alcohols with 












































They observed that treatment of a range of 1,2-disubstituted allylic systems with excess of 
diethyl zinc and diiodomethane resulted in hydroxyl-directed cyclopropanations with excellent 
levels of diastereocontrol.219 The mechanism of the cyclopropanation reaction has been much 
investigated with attention having been focused on determining the nature of the active species 
responsible for asymmetric induction. Upon reaction of activated zinc with diiodomethane it is 
postulated that a “ZnCH2I” species is generated; however the actual structure of this zinc 
species has been much debated, with various halomethylzinc species having been isolated in the 
solid state.214,217,220-222 Upon addition of these active zinc species to an alkene it is envisaged that 
a zinc-carbenoid equivalent is delivered to one faces of the alkene bond via a “butterfly-type” 


















It is proposed that treatment of allylic alcohol substrates with these halomethylzinc species, 
results in coordination of zinc to the hydroxyl functionality, with a methylene equivalent then 
being delivered selectively to one of the diastereotopic faces of the alkene bond (Scheme 
4.5).224,225 The high levels of diastereocontrol observed by Charette for substituted alkenes can 
then be rationalised by consideration of the allylic strain generated in the respective 
diastereoisomeric intermediate transition states.  
 
For 1,2-disubstituted alkenes and 1,2,2-trisubstituted allylic alcohols, the absence of a sterically 
demanding group at the #-position of the allylic system means that any contributions from A1,2 
strain can be considered to be negligible. As a consequence, minimisation of A1,3 strain in the 
transition state is the dominant consideration that determines the facial selectivity of the 
cyclopropanation reaction. Therefore, for 1,2-disubstituted allylic alcohols, a carbenoid species 
is delivered to the syn-face of the alkene functionality due to A1,3 strain being minimised in the 
transition state (TS1) when compared to the transition state (TS2) required to form an anti-
cyclopropane. The presence of a cis-$-substituent increases the syn-selectivity further, as a 

























A1,3 strain is maximised
Disfavoured conformation















My initial target was therefore to use Furukawa’s modified cyclopropanation conditions 
previously developed within the group to prepare a range of cyclopropane aldol adducts 295f-j 
as substrates for the proposed oxymercuration/demercuration methodology. Therefore, syn-
aldols 163f-j were treated with diethyl zinc (5.0 equivalents) and diiodomethane (5.0 
equivalents) at -10 °C to afford a series of cyclopropane-aldols 295f-j in 95% de. Excess 
cyclopropanating reagents were used in order to ensure complete consumption of starting 
material, with the (syn)-configuration of the resultant cyclopropane-aldols being inferred from 




































































a Syn-selectivity is inferred from literature precedent and confirmed previously by X-ray crystal structure of ortho-
nitro-cinnamaldehyde derivative synthesised by Matt Cheeseman;141,226 b Isolated yields after column chromatography; 
c Diastereoisomeric excess determined from analysis of their crude 1H NMR spectra. 
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It had previously been proposed that the hydroxyl group of aldols 163f-j were solely responsible 
for the high diastereocontrol in these cyclopropanation reactions and that their other 
stereocentres played no role in determining facial selectivity. Consequently it was decided to 
take this opportunity to confirm this rationale, by examining what effect changing the steric or 
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electronic demand of the $-substituent of these aldol substrates would have on the 
diastereoselectivity of their cyclopropanation reactions. As such, #-phenyl-aldol 163o, #-
chloro-aldol 163p and #-isopropyl-aldol 163q were prepared using our standard boron aldol 
conditions and cyclopropanated under Furukawa conditions to yield their corresponding 

























































We wished to further confirm that the high diastereoselectivities observed in the 
cyclopropanation reactions of syn-aldols 295f-j and 295o-q were solely due to the 
stereodirecting effect of the $-hydroxyl stereocentre and that the oxazolidin-2-one and/or #-
methyl stereocentres were not contributing towards diastereocontrol. Therefore, it was decided 
to determine what level of diastereoselectivity would be observed for cyclopropanation of the 




Consequently, ester 297 was prepared in three steps via reaction of the (Z)-boron enolate of #-
chloro-propionyl-oxazolidin-2-one 241b with crotonaldehyde to afford syn-aldol 163p in 83% 
yield that was #-dechlorinated via treatment with zinc and ammonium chloride in methanol to 
afford syn-aldol 296 in 74% yield.196 Subsequent cleavage of the oxazolidin-2-one via treatment 
with sodium methoxide gave $-vinyl-aldol-ester 297 containing a single stereocentre in 71% 
yield. Subsequent cyclopropanation of $-vinyl-aldol-ester 297 using our previously developed 
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Therefore, since the cyclopropanation reactions of $-vinyl-N-acyl-oxazolidin-2-one 296 and $-
vinyl-aldol-ester 297 both proceed with essentially identical diastereoselectivity, we can 
conclude that the oxazolidin-2-one and #-stereocentres of $-vinyl-N-acyl-oxazolidin-2-one 163 
do not play an important role in diastereocontrol. Furthermore, these results provide compelling 
evidence that the concept of using aldol/retro-aldol reactions to reversibly generate ‘temporary’ 
$-hydroxyl stereocentres for the stereoselective functionalisation of remote allylic alkene 





The reactivity of the cyclopropane functionality is often attributed to the strain of the ring 
system with three sp3 carbon centres being confined in a ring system with C-C-C bond angles of 
60°, which is much reduced from the optimal bond angle of 109.5° normally observed for 
tetrahedral carbon centres.206 This results in cyclopropane ring systems undergoing reactions 
that are normally associated with double bond systems, meaning that they are much more 
reactive than other cyclic counterparts.  
 
Walsh’s model of the bonding that occurs in cyclopropanes envisages a ring system constructed 
of three sp2 hybridised carbon centres, that are directed towards the centre of the ring system, as 
shown in +1 (Figure 5.4).
227 This can be used to rationalise the concept of ,-aromaticity, which 
arises from occupation of the +1 orbital generating a three-centre-two-electron bond, that fits 













The presence of ,-aromaticity within its ring system accounts for the reactivity of 
cyclopropanes toward electrophiles and the upshield shift of the cyclopropane protons in their 
1H NMR spectra.206,209 Cyclopropanes employ their ,-aromatic component to coordinate to an 
adventitious electrophiles, which are then ring opened to afford stable carbocation 
intermediates, or trigger ring opening via reaction with an incipient nucleophile.228  
 
Synthetic strategies that incorporate mercury mediated intramolecular ring-opening reactions of 
cyclopropanes have been reported to generate !-lactone products.205 Collum and co-workers 
previously reported that treatment of cyclopropane methyl ester 299 with mercury(II) 
trifluoroacetate generates both a !-lactone 300 and "-lactone 301. These lactonisation reactions 
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proceeds with inversion of stereochemistry to generate a mixture of 5- and 6-membered anti-

















With this literature precedent in mind, it was decided to apply these conditions to syn-
cyclopropane aldol 295f in order to determine whether its N-acyl-oxazolidin-2-one fragment 





SuperQuat aldol 295f was treated with mercury(II) trifluoroacetate and stirred for 24 hours, 
after which time the reaction was quenched with saturated sodium chloride solution. Analysis of 
the crude 1H NMR spectrum of the crude reaction product indicated that cleavage had occurred 
to afford the parent N-H oxazolidin-2-one 157 and a new product which was tentatively 
assigned as #,$-unsaturated-"-lactone 302. This was proposed from the indicative resonance of 
its vinyl proton at " 6.34 ppm, an infra-red carbonyl absorption at 1684 cm-1, and a molecular 





                                                      
- A preliminary report of a single example of this cyclopropane ring-opening transformation appears in a 























The mechanism of formation of lactone 302 may be rationalised via a mechanism, whereby 
initial coordination of the mercury species to its cyclopropane ring system activates it to ring 
opening at its "-centre using the exocyclic carbonyl of its N-acyl-oxazolidin-2-one fragment as 
an intramolecular nucleophile. This pathway would result in an unstable cyclic imminium 
intermediate 302, whose $-hydroxyl group can potentially coordinate to the mercury atom to 
trigger an elimination reaction that generates the alkene functionality of imminium species 306. 
Subsequent hydrolysis of imminium species 306 then generates the N-H oxazolidin-2-one 157 
























































Although "-lactones that contain #,$-unsaturated functionality of this type are interesting 
synthetic targets that also appear widely in the side-chains of polyketide natural products 
(Figure 5.6), it is clear that the resultant destruction of two stereocentres that occurs in this 
reaction was far from desirable. As previously discussed, Collum reported the efficient 
generation of functionalised "-lactones 300 via treatment of cyclopropane methyl ester 299 with 
mercury(II) trifluoroacetate (Scheme 5.7), with no report of any elimination products having 
been formed.229 Consequently, it was decided to convert our SuperQuat-cyclopropyl aldols 295 


















Therefore, cyclopropyl-aldols 295f-h and 295i were treated with sodium methoxide in CH2Cl2 
for 5 minutes which resulted in clean conversion to their parent oxazolidin-2-one and 








































































a Isolated yields reported after column chromatography; b  de determined from crude 1H NMR spectroscopy, the high 
de indicates that no racemisation of the #-stereocentre occurs.  
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For the majority of aldol substrates (Entries1-5), treatment with 1.1 equivalents of sodium 
methoxide cleanly generated a 1:1 mixture of N-H oxazolidin-2-one 157 and the desired 
methyl-ester 309 in good yields with no evidence of any racemisation at their #-stereocentres. 
However, examination of the 1H NMR spectra of the methanolysis products of aldols 295o and 
295p revealed that these substrates had instead undergone a clean sodium methoxide catalysed 
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retro-aldol reaction to afford its parent oxazolidin-2-one and cyclopropyl aldehyde 310 (not 














































Therefore, it is clear that the competing retro-aldol pathway available to these aldol products is 
not accelerated by the presence of sterically demanding substituents at their #-position, since 
methanolysis of #-isopropyl aldol 295q resulted in clean conversion to its parent oxazolidin-2-
one 157 and methyl ester 309q. However, the presence of an electron withdrawing #-chloro and 
#-phenyl functionalities of aldol products 295p and 295o clearly favour retro-aldol reaction, 
presumably via stabilisation of the resultant sodium enolate intermediate 311 that is generated 












































With a range of cyclopropane methyl esters in hand, we then carried out mercury mediated ring 
opening of their cyclopropane ring systems in order to determine whether their 
oxymercuration/demercuration reactions could be used to generate chiral "-lactones retaining 




To this end, cyclopropane methyl ester 295f was treated with mercury trifluoroacetate (2.5 
equivalents) in dichloromethane at ambient temperature for 24 hours before quenching with 
saturated sodium chloride solution. To our delight, 1H NMR spectroscopic analysis revealed 
that it had been cleanly converted into its corresponding tetrasubstituted-"-mercuro-lactone 


















The structure of "-lactone 313f was confirmed from analysis of its spectroscopic data. 
Therefore, infrared analysis revealed strong absorptions at 3335 cm-1 and 1681 cm-1 
corresponding to the hydroxyl and carbonyl functionalities of its six-membered lactone ring 
respectively. The 1H NMR spectra indicated a dq at 2.43 ppm, which was indicative of a CH 
proton #- to the carbonyl group and a dq at 4.06 ppm assigned to a proton adjacent to the 
oxygen atom. The 13C NMR indicated a single carbonyl resonance at 173.2 ppm and two carbon 
centres attached to oxygen heteroatoms at 80.1 ppm and 74.8 ppm. The 199Hg NMR spectra 
indicated the presence of a species containing a single mercury atom, with a singlet present at -
933.92 ppm that is consistent for the proposed sp3 organomercurial lactone 133f.  The structure 
of lactone 313f was further confirmed by HRMS, which revealed a molecular ion [M+H]+ at 
395.0338 with a multiple isotope pattern consistent for a compound with a molecular formula of 
C8H13O3ClHg. 
 
All of the protons of lactone 313f were then assigned from examination of its 1H and COSY 
NMR spectrum, which allowed us to use NOE spectroscopy to confirm the absolute 
configuration of stereocentres of lactone 313f. Therefore, this NOE experiment revealed that the 
C3 hydrogen atom strongly interacts with the C5 hydrogen (Figure 5.8) indicating a syn 
relationship between these substituents. Further to this, the C4 hydrogen atom strongly interacts 
with the C6 hydrogen atom indicating that these functionalities are on the same face of the six-
membered ring. Given the known (2S,3S)- configuration of the syn-aldol 295f that was initially 
cyclopropanated, these NOE’s are indicative of an (R)- configuration at the newly formed C5 
and an (S)-configuration at the C6  stereocentres of lactone 313f. Further to this, coupling 
constants confirmed the relative stereochemistry with the 3J5,6 = 9.9 Hz indicating a trans 






















We considered that there were two potential mechanisms operating that would result in the 
observed inversion of stereochemistry at the " cyclopropyl centre of syn-cyclopropyl-aldol. 
Firstly, an external nucleophile mechanism could be envisaged whereby the mercury ion 
undergoes electrophilic coordination to the cyclopropane ring in methyl ester 295f followed by 
concomitant anti nucleophilic attack of a trifluroacetate counter-anion at the most electron-rich 
carbon centre of the cyclopropane ring to generate organomercurial species 315. Subsequent 
treatment with saturated sodium chloride solution would hydrolyse the resultant trifluoroacetate 

































An alternative explanation could invoke the neighbouring group participation mechanism 
described previously for the epoxidation/lactonisation reactions of $-vinyl-N-acyl-oxazolidin-2-
ones (see Chapter 3). Therefore, initial electrophilic coordination of mercury to the 
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cyclopropane ring of methyl ester 295f would facilitate intramolecular nucleophilic attack of the 
endocyclic carbonyl of its N-acyl-oxazolidin-2-one fragment to generate an oxonium 
intermediate 318, which is subsequently hydrolysed to afford the observed lactone 313f. 
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Compelling evidence that this latter neighbouring group participation mechanism was likely to 
be operating in our system comes from work from Cossy and co-workers who have previously 
reported the role of remote ester functionalities in the oxymercuration ring-opening reactions of 
cyclopropanemethanols 319.205 They rationalised their results by proposing that attack of the 
oxygen lone pair of the remote carbonyl functionality of ester 319 at the mercury-coordinated 
cyclopropane ring proceeds with inversion of stereochemistry to generate an oxonium 
intermediate 320, which on hydrolysis generates a mixture of the regioisomeric organomercuric 






















These oxymercuration conditions were then applied to ring-open a range of cyclopropane 
methyl esters 309 in good yield. Treatment of the trans-alkene derived cyclopropanes 309g and 
309q with mercury(II) trifluoroacetate yielded the desired tetra-substituted-"-lactones 313g and 
313q respectively in 83-84% yields and with high levels of diastereocontrol. These reactions 
gave only six membered lactones 313g and 313q with no !-lactone species being observed in 
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the crude 1H NMR spectra. 1H NMR and NOE analysis once again indicated that the 
oxymercuration reaction had proceeded with inversion of the "-stereocentre to generate 

































































Oxymercuration of the cis-alkene derived cyclopropane ester 309j with mercury(II) 
trifluoroacetate under these reactions did not proceed as cleanly, with the crude 1H NMR spectra 
indicating formation of a mixture of (3S,4S,5R,6R)-lactone 313j and #,$-unsaturated-"-lactone 
(5R,6R)-323 had been formed in a 3:1 ratio. Chromatographic purification of this mixture 
allowed access to both the purified tetrasubstituted lactone (3S,4S,5R,6R)-313j in 55 % yield 
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and >95% de and the #,$-unsaturated derivative (5R,6R)-323 in 30 % yield and >95 % de, 







































Further to this, treatment of gem-dimethyl aldol derivative 309h under oxymercuration 
conditions gave clean conversion to the #,$-unsaturated-"-lactone substrate 324 with no 
tetrasubstituted-"-lactone having been formed after 24 hours. The stereochemistry of this #,$-
unsaturated lactone was inferred as (5R) from consideration of the mechanism previously 


















In order to rationalise these results it was proposed that the elimination reaction of trans-
substituted cyclopropyl-aldols 309f,g,q are slower than for cyclopropyl-aldols 309j and 309h 
containing a cis-substituent. This is because the organomercurial species derived from trans-
substituted cyclopropyl-aldols 309f,g,q can adopt a chair-like conformation whose ring-
substituents all occupy stable equatorial conformations, whilst cis-substituted cyclopropyl-
aldols 309j and 309h  contain an axial C5-substituent which is less stable and more prone to 
































































All functionality arranged 
equitorially, Favoured 
conformation
All functionality arranged 
axially, Disavoured 
conformation
Three groups arranged 
equitorially and one axially, 
Favoured configuration, more 
strained than trans-equivalent









With a range of mercuro-"-lactones accessed, it was now necessary to develop a demercuration 
strategy to access the desired highly functionalised chiral-%-lactones. Initially it was decided to 
investigate the tin mediated radical demercuration methodology developed by Cossy and co-
workers.205 As such, mercuro-"-lactone 313g was treated with tributyltin hydride (1.2 equiv) 
and a catalytic amount of AIBN in dry tetrahydrofuran at ambient temperature and stirred for 30 
minutes. After this time, the reaction was hydrolysed with saturated sodium fluoride and 





















Although crude 1H NMR spectra indicated that the majority of the starting material had been 
consumed, many of the diagnostic resonances of the target lactone were swamped by the 
presence of excess tributyltin species, although its presence was confirmed from its molecular 
ion of [M+H]+ = 159.1 in its mass spectrum. All Attempts to purify the "-lactone 325 from this 
reaction to homogeneity via chromatography/distillation proved unsuccessful, because of 
residual contamination from unseparable tributyltin residues. 
 
A survey of the literature revealeded that mercuro lactones of this type could be readily 
demercurated utilising sodium borohydride.233 Therefore, mercuro-"-lactone 313f was dissolved 
in methanol and sodium hydroxide solution (2.0 M) and the resulting solution treated with 
sodium borohydride (3 equiv, 0.5 M in 2.0 M sodium hydroxide) for one minute at 0 ºC. After 
this time the reaction mixture was immediately quenched with 1.0 M hydrochloric acid solution 

















The structure of lactone 326 was confirmed from analysis of spectroscopic data. Therefore, 
infrared analysis revealed strong absorptions at 3423.7 cm-1 and 1711.8 cm-1 corresponding to 
the hydroxyl functionality and the carbonyl of a six-membered lactone respectively. The 1H 
NMR spectra indicated; a dq at 2.43 ppm, which was indicative of a CH #- to the lactone 
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carbonyl, a dq at 4.06 ppm assigned to the C6 proton which is adjacent to an electron 
withdrawing lactone oxygen. The 13C NMR spectra indicated a single carbonyl resonance at 
173.5 ppm and two carbon centres adjacent to oxygen centres at 79.0 ppm and 75.6 ppm. The 
structure of lactone 326 was further confirmed by HRMS, which revealed a molecular ion 
[M+H]+ at 159.1026 with an isotope pattern consistent for a molecular formula of C8H14O3. 
 
All of the protons of lactone 326 were assigned from examination of its 1H and COSY NMR 
spectrum, which allowed us to use NOE spectroscopy to confirm the absolute configuration of 
stereocentres of lactone 326. Therefore, this NOE experiment revealed that the C3 hydrogen 
atom strongly interacts with the C5 hydrogen (Figure 5.5) indicating a syn relationship between 
these substituents. Further to this, the C4 hydrogen atom strongly interacts with the C6 hydrogen 
atom indicating that these functionalities are on the same face of the six-membered ring. Given 
the known (2S,3S)-configuration of the syn-aldol 163f that was initially cyclopropanated, these 
NOE’s indicated the generated "-lactone as (3S,4R,5R,6S)-326 which is consistent with the 



















Further to this, mercuro-"-lactone 313h was also shown to cleanly undergo reductive 
demercuration to generate tetrasubstituted "-lactone in a comparable 73 % yield. Analysis of the 


































However, attempts to demercurate the #,$-unsaturated-"-lactone proved problematic. Treatment 
with sodium borohydride did not result in clean conversion to the desired demercurated product, 
with a complex mixture of products being observed, which according to examination of the 
crude TLC were inseparable. Further investigations into this methodology are currently 
underway in the SDB group, directed towards applying this strategy to new substrates 
containing different ring- substitution patterns. 
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We have demonstrated that $-vinyl-syn-aldols can be used as efficient precursors to access both 
tetrasubstituted "-lactones and #,$-unsaturated-"-lactones in high levels of stereocontrol (See 
Scheme 5.17). It has been shown that cyclopropanes accessed from trans-alkenyl systems are 
readily ring-opened to afford tetrasubstituted-"-lactones with high levels of diastereocontrol. 
Those cyclopropanes derived from cis-alkenyl systems proceed with less selectivity generating 















































when R' = H and R'' = Alk/Ar















































All reactions were performed under a nitrogen or argon atmosphere in oven-dried apparatus, 
unless otherwise stated. Anhydrous acetonitrile, diethyl ether, dichloromethane, hexane, toluene 
and tetrahydrofuran were obtained from an Innovative Technology Inc. PS-400-7 solvent 
purification system. All other commercially available compounds were used as obtained from 
the chemical suppliers. Analytical thin layer chromatography was carried out using 
commercially available aluminium backed plates coated with Merck G/UV254 silica gel. Plates 
were visualised under UV light (at 254 nm) or by staining with phosphomolybdic acid followed 
by heating. Flash chromatography was carried out using chromatography grade silica (60Å 
particle size, 35-70 microns) from Fisher Scientific. Samples were pre-absorbed onto silica or 
loaded as saturated solutions in an appropriate solvent. Petrol refers to the fraction of petroleum 
ether boiling at 40-60 °C. 
 
Proton NMR spectra were recorded at 300 MHz on a Brüker Avance 300 spectrometer or at 500 
MHz on a Brüker Avance 500 spectrometer. The following abbreviations are used: s, singlet; d, 
doublet; t, triplet; q, quartet; dd, doublet of doublets; ddd, doublet of doublet of doublets; ddt, 
doublet of doublet of triplets; dtd, doublet of triplets of doublets; dq, doublet of quartets; dqd, 
doublet of quartets of doublets; tt, triplet of triplets; qd, quartet of doublets; m, multiplet; app., 
apparent and br, broad. Chemical shifts % are quoted in parts per million and are referenced to 
the residual solvent peak. Coupling constants (J) are quoted to the nearest 0.1 Hz. 13C{1H} 
NMR spectra were recorded at 75 MHz on a Brüker Avance 300 spectrometer. Chemical shifts 
% are quoted in parts per million and are referenced to the residual solvent peak.  
 
Mass spectra were either recorded at the EPSRC National Mass Spectrometry Service 
Centre, Swansea or were obtained on a Brüker Daltonics micrOTOF spectrometer using either 
positive or negative electrospray ionisation (ESI) as stated. Infrared spectra were recorded on a 
Perkin Elmer Spectrum 100 FT-IR spectrometer, using a Universal ATR accessory for 
sampling, with only selected absorbances quoted as & in cm-1. All capillary melting points 
were measured using a Büchi 535 melting point apparatus and are reported uncorrected.  
 
X-ray data were collected at 150 K on a Nonius KappaCCD area detector diffractometer using 
Mo-K$ radiation (' = 0.71073 Å), and all structures were solved by direct methods and refined 
on all F2 data using SHELXL-97 suite of programs, with hydrogen atoms included in idealized 
positions and refined using the riding model. 





A solution of butyllithium (1.1 equiv) was added dropwise to a stirring solution of oxazolidin-2-
one (1.0 equiv) in dry tetrahydrofuran at -78 °C under nitrogen. The reaction was stirred for 30 
minutes, after which the appropriate acid chloride (1.1 equiv) was added dropwise and the 
reaction was allowed to warm to 0 °C over 2 hours. After this period the reaction was quenched 
with saturated ammonium chloride solution and diluted with ethyl acetate, the resulting organics 
were washed with saturated sodium hydrogencarbonate solution (enough to dissolve the white 
precipitate) and brine and dried over magnesium sulphate. The solvent was removed under 
reduced pressure and the resulting crude product was purified either by recrystallisation from an 
appropriate solvent or over a column of silica gel. 
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A solution of 9-Borabicyclo[3.3.1]nonyl trifluoromethanesulphonate (1.1 equiv, 0.5M solution 
in hexanes) was added in one portion to a stirring solution of the required N-acylated auxiliary 
(1.0 equiv) in dry dichloromethane at 0 °C under nitrogen. After 30 minutes N,N-
diisopropylethylamine (1.3 equiv) was added in one portion and stirred for a further 30 minutes 
at 0 °C. After this period the reaction mixture was cooled to -78 °C and stirred for 30 minutes, 
upon which the appropriate aldehyde (1.3 equiv) was added in one portion. The resulting 
mixture was allowed to warm to room temperature overnight and was subsequently quenched 
with Na2PO4/NaH2PO4 (pH7 buffer solution, 10 cm
3) and was stirred for 10 minutes, followed 
by the addition of hydrogen peroxide/methanol solution (1:2 mixture, 10 cm3) and stirred for up 
to 24 hours. The mixture was concentrated under reduced pressure and dissolved in 
dichloromethane, the resulting organics were washed with saturated sodium hydrogencarbonate 
solution, brine and dried over magnesium sulphate. The solvent was removed under reduced 
pressure and the resulting crude was purified either by recrystallisation from an appropriate 
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A stirring solution of S-4-benzyl-3-(2-chloroacetyl)-5,5-dimethyloxazolidin-2-one (142d, 1.0 
equiv) under nitrogen was cooled to -78 °C. A solution of dibutylboron 
trifluoromethanesulphonate (1.1 equiv, 1.0M in dichloromethane) was added dropwise over 20 
minutes and was immediately followed by the addition of N,N-diisopropylethylamine (1.25 
equiv) in one portion and was stirred for 30 minutes. After which the reaction mixture was 
allowed to warm to room temperature and stirred for 90 minutes, and was subsequently 
recooled to -78 °C and stirred for 20 minutes. After this period the appropriate aldehyde (1.25 
equiv) was added dropwise, the temperature was maintained for 5 hours. The resulting mixture 
was allowed to warm to room temperature overnight and was subsequently cooled to 0 °C, 
quenched with Na2PO4/NaH2PO4 (pH7 buffer solution, 10 cm
3), methanol (10 mL) and was 
stirred for 30 minutes. After which hydrogen peroxide (20 cm3) was added dropwise and stirred 
for 1 hour. The mixture was concentrated under reduced pressure and dissolved in 
dichloromethane, the resulting organics were washed with saturated sodium hydrogencarbonate 
solution, brine and dried over magnesium sulphate. The solvent was removed under reduced 
pressure and the resulting crude was purified over a column of silica gel. 
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Magnesium chloride (0.1 equiv) was added in one portion to a stirring mixture of N-acylated-
oxazolidin-2-one (1.0 equiv), triethylamine (2.0 equiv), trimethylsilyl chloride (1.5 equiv), 
sodium hexafluoroantimonate (0.3 equiv), the appropriate aldehyde (1.5 equiv) and dry 
ethylacetate (0.5 M) under nitrogen and was stirred at room temperature for 24 hours. The 
resulting reaction mixture was concentrated under reduced pressure; the concentrate was 
dissolved in methanol (30 ml) and trifluoroacetic acid (1 mL) and stirred for 30 minutes. After 
which the reaction mixture was concentrated under vacuum and partitioned between saturated 
sodium hydrogencarbonate and DCM, the resulting organics were washed with brine and dried 
over magnesium sulphate. The solvent was removed under reduced pressure and the resulting 
crude was purified over a column of silica gel. 
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A mixture of the aldehyde (1.0 equiv), dimethylamine hydrochloride (1.2 equiv) and 37 % 
aqueous formaldehyde (1.2 equiv) was stirred at 70 °C for 24 hours. After this time an excess of 
saturated aqueous sodium hydrogencarbonate was added; the aqueous phase was separated and 
extracted with hexane (3 x 10mL). The organics were combined, washed with brine and dried 
over magnesium sulphate. The solvent was removed under reduced pressure to afford the #-
methylene aldehyde.  
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Vanadyl acetylacetonate (0.1 equiv) was added in one portion to a stirring solution of the 
appropriate aldol product (1.0 equiv) in benzene under nitrogen. After 5 minutes, tert-butyl 
hydroperoxide (5 to 6M solution in decane, 1.1 equiv) was added in one portion and stirred. 
After one hour, 1 mL of water was added to the reaction mixture and was allowed to stir 
overnight. The resulting reaction mixture was concentrated under reduced pressure and 
immediately purified over a column of silica gel. 
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Osmium tetroxide (0.1 equiv) was added in one portion to a stirring solution of the appropriate 
aldol product (1.0 equiv) in acetone/water (8:1 ratio) under nitrogen. After 5 minutes, 4-
methylmorpholine N-oxide (50 wt. % solution in water, 1.1 equiv) was added in one portion and 
stirred for 48 hours. The resulting reaction mixture was concentrated under reduced pressure 
and immediately purified over a column of silica gel. 
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Zinc dust (4 equiv.) and ammonium chloride were added to a solution of the appropriate #-
chloro-syn-aldol (1.0 equiv.) in methanol (14 mL/g) and sonicated for 5 minutes at ambient 
temperature. The resulting reaction mixture was stirred for 3 hours under nitrogen for 3 hours. 
After this time, the reaction mixture was diluted with an excess of diethyl ether and filtered 
through a pad of Celite ® and concentrated under reduced pressure and the filtration process 
repeated. The resulting crude was purified over a column of silica gel. 
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The appropriate syn-aldol product (1 equiv.) was dissolved in dichloromethane and stirred at -10 
°C under nitrogen. Diethyl zinc (5 equiv.) was added in one portion followed by diiodomethane 
(5 equiv.). The reaction was stirred for 2 hours in the absence of light and allowed to warm to 0 
°C. The reaction was quenched with saturated sodium sulphite (5 mL) and stirred for 10 minutes 
before sufficient 1.0 M HCl was added to dissolve the white precipitate. The aqueous layer was 
separated and extracted with dichloromethane and the combined organic layers were washed 
with brine, dried over MgSO4 and concentrated to afford the crude syn-aldol cyclopropane 
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The appropriate syn-aldol cyclopropane product (1 equiv.) was dissolved in dichloromethane 
under nitrogen. A solution of sodium methoxide (1 equiv.) was added and the reaction was 
stirred for 5 minutes. The reaction was quenched with saturated ammonium chloride (5 mL) and 
the organic layer was washed with brine, dried over MgSO4 and concentrated to afford the 
crude methyl ester cyclopropane product, which was purified over a column of silica gel. 
 
_*,*$%&'S$10*-($*'<<='O)3:*$0($%/#1,'
Mercury trifluoroacetate (2.5 equiv) was added in one portion to a stirred solution of the 
appropriate cyclopropane methyl ester (1.0 equiv) in dichloromethane (10 mL). The reaction 
was stirred at ambient temperature for 24 hours, before being quenched with brine (5 mL) and 
stirred for one hour. The solution was extracted with dichloromethane, washed with saturated 
sodium hydrogen carbonate, dried over MgSO4 and concentrated to afford crude product, which 
was purified over a column of silica gel. 
 
 













The preparation of the title compound was adapted from the previously published procedure.156 
Thionyl chloride (33.1 mL, 0.45 mol, 1.1 equiv) was added dropwise to a stirring solution of L-
phenyl alanine (50 g, 0.30 mol, 1.0 equiv) in methanol (500 mL), and was allowed to react 
under nitrogen overnight. The resulting reaction mixture was concentrated under reduced 
pressure, (S)-methyl 2-amino-3-phenylpropanoate hydrochloride, 154 was subsequently 
precipitated from the concentrate by addition of diethyl ether (100 mL). The precipitate was 
filtered and washed with a further 30 mL portion of diethyl ether and the resulting product was 
carried forward without any further purification. 
 
[#]D
23 = -38 (c = 1.0 in MeOH); 1H NMR (300 MHz, MeOD) " 7.43 – 7.20 (5H, m, Ph), 4.32 
(1H, dd, CHN, J = 8.1 and 5.0 Hz), 3.78 (3H, s, CH3O), 3.20 (1H, dd, CHAHBPh, J = 14.0 and 
5.0 Hz), 3.25 (1H, dd, CHAHBPh, J = 14.0 and 5.0 Hz); 
13C (75 MHz, MeOD) " 170.9, 135.7, 
130.9, 130.6, 129.4, 55.6, 54.0, 37.8; IR (ATR) . (cm-1): 1740.7 (C=O); HRMS (ES+): m/z 
calculated for C10H13NO2 requires 180.1024 for [M+H]
+, found 180.1016; requires 










The preparation of the title compound was adapted from the previously published procedure. 
Boc2O (72.5 g, 0.332 mol, 1.1 equiv) was added in one portion to a solution of (S)-methyl 2-
amino-3-phenylpropanoate hydrochloride 154 (65.1 g, 0.302 mol, 1.0 equiv) in absolute ethanol 
(sufficient to dissolve the compound) at 0 °C. Solid sodium hydrogencarbonate (76.11 g, 0.906 
" " " 63)7*('"U8"/$7('!0(,*)4"
.ZQ"
mol, 3 equiv) was added in one portion and the reaction was stirred for 48 hours. The solvent 
was then removed under reduced pressure and the crude mixture dissolved in ether (50 cm3). 
The mixture was filtered through a pad of Celite® with diethyl ether as eluent (3 x 20 cm3). The 
solvent was removed under reduced pressure to give the crude product (S)-methyl 2-(tert-
butoxycarbonyl)-3-phenylpropanoate 155, which matched the previously published data for 
this compound.234 The crude product was carried on to the next step without further purification. 
 
[#]D
23 = -42 (c = 1.0 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 7.31-7.10 (5H, m, Ph,), 4.97 
(1H, broad d, J = 6.0 Hz, NH), 4.61 (1H, dd, J = 14.0 Hz and 6.0 Hz NCH), 3.73 (3H, s, OCH3), 
3.10 (2H, m, CH2Ph), 1.40 (9H, s, Boc); 
13C (75 MHz, CDCl3) " 172.5, 156.0, 137.3, 129.3, 
128.6, 127.4, 80.2, 54.2, 52.3, 38.2, 28.5; IR (ATR) . (cm-1): 1735.7 (C=O), 1701.6 (C=O); 
HRMS (ES+): m/z calculated for C15H21NO4 requires 280.1549 for [M+H]
+, found 









The preparation of the title compound was adapted from the previously published procedure.133 
A small volume of methyl iodide (12.97 g, 208.3 mmol, 4.0 equiv) was added to a stirring 
suspension of magnesium turnings (5.07 g, 208.3 mmol, 4.0 equiv) in dry diethyl ether (100 
mL), and gently heated to initiate the formation of Grigniard reagent, sufficient is added to 
maintain a gentle reflux. The remainder of methyl iodide was diluted with diethyl ether (50 mL) 
and added dropwise to the reaction mixture over a period of 30 minutes. The solution was 
allowed to cool to room temperature, after this period (S)-methyl 2-(tert-butoxycarbonyl)-3-
phenylpropanoate, 155 (15.27 g, 52.1 mmol, 1.0 equiv) in 50 mL of diethyl ether was added 
drop-wise to the reaction mixture over a period of 15 minutes. The reaction was stirred for 48 
hours after which the reaction mixture was quenched with Rochelle’s salt, filtered through 
Celite® and washed with ethyl acetate (3 x 20 cm3). The organics were washed with brine and 
dried over magnesium sulphate. The solvent was removed under reduced pressure to give the 
crude product (S)-tert-butyl 3-hydroxy-3-methyl-1-phenylbutan-2-ylcarbamate, 156, which 
was carried on to the next step without purification. 
 
mp 100 – 103 °C; [#]D
24 = -45.1 (c = 1.0 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 7.10 – 7.29 
(5H, m, Ph),  4.52 (1H, d, NH, J = 8.9 Hz), 3.60 (1H, m, CHN),  3.02 (1H, dd, CHAHBPh, J = 
" " " 63)7*('"U8"/$7('!0(,*)4"
.Z\"
13.5 and 3.5 Hz), 2.53 (1H, m, CHAHBPh), 1.23 (6H, s, (CH3)2), 1.20 (9H, s, t-Bu); 
13C NMR 
(75 MHz, CDCl3) " 156.9, 139.3, 129.2, 128.7, 126.4, 79.7, 73.4, 60.7, 36.4, 28.5, 27.5, 26.6; 
IR (ATR) . (cm-1): 3500 (broad OH), 3334 (NH), 1670 (C=O); HRMS (ES+): m/z calculated 
for C16H25NO3: requires 280.1907 for [M+H]









The preparation of the title compound was adapted from the previously published procedure. 156 
Potassium tert-butoxide (4.5 g, 40.3 mmol, 1.1 equiv) was added in one portion to a stirring 
solution of (S)-tert-butyl 3-hydroxy-3-methyl-1-phenylbutan-2-ylcarbamate, 156 (7.5 g, 26.0 
mmol, 1.0 equiv) in dry tetrahydrofuran (40 cm3) under nitrogen and stirred for two hours at 
room temperature. The reaction mixture was quenched with saturated ammonium chloride (10 
cm3), extracted with diethyl ether (3 x 20 cm3) washed with saturated sodium 
hydrogencarbonate solution (10 cm3), brine (10 cm3) and dried over magnesium sulphate. The 
solvent was removed under reduced pressure to yield the crude product. Purification by 
recrystallisation (diethyl ether and hexane) gave  (S)-4-benzyl-5,5-dimethyloxazolidin-2-one, 
157 (4.0 g, 19.5 mmol, 77 %) as a white solid, which matched the previously published data for 
this compound.133 
 
mp = 60 – 61 °C, [#]D
23
 = -103.0 (c = 1.0 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 7.34-7.08 
(5H, m Ph), 5.09 (1H, broad s, NH), 3.63 (1H, dd, J = 10.5 Hz and 4.0 Hz, CHN), 2.77 (1H, dd, 
J = 13.5 Hz and 4.0 Hz, CHAHBPh), 2.62 (1H, dd, J = 13.5 Hz and 10.0 Hz, CHAHBPh), 1.39 
(3H, s, (CH3)C(CH3)), 1.38 (3H, s, (CH3)C(CH3)); 
13C NMR (75 MHz, CDCl3) " 158.3, 137.3, 
129.5, 129.3, 127.6, 83.6, 63.5, 37.5, 27.9, 22.4.; IR (ATR) . (cm-1): 3254.4 (N-H), 1717.2 
(C=O); HRMS (ES+): m/z calculated for C12H15NO2 requires 206.1181 for [M+H]
+, found 















Boron trifluoride diethyl etherate (7.60 mL, 60.6 mmol) was added dropwise over 15 minutes to 
a suspension of L-Phenylalanine  (10 g, 60.5 mmol) in 70 mL of dry tetrahydrofuran. The 
resulting mixture was stirred at ambient temperature for 15 minutes and subsequently heated to 
reflux and stirred for 2 hours. Borane dimethyl sulphide complex (7.2 mL, 75.6 mmol) was 
subsequently added over 90 minutes and the solution refluxed for 16 hours before cooling to 
room temperature. After this time tetrahydrofuran/methanol (1:1, 10 mL) and sodium hydroxide 
solution (5.0 M, 50 mL) were added dropwise and the resulting mixture heated to reflux for six 
hours. The resulting precipitate was filtered and the resulting filtrate concentrated under reduced 
pressure. The resulting mixture was extracted into dichloromethane (30 mL x 3), and the 
resulting organics were washed with brine and dried over magnesium sulphate. Purification of 
the resulting pale yellow solid by recrystallisation (diethyl ether and hexane) gave  (S)-2-
amino-3-phenylpropan-1-ol, 327 (7.9 g, 52.1 mmol) as a white solid in 85% yield. 
 
mp = 83 – 84 °C; [#]D
24
 = -21.0 (c = 1.0 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 7.20-7.35 
(5H, m, Ph), 3.65 (1H, dd, J = 10.5 Hz and 3.4 Hz, CHAHBOH), 3.40 (1H, dd, J = 10.5 Hz and 
7.4 Hz, CHAHBOH), 3.10 (1H, m, CHN), 2.80 (1H, dd, J = 13.5 Hz and 5.5 Hz, CHAHBPh), 
2.55 (1H, dd, J = 13.5 Hz and 8.7 Hz, CHAHBPh), 1.68 (3H, br. s, OH, NH2); 
13C NMR (75 
MHz, CDCl3) " 139.0, 129.6, 129.1, 126.8, 66.3, 54.6, 41.1; IR (ATR) . (cm
-1): 3330 (broad N-









(S)-2-Amino-3-phenylpropan-1-ol 327 (10 g, 66.3 mmol, 1.0 equiv), anhydrous potassium 
carbonate (0.92 g, 6.63 mmol, 0.1 equiv.) and diethyl carbonate (16.07 ml, 132.6 mmol, 2.0 
equiv) were placed in round bottom flask fitted with Vigreux column and distillation head and 
" " " 63)7*('"U8"/$7('!0(,*)4"
.WP"
receiving flask. The mixture was heated to 135 °C and stirred for 4 hours, after which time the 
resulting pale yellow solution was cooled to room temperature, diluted with dichloromethane 
and washed with water and brine. The resulting organics were dried over magnesium sulphate 
and concentrated under reduced pressure to yield the crude product. Recrystallisation from hot 
ethyl acetate and hexane yielded (S)-4-benzyloxazolidin-2-one, 225 (8.57 g, 48.4 mmol, 73 %) 
as white solid. 
 
mp = 83 – 85 °C; [#]D
24 = 5.5 (c = 0.66 in EtOH); 1H NMR (300 MHz, CDCl3) " 7.27-7.38 (3H, 
m, Ph), 7.20 (2H, app. d, J = 7.0 Hz, Ph), 5.05 (1H, br. s, NH), 4.50 (1H, app. t, J =8.5 Hz 
CHAHBOH), 4.20 (1H, m, CHAHBOH), 4.10 (1H, m, CHN), 2.90 (1H, m, CH2Ph); 
13C NMR (75 
MHz, CDCl3) " 160.1, 136.3, 129.5, 129.3, 127.5, 70.1, 54.2, 41.8; IR (ATR) . (cm
-1): 3278.7 
(N-H), 1746.9 (C=O); HRMS (ES+): m/z calculated for C10H11NO2: requires 178.0863 for 










The title compound was prepared according to General Procedure 1 from (S)-4-benzyl-5,5-
dimethyloxazolidin-2-one, 157 (2.0 g, 9.75 mmol), butyllithium (2.5 M in hexanes, 4.29 mL, 
10.76 mmol) and propionyl chloride (1.02 mL, 9.75 mmol). Purification by recrystallisation 
(diethyl ether and hexane) gave (S)-4-benzyl-5,5-dimethyl-3-propionyloxazolidin-2-one 142a as 
a white solid (2.40 g, 9.16 mmol, 94%). 
 
[#]D
24 = -46.0 (c = 1.0 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 7.33-7.21 (5H, m, Ph), 4.50 
(1H, dd, J = 9.5, 4.0 Hz, NCH), 3.15 (1H, dd, J = 14.5, 4.0 Hz, CHAHBPh), 2.96-2.84 (3H, m, 
CHAHBPh, CH2CH3), 1.37 (3H, s, CCH3), 1.36 (3H, s, CCH3), 1.14 (3H, t, J = 7.5 Hz, 
CH2CH3); 
13C NMR (75 MHz, CDCl3)  " 174.3, 137.0, 129.1, 128.6, 126.8, 82.2, 63.5, 35.4, 
30.9, 29.3, 28.6, 22.3, 8.3; IR (KBr)/ cm-1 . = 1774 (C=O), 1708 (C=O); HRMS (ESI): m/z for 
C15H20NO3 requires [M+H]
+ requires 262.1438; found 261.1442; 
 
 











The title compound was prepared according to General Procedure 1 from (S)-4-benzyl-5,5-
dimethyloxazolidin-2-one, 157 (3.048 g, 14.80 mmol), butyllithium (2.5 M in hexanes, 6.6 mL, 
16.30 mmol) and chloroacetyl chloride (1.42 mL, 17.80 mmol). Purification by recrystallisation 
(diethyl ether and hexane) gave (S)-4-benzyl-3-(2-chloroacetyl)-5,5-dimethyloxazolidin-2-
one, 142d as a pale yellow solid (2.87 g, 10.21 mmol, 69 %). 
 
Rf (CH2Cl2) = 0.74; [#]D
25
 = +40 (c = 1.0 in CHCl3); 
1H NMR (300 MHz, CDCl3) "7.34-7.19 
(5H, m, Ph), 4.56 (1H, d, J = 12.5 Hz, CHAHBBr), 4.49 (1H, dd, J = 10.0 Hz and 4.0 Hz, CHN), 
4.42 (1H, d, J = 12.5 Hz, CHAHBBr), 3.18, (1H, dd, J = 14.5 Hz and 4.0 Hz, PhCHAHB), 2.89 
(1H, dd, J = 14.5 Hz and 10.0 Hz, PhCHAHB), 1.38 (3H, s, (CH3)C(CH3)), 1.37 (3H, s, 
(CH3)C(CH3)); 
13C NMR (75 MHz, CDCl3) " 166.7, 152.3, 137.1, 129.4, 129.2, 127.4, 84.0, 
63.4, 35.3, 29.0, 28.7, 22.7; IR (ATR) . (cm-1): 1787.4 (C=O), 1711.4 (C=Oox); HRMS (ES+): 
m/z calculated for C14H16ClNO3 requires 304.0716 for [M+Na]










The title compound was prepared according to General Procedure 1 from (S)-4-benzyl-5,5-
dimethyloxazolidin-2-one, 157 (991.0 mg, 4.83 mmol), butyllithium (2.5 M in hexanes, 2.12 
mL, 5.31 mmol) and phenylacetyl chloride (0.83 mL, 6.28 mmol). Purification by 
recrystallisation (diethyl ether and hexane) gave (S)-4-benzyl-5,5-dimethyl-3-(2-
phenylacetyl)oxazolidin-2-one, 142c as a white solid (1.11 g, 3.43 mmol, 71 %). 
 
Rf (CH2Cl2) = 0.45; [#]D
25 = -17.0 (c = 0.73 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 7.37-7.19 
(10H, m, Ph), 4.50 (1H, dd, J = 10.0 Hz and 4.0 Hz, CHN), 4.30 (2H, app. s, COCH2), 3.18 
" " " 63)7*('"U8"/$7('!0(,*)4"
.W<"
(1H, dd, J = 14.5 Hz and 10.0 Hz, CHAHBPh), 2.85 (1H, dd, J = 14.5 Hz and 4.0 Hz, 
CHAHBPh), 1.37 (3H, s, (CH3)C(CH3), 1.32 (3H, s, (CH3)C(CH3)); 
13C NMR (75 MHz, CDCl3) 
" 171.9, 153.0, 137.2, 134.1, 130.1, 129.5, 129.1, 129.0, 127.6, 127.2, 82.8, 64.2, 42.2, 35.6, 
29.0, 22.7; IR (ATR) . (cm-1): 1766.4 (C=O); 1712.7 (C=Oox); HRMS (ES+): m/z calculated for 
C20H21NO3 requires 324.1600 for [M+H]
+, found 324.1607; requires 346.1419 for 










The title compound was prepared according to General Procedure 1 (S)-4-benzyl-oxazolidin-2-
one, 225 (6.18 g, 34.90 mmol) butyllithium (2.5 M in hexanes, 15.36 mL, 38.39 mmol) and 
propionyl chloride (3.65 mL, 41.8 mmol). Purification by recrystallisation (diethyl ether and 
hexane) gave (S)-4-benzyl-3-propionyloxazolidin-2-one, 241 as a white solid (5.61 g, 24.08 
mmol, 69 %). 
 
mp = 41-42 °C, [#]D
26
 = + 90.4 (c = 0.95 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 7.25-7.19 
(5H, m, Ph), 4.65 (1H, m, NCH), 4.10 (2H, m, CH2O), 3.25 (1H, dd, J = 13.5, 3.5 Hz, 
CHAHBPh), 2.88 (2H, m, CH2CH3), 2.72 (1H, dd, J = 13.5, 9.5 Hz CHAHBPh), 1.14 (3H, t, J = 
7.3 Hz, CH2CH3); 
13C NMR (75 MHz, CDCl3)  " 174.6, 154.1, 135.6, 129.7, 129.3, 127.9, 66.5, 
55.4, 38.3, 29.1, 8.8; IR (ATR) . (cm-1):  1782.0 (C=O), 1699.3 (C=Oox); HRMS (ESI): m/z 
calculated for C13H16NO3: requires: 234.1130 for [M+H]
+; found: 234.1134; requires 256.0950 






















9-Borabicyclo[3.3.1]nonyl trifluoromethanesulphonate (3.78 mL, 1.89 mmol) was added to a 
solution of (S)-4-benzyl-5,5-dimethyl-3-propionyloxazolidin-2-one, 142a (0.400 g, 1.71 mmol) 
in dichloromethane (90 mL) followed by addition of N,N-diisopropylethylamine (0.43 ml, 2.45 
mmol) and acrolein (0.16 mL, 2.45 mmol) according to General Procedure 2 to afford the crude 
product as a pale yellow oil. Purification via column chromatography afforded (S)-4-benzyl-3-
((2S,3R)-3-hydroxy-2-methylpent-4-enoyl)-5,5-dimethyloxazolidin-2-one, 163a (0.26 g, 0.90 
mmol, 53 %) as a colourless oil. 
 
Rf (CH2Cl2) = 0.13; 
1H NMR (300 MHz, CDCl3) " 7.26-7.12 (5H, m, Ph), 5.83-5.70 (1H, ddd, J 
= 10.5 Hz, 5.5 Hz and 5.275 Hz, CH=CH2), 5.25 (1H, dt, J = 1.5 Hz, CHcisHtrans=C), 5.13 (1H, 
dt, J = 10.5 Hz and 1.5 Hz, CHcisHtrans=C), 4.49 (1H, dd, J = 9.0 Hz and 4.5 Hz, CHN), 4.38 
(1H, m, CHOH), 3.85 (1H, dq, J = 7.0 Hz and 4.0 Hz, CHCH3), 3.0 (1H, dd, J = 14.5 Hz and 
4.5 Hz, CHAHBPh), 2.85 (1H, dd, J =14.5 Hz and 9.0 Hz, CHAHBPh), 2.65 (1H, broad s, OH), 
1.33 (3H, s, (CH3)C(CH3)), 1.31 (3H, s, (CH3)C(CH3)), 1.10 (3H, d, J = 7.0 Hz, CH3CH); 
13C 
NMR (75 MHz, CDCl3) " 176.9 152.8, 137.7, 137.0, 129.5, 129.1, 127.3, 116.8, 82.8, 73.2, 
63.8, 42.85, 35.9, 28.8, 22.6, 11.7; IR (ATR) . (cm-1): 3501.1 (broad OH), 1754.2 (C=O), 
1702.2 (C=Oox); HRMS (ESI); m/z calculated for C16H19NO4: requires 290.1392 for [M+H]
+; 
























9-Borabicyclo[3.3.1]nonyl trifluoromethanesulphonate (9.46 mL, 4.7 mmol) was added to a 
solution of (S)-4-benzyl-5,5-dimethyl-3-propionyloxazolidin-2-one, 142a (1.080 g, 4.3 mmol) 
in dichloromethane (90 mL) followed by addition of N,N-diisopropylethylamine (0.94 ml, 5.37 
mmol) and ethacrolein (0.450 g, 5.37 mmol) according to General Procedure 2 to afford the 
crude product as a pale yellow oil. Purification via column chromatography afforded (S)-4-
benzyl-3-((2S,3S)-3-hydroxy-2-methyl-4-methylenehexanoyl)-5,5-dimethyloxazolidin-2-




 = -36 (c = 1.0 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 7.34-7.20 (5H, m, Ph), 5.16 (1H, 
app. t, J = 1.0 Hz, CHcisHtrans=C), 4.98 (1H, app. t, J = 1.0 Hz, CHcisHtrans=C), 4.53 (1H, dd, J = 
9.0 Hz and 4.0 Hz, CHN), 4.40 (1H, d, J = 3.5 Hz, CHOH), 3.96 (1H, qd, J = 7.0 Hz and 3.5 
Hz, CHCO), 3.08 (1H, dd, J = 14.0 Hz and 4.0 Hz, CHAHBPh), 2.91 (1H, dd, J =14.0 Hz and 
9.5 Hz, CHAHBPh), 2.91 (1H, br. s, OH), 2.02 (2H, m, CH2CH3) 1.40 (3H, s, (CH3)C(CH3)), 
1.38 (3H, s, (CH3)C(CH3)), 1.11 (3H, d, J = 7.0 Hz, CH3CH), 1.07 (3H, t, J = 7.0, CH3CH2); 
13C 
NMR (75 MHz, CDCl3) " 177.5, 152.6, 150.3, 137.0, 129.5, 129.1, 127.3, 109.9, 82.7, 74.1, 
63.8, 41.1, 35.8, 28.8, 25.7, 22.6, 12.5, 11.1; IR (thin film / cm-1) 3497 (broad O-H), 1773 
(C=Oox), 1700 (C=O); HRMS (ES+): m/z calculated for C20H27NO4: requires 346.2013for 
























9-Borabicyclo[3.3.1]nonyl trifluoromethanesulphonate (9.7 mL, 4.85 mmol) was added to a 
solution of (S)-4-benzyl-5,5-dimethyl-3-propionyloxazolidin-2-one, 142a (1.0551 g, 4.04 
mmol) in dichloromethane (100 mL) followed by addition of N,N-diisopropylethylamine (0.46 
ml, 4.85 mmol) and methacrolein (0.46 mL, 4.85 mmol) according to General Procedure 2 to 
afford the crude product as a coloured oil. Purification via column chromatography afforded 
(S)-4-benzyl-3-((2S,3S)-3-hydroxy-2,4-dimethylpent-4-enoyl)-5,5-dimethyloxazolidin-2-




 = -34 (c = 1.0 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 7.35-7.19 (5H, m, Ph), 5.12 (1H, 
app. t, J = 1.1 Hz, CHcisHtrans=C), 4.96 (1H, app. t, J = 1.1 Hz, CHcisHtrans=C), 4.53 (1H, dd, J = 
9.0 Hz and 4.5 Hz, CHN), 4.43 (1H, m, CHOH), 3.98 (1H, qd, J = 7.0 Hz and 4.0 Hz, CHCO), 
3.08 (1H, dd, J = 14.5 Hz and 4.5 Hz, CHAHBPh), 2.91 (1H, dd, J =14.5 Hz and 9.0 Hz, 
CHAHBPh), 2.84 (1H, broad s, OH), 2.40 (3H, s, CH3C=C), 1.42 (3H, s, (CH3)C(CH3)), 1.39 
(3H, s (CH3)C(CH3)), 1.29 (3H, d, J = 7.0 Hz, CH3CH); 
13C NMR (75MHz, CDCl3) " 177.4, 
152.7, 144.3, 137.0, 129.5, 129.0, 127.3, 112.3, 82.8, 74.6, 63.8, 40.8, 35.8, 28.8, 22.6, 19.7; 
11.0; IR (KBr / cm-1) 3501 (broad O-H), 1770 (C=Oox), 1685 (C=O); HRMS (ES+): m/z 
calculated for C19H25NO4: requires 354.1681 for [M+Na]








Octanal (10 mL, 64.0 mmol), formaldehyde (6.3 mL, 84.4 mmol, 37% in water) and 
dimethylamine hydrochloride (6.89 g, 84.4 mmol) were treated according to General Procedure 
5. Concentration of the combined organics yielded 2-methyleneoctanal, 165 (6.91 g, 49.28 
mmol, 77 %) as a clear oil without the need for further purification. 
 
" " " 63)7*('"U8"/$7('!0(,*)4"
.WU"
1H NMR (300 MHz, CDCl3) " 9.50 (1H, s, CHO), 6.18 (1H, s, C=CHAHB), 5.93 (1H, s, 
C=CHAHB), 2.20 (1H, t, J = 7.5 Hz, CH2C=CH2), 1.17-1.27 (8H, br. m, (CH2)4), 0.87 (3H, 
CH3CH2); 
13C NMR (75 MHz, CDCl3) " 196.0, 150.7, 134.2, 30.5, 20.3, 27.4, 26.7, 23.1, 14.7; 












9-Borabicyclo[3.3.1]nonyl trifluoromethanesulphonate (8.58 mL,  4.29 mmol) was added to a 
solution of (S)-4-benzyl-5,5-dimethyl-3-propionyloxazolidin-2-one, 142a (1.020 g, 3.90 mmol) 
in dichloromethane (100 mL) followed by addition of N,N-diisopropylethylamine (0.88 mL, 
5.07 mmol) and 2-methyleneoctanal (0.711 mg, 5.03 mmol) according to General Procedure 2 
to afford the crude product as a yellow oil. Purification via column chromatography afforded 
(S)-4-benzyl-3-((2S,3S)-3-hydroxy-2-methyl-4-methylenedecanoyl)-5,5-dimethyloxazolidin-




 = -27.8 (c = 1.15 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 7.33-7.19 (5H, m, Ph), 5.15 
(1H, app. s, CHcisHtrans=C), 4.96 (1H, m, CHcisHtrans=C), 4.53 (1H, dd, J = 9.0 Hz and 4.5 Hz, 
CHN), 4.38 (1H, d, J = 3.4 Hz, CHOH), 3.95 (1H, qd, J = 7.2 Hz and 3.4 Hz, CHCO), 3.08 (1H, 
dd, J = 14.5 Hz and 4.5 Hz, CHAHBPh), 2.90 (1H, dd, J =14.5 Hz and 9.0 Hz, CHAHBPh), 2.76 
(1H, br. s, OH), 1.98 (2H, m, CH2C=C) 1.45 (2H, m, CH2CH3) 1.39 (3H, s, (CH3)C(CH3)), 1.37 
(3H, s, (CH3)C(CH3)), 1.28 (6H, m, (CH2)3), 1.11 (3H, d, J = 7.2 Hz, CH3CH), 0.87 (3H, t, J = 
7.0, CH3CH2); 
13C NMR (75 MHz, CDCl3) " 177.7, 152.6, 148.8, 137.0, 129.5, 129.1, 127.3, 
110.8, 82.7, 73.8, 63.8, 41.0, 35.8, 33.1, 32.1, 29.5, 28.8, 28.27, 23.0, 22.6, 14.5, 11.0 ; IR (thin 
film / cm-1) 3499 (broad O-H), 1780 (C=Oox), 1700 (C=O); HRMS (ES): m/z calculated for 
C24H35NO4: requires 402.2639 for [M+H]


















According to General Procedure 4, to a stirring mixture of (S)-4-benzyl-5,5-dimethyl-3-
propionyloxazolidin-2-one (100 mg, 0.38 mmol) in dry ethyl acetate (2 mL) was added 
magnesium chloride (7.3 mg, 0.076 mmol), sodium hexafluoroantimonate (29.5mg, 0.114 
mmol), triethylamine (0.11 mL, 0.76 mmol), trimethylsilyl chloride (0.07 mL, 0.57 mmol) and 
the 2-methyleneoctanal (64 mg, 0.46 mmol) under nitrogen and was stirred at room temperature 
for 48 hours. The resulting reaction mixture was filtered through a pad of Celite® and washed 
with diethyl ether and concentrated under reduced pressure. The concentrate was dissolved in 
methanol (30 ml) and trifluoroacetic acid (1 mL) and stirred for 30 minutes. The resulting crude 
was purified via column chromatography to yield (S)-4-benzyl-3-((2R,3S)-3-hydroxy-2-
methyl-4-methylenedecanoyl)-5,5-dimethyloxazolidin-2-one, 146 (101.9 mg, 0.253 mmol, 67 




 = -42.1 (c = 1.2 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 7.15-7.31 (5H, m, Ph), 5.03 
(1H, app. s, CHcisHtrans=C), 4.91 (1H, m, CHcisHtrans=C), 4.47 (1H, dd, J = 9.8 and 3.4 Hz, CHN), 
4.14 (2H, m, CHOH and CHCO), 3.15 (1H, dd, J =14.7 and 3.4 Hz CHAHBPh),  2.83 (1H, dd, J 
= 14.7 and 9.8 Hz, CHAHBPh), 2.77 (1H, br. s, OH), 2.10 (1H, m, CHAHBC=C), 2.0 (1H, m, 
CHAHBC=C), 1.46 (2H, m, CH2CH3), 1.33 (3H, s, (CH3)C(CH3)), 1.31 (3H, s, (CH3)C(CH3)), 
1.28 (6H, m, (CH2)3), 1.13 (3H, d, J = 6.4 Hz, CH3CH), 0.87 (3H, t, J = 6.7 Hz, CH3CH2); 
13C 
NMR (75 MHz, CDCl3) " 177.5, 153.2, 149.7, 137.5, 129.4, 129.1, 127.2, 112.4, 82.7, 79.1, 
64.5, 41.3, 35.6, 32.2, 31.4, 29.6, 28.9, 28.3, 23.0, 22.7, 15.4, 14.5; IR (ATR) . (cm-1): 3499 
(broad O-H), 1780 (C=O), 1700 (C=O); HRMS (ES): m/z calculated for C24H35NO4: requires 














Isovaleraldehyde (10 mL, 0.08 mol), formaldehyde (9 mL, 37% in water) and dimethylamine 
hydrochloride (9.12 g, 0.23 mol) were treated according to General Procedure 5. Concentration 
of the combined organics yielded 3-methyl-2-methylenebutanal, 164 (8.53 g, 88%) as a clear 
oil without the need for further purification. 
 
1H NMR (300 MHz, CDCl3) " 9.49 (1H, s, CHO), 6.18 (1H, s, C=CHAHB), 5.90 (1H, s, 
C=CHAHB), 2.69 (1H, d.sept, J = 7.0 Hz and 1.1 Hz, CH(CH3)2), 1.17-1.27 (6H, d, J = 7.0 Hz, 
CH(CH3)2), 1.18 (3H, CH3CH2); 
13C NMR (75 MHz, CDCl3) " 193.7, 156.0, 132.1 , 25.3, 19.8; 












9-Borabicyclo[3.3.1]nonyl trifluoromethanesulphonate (13.2 mL, 6.61 mmol) was added to a 
solution of (S)-4-benzyl-3-propionyloxazolidin-2-one, 142a (1.4023 g, 6.01 mmol) in 
dichloromethane (100 mL) followed by addition of N,N-diisopropylethylamine (1.50 ml, 8.59 
mmol) and 3-methyl-2-methylenebutanal, 164 (0.46 mL, 4.85 mmol) according to General 
Procedure 2 to afford the crude product as a coloured oil. Purification via column 
chromatography afforded (S)-4-benzyl-3-((2S,3S)-3-hydroxy-2,5-dimethyl-4-
methylenehexanoyl)oxazolidin-2-one, 163d (1.708 g, 4.82 mmol, 71%) as a colourless oil 
which was recrystallised from Et2O and petroleum ether.  
 
mp = 97-99 °C; [#]D
27
 = +38.9 (c = 0.88 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 7.34-7.07 
(5H, m, Ph), 5.13 (1H, t, J = 1.1 Hz, CHcisHtrans=C), 4.98 (1H, t, J = 1.1 Hz, CHcisHtrans=C), 4.65 
(1H, CHN), 4.43 (1H, br. d, J = 2.1 Hz, CHOH), 4.22 - 4.07 (2H, m, CH2O), 3.89 (1H, dq, J = 
7.2 and 3.2 Hz, CHCO), 3.20 (1H, dd, J = 13.45 and 3.25 Hz, CHAHBPh), 2.82 (1H, br. s, OH), 
" " " 63)7*('"U8"/$7('!0(,*)4"
.WJ"
2.73 (1H, dd, J = 13.6 and 9.5 Hz, CHAHBPh), 2.13 (1H, p, J = 6.9 Hz), 1.13 (3H, d, J = 6.9 Hz, 
CH3), 1.02 (3H, d, J = 6.8 Hz, CH3), 0.99 (3H, d, J = 6.9 Hz, CH3); 
13C NMR (75 MHz, CDCl3) 
" 177.7, 155.2, 153.37, 135.4, 129.8, 129.4, 127.9, 108.8, 72.8, 66.6, 55.6, 40.8, 38.1, 30.8, 
23.8, 22.3, 10.6; IR (thin film / cm-1) 3684.3 (broad O-H), 1781.2 (C=Oox), 1681.1 (C=O); 
HRMS (ESI): m/z calculated for C19H25NO4: requires 354.1681 for [M+Na]












9-Borabicyclo[3.3.1]nonyl trifluoromethanesulphonate (7.08 mL, 3.539 mmol) was added to a 
solution of (S)-4-benzyl-5,5-dimethyl-3-propionyloxazolidin-2-one, 142a (841 mg, 3.217 
mmol) in dichloromethane (100 mL) followed by addition of N,N-diisopropylethylamine (0.73 
mL, 4.182 mmol) and 2-methyl-pent-2-enal (0.477 mL, 4.182 mmol) according to General 
Procedure 2 to afford the crude product as a dark yellow oil. Purification via column 
chromatography afforded (S)-4-benzyl-3-((2S,3S,E)-3-hydroxy-2,4-dimethylhept-4-enoyl)-




 = -5 (c = 1.0, CHCl3); 
1H NMR (300 MHz, CDCl3) " 7.27-7.12 (5H, m, Ph), 6.51 (1H, tt, 
J = 7.0 Hz and 1.5 Hz, C=CH), 4.45 (1H, dd, J = 9.0 Hz and 4.5 Hz), 4.23 (1H, br. s), 3.91 (1H, 
dq, J = 7.0 and 4.0 Hz), 3.10 (1H, dd J = 14.5 and 4.5 Hz), 2.84 (1H, dd, J = 14.5 and 9.0 Hz), 
2.84 (1H, broad d), 2.1 – 1.9 (2H, m), 1.53 (3H, s), 1.32 (3H, s), 1.29 (3H, s), 1.00 (3H, d, J = 
7.0 Hz) 0.90 (3H, t, J = 7.5 Hz); 13C NMR (75 MHz, CDCl3) " 177.3, 152.7, 137.1, 133.4, 
129.5, 129.0, 128.8, 127.2, 82.67, 76.1, 63.8, 41.1, 35.8, 28.7, 22.5, 21.3, 14.4, 13.5, 11.5; IR 
(ATR) . (cm-1): 3493 (broad O-H), 1777 (C=O), 1680 (C=O); HRMS (ES): m/z calculated for 
C21H29NO4 requires 382.1994 for [M+Na]



















9-Borabicyclo[3.3.1]nonyl trifluoromethanesulphonate (6.31 mL, 3.157 mmol) was added to a 
solution of (S)-4-benzyl-5,5-dimethyl-3-propionyloxazolidin-2-one, 142a (750 mg, 2.87 mmol) 
in dichloromethane (100 mL) followed by addition of N,N-diisopropylethylamine (0.65 ml, 3.73 
mmol) and 2-octynal (0.53 mL, 3.73 mmol) according to General Procedure 2 to afford the 
crude product as a yellow oil. Purification via column chromatography afforded (S)-4-benzyl-3-
((2S,3S)-3-hydroxy-2-methyldec-4-ynoyl)-5,5-dimethyloxazolidin-2-one, 170 (929.4 mg, 




 = -7.5 (c = 0.75 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 7.27-7.15 (5H, m), 4.63 (1H, 
m), 4.50 (1H, dd, J = 9.0 Hz and 4.5 Hz), 3.84 (1H, qd, J = 7.0 and 4.5 Hz), 3.00 (1H, dd J = 
14.0 Hz and 4.5 Hz), 2.85 (1H, dd, J = 14.0 Hz and 9.0 Hz), 2.66 (1H, d, J = 4.0 Hz, OH), 2.12 
(2H, app. td, J = 7.0 Hz and 2.5 Hz), 1.48-1.19 (6H, m), 1.33 (3H, s), 1.31 (3H, s), 1.25 (3H, d, 
J = 7.0 Hz), 0.82 (3H, t, J = 7.0 Hz); 13C NMR (75MHz, CDCl3) "  176.0, 152.6, 137.1, 129.6, 
129.0, 127.3, 87.0, 83.0, 78.9, 64.0, 63.8, 44.6, 36.0, 31.4, 26.8, 26.5, 22.6, 19.1, 14.3, 12.8; IR 
(film / cm-1): 3494 (broad OH), 1778 (C=Oox), 1698 (C=O); HRMS (ES): m/z calculated for 
C23H31NO4 requires 386.2326 for [M+H]












Lindlar’s catalyst (10 mol%) was added to a solution of alkyne-aldol 170 (230 mg, 0.60 mmol) 
in dry methanol (10 mL), and the reaction mixture stirred under one atmosphere of hydrogen for 
one hour before the crude reaction mixture was filtered through Celite® using dichloromethane 
" " " 63)7*('"U8"/$7('!0(,*)4"
.U."
(3 x 10 mL) as an eluent. The combined solvent was removed under reduced pressure to give a 
crude product, that was purified by chromatography to afford the title compound (S)-4-benzyl-
3-((2S,3R,Z)-3-hydroxy-2-methyldec-4-enoyl)-5,5-dimethyloxazolidin-2-one, 163j (220 mg, 




 = -28 (c = 0.75, CH2Cl2); 
1H NMR (300 MHz, CDCl3) " 7.27- 7.12 (5H, m), 5.48 (1H, 
dtd, J = 11.0, 7.0, 1.0 Hz), 5.36 (1H, ddt, 11.0, 8.5, 1.5 Hz), 4.62 (1H, dd, J = 8.5, 5.0 Hz), 4.45 
(1H, dd, J = 9.0, 4.5 Hz), 3.89 (1H, qd, J = 7.0, 5.0 Hz), 3.00 (1H, dd, J = 14.5, 4.5 Hz), 2.83 
(1H, dd, J = 14.5, 9.0 Hz), 2.28 (1H, broad s, OH), 2.01 (2H, m), 1.33-1.17 (6H), 1.32 (3H, 
s),1.31 (3H, s), 1.12 (3H, d, J = 7.0 Hz), 0.82 (3H, t, J = 7.0 Hz); 13C NMR (75MHz, CDCl3) " 
176.5, 152.9, 137.1, 134.4, 129.5, 129.0, 128.9, 127.2, 82.6, 69.0, 63.8, 43.5, 35.9, 31.8, 29.6, 
28.8, 28.2, 22.9, 22.6, 14.4, 12.7; IR (film / cm-1): 3497 (broad OH), 1778 (C=Oox), 1698 














9-Borabicyclo[3.3.1]nonyl trifluoromethanesulphonate (8.05 mL, 4.023 mmol) was added to a 
solution of (S)-4-benzyl-5,5-dimethyl-3-propionyloxazolidin-2-one, 142a (956.1 mg, 3.658 
mmol) in dichloromethane (100 mL) followed by addition of N,N-diisopropylethylamine (0.828 
ml, 4.755 mmol) and 3-methyl-2-butenal (0.46 mL, 4.76 mmol) according to General Procedure 
2 to afford the crude product as a pale yellow oil. Purification via column chromatography 
afforded (S)-4-benzyl-3-((2S,3R)-3-hydroxy-2,5-dimethylhex-4-enoyl)-5,5-




 = -27 (c = 1.0 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 7.35-7.17 (5H, m), 5.23 (1H, d, J 
= 9.0 Hz), 4.60 (1H, m), 4.52 (1H, dd, J = 9.0 Hz and 4.5 Hz), 3.93 (1H, qd, J = 7.0 and 5.0 
Hz), 3.05 (1H, dd J = 14.5 Hz and 4.5 Hz), 2.90 (1H, dd, J = 14.5 Hz and 9.0 Hz), 2.35 (1H, 
broad s), 1.72 (3H, s), 1.68 (3H, s), 1.39 (3H, s), 1.37 (3H, s), 1.18 (3H, d, J = 7.0 Hz); 13C 
NMR (75MHz, CDCl3) " 176.7, 153.0, 137.2, 137.1, 129.5, 129.1, 127.3, 124.5, 82.6, 69.9, 
" " " 63)7*('"U8"/$7('!0(,*)4"
.U<"
63.8, 43.4, 35.9, 28.6, 26.4, 22.5, 18.8, 12.6; IR (ATR) . (cm-1): 3479 (broad O-H), 1769 














9-Borabicyclo[3.3.1]nonyl trifluoromethanesulphonate (5.56 mL, 2.78 mmol) was added to a 
solution of (S)-4-benzyl-5,5-dimethyl-3-propionyloxazolidin-2-one, 142a (605.8 mg, 2.32 
mmol) in dichloromethane (50 mL) followed by addition of N,N-diisopropylethylamine (0.53 
ml, 3.02 mmol) and (E)-crotonaldehyde (0.25 mL, 3.02 mmol) according to General Procedure 
2 to afford the crude product as a pale yellow oil. Purification via column chromatography 
afforded (S)-4-benzyl-3-((2S,3R,E)-3-hydroxy-2-methylhex-4-enoyl)-5,5-




 = -14 (c = 0.84 in CHCl3) 
1H NMR (300 MHz, CDCl3) " 7.39-7.17 (5H, m), 5.74 (1H, 
dqd, J = 15.5 Hz, 6.5 Hz and 1.0 Hz), 5.48 (1H, ddd, J = 15.5 Hz, 6.5 Hz and 1.0 Hz), 4.60 (1H, 
dd, J = 9.0 Hz and 4.5 Hz), 4.53 (1H, m), 3.91 (1H, qd, J = 7.0 and 4.5 Hz), 3.05 (1H, dd. J = 
14.5 and 4.5 Hz), 2.90 (1H, dd. J = 14.5 and 9.0 Hz), 2.60 (1H, d, J = 2.5 Hz), 1.70 (3H, d, J = 
7.0 Hz), 1.39 (3H, s), 1.38 (3H, s), 1.15 (3H, d, J = 7.0 Hz); 13C NMR (75 MHz, CDCl3) " 
176.9, 152.9, 137.1, 130.5, 129.5, 129.1, 128.9, 127.3, 82.7, 73.6, 63.8, 43.2, 35.9, 28.7, 
22.5, 18.2, 12.1; IR (KBr / cm-1): 3508 (broad OH), 1775 (C=Oox), 1696 (C=O); HRMS 
(ES): m/z calculated for C19H25NO4: requires 332.1856 for [M+H]





















9-Borabicyclo[3.3.1]nonyl trifluoromethanesulphonate (8.42 mL, 4.209 mmol) was added to a 
solution of (S)-4-benzyl-5,5-dimethyl-3-propionyloxazolidin-2-one, 142a (1000.0 mg, 3.83 
mmol) in dichloromethane (50 mL) followed by addition of N,N-diisopropylethylamine (0.80 
ml, 4.59 mmol) and iso-butyraldehyde (0.41 mL, 4.59 mmol) according to General Procedure 2 
to afford the crude product as a pale yellow oil. Purification via column chromatography 
afforded (S)-4-benzyl-3-((2S,3R)-3-hydroxy-2,4-dimethylpentanoyl)-5,5-
dimethyloxazolidin-2-one, 198 (1033.5 mg, 3.10 mmol, 81%) as a clear oil. 
 
Rf (CH2Cl2) = 0.24; [#]D
24= -35 (c = 0.91 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 7.35-7.20 
(5H, m, Ph), 4.53 (1H, dd, J = 8.4 Hz and 4.5 Hz, CHN), 3.92 (1H, qd, J = 7.3 Hz and 3.2 Hz, 
COCH), 3.53 (1H, app. dt, J = 8.5 Hz and 3.2 Hz, CHOH), 3.06 (1H, dd, J = 14.5 Hz and 4.5 
Hz, CHAHBPh), 2.90 (1H, dd, J = 14.5 Hz and 8.4) Hz, CHAHBPh), 1.70 (1H, m, CH(CH3)2), 
1.42 (3H, s, (CHA3)C(CH
B




3), 1.18 (3H, d, J = 7.3 Hz, CHCH3), 
1.01 (3H, d, J = 7.0 Hz, (CHA3)CH(CH
B






NMR (75 MHz, CDCl3) " 178.4, 152.5, 137.0, 129.5, 129.1, 127.3, 82.7, 77.3, 63.2, 40.2, 35.9, 
31.1, 28.9, 22.6, 19.5, 19.2, 10.7; IR (ATR) . (cm-1): 3530 (O-H), 1780 (C=Oox), 1694 (C=O); 
HRMS (ES): m/z calculated for C19H27NO4: requires 334.2018 for [M+H]
+; found: 334.2012: 









Vanadyl acetyl acetonate (9.75 mg, 0.037 mmol) was added to a solution of aldol 163c (169.2 
mg, 0.368 mmol) in benzene (3 mL) followed by addition of tert-butyl hydroperoxide (0.088 
mL, 0.442 mmol) according to General Procedure 5 to afford the crude product as a green oil. 
" " " 63)7*('"U8"/$7('!0(,*)4"
.UZ"
Purification via column chromatography afforded (3S,4S,5S)-5-ethyl-4-hydroxy-5-
(hydroxymethyl)-3-methyl-dihydrofuran-2(3H)-one, 181c (49.9 mg, 0.287 mmol, 78%) as a 
white solid, recrystallisation of the pure material was achieved using petroleum ether and 
diethyl ether. 
 
Rf (7:3 DCM/EtOAc) = 0.32; [#]D
25
 = -44.4 (c = 0.14 in CHCl3); mp = 76-77 °C; 
1H NMR (300 
MHz, CDCl3) " 3.91 (1H, d, J = 12.3 Hz, CHOH), 3.88 (1H, d, J = 8.4 Hz, CHAHBOH), 3.79 
(1H, d, J = 12.3 Hz, CHAHBOH), 2.79 (1H, dq, J = 8.7 and 7.2 Hz, CHACHBCH3), 1.76-1.53 
(2H, m, CHACHBCH3, CHCH3), 1.26 (3H, d, J = 7.2, CHCH3), 0.90 (3H, t, J = 7.6, CH2CH3); 
13C NMR (75 MHz, CDCl3) " 177.5, 88.0, 80.9, 65.3, 44.9, 28.8, 14.4, 7.7; IR (ATR) . (cm
-1): 
3286.5 (O-H), 1740.4 (C=O); HRMS (ES): m/z calculated for C8H14O4 requires 192.1230 for 
[M+NH4]









Vanadyl acetyl acetonate (27.8 mg, 0.105 mmol) was added to a solution of aldol 163b (348.7 
mg, 1.052 mmol) in benzene (5 mL) followed by addition of tert-butyl hydroperoxide (0.22 mL, 
1.157mmol) according to General Procedure 5 to afford the crude product as a green oil. 
Purification via column chromatography afforded (3S,4S,5S)-4-hydroxy-5-(hydroxymethyl)-




Lit for (ent)-181b [#]D
25
 = +26.8 (c = 0.91 in CHCl3)
157 
Rf (7:3 DCM/EtOAc) = 0.26; [#]D
25
 = -35.8 (c = 0.34 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 
3.78 (1H, d, J = 10.5 Hz, CHOH), 3.77 (1H, d, J = 12.1 Hz, CHACHBOH), 3.62 (1H, d, J = 12.1 
Hz, CHACHBOH), 2.83 (1H, dq, J = 9.3, and 7.1 Hz, CHCO), 1.29 (3H, s, CH3), 1.22 (3H, d, J 
= 7.3 Hz, CHCH3); 
13C NMR (75 MHz, CDCl3) " 178.4, 86.2, 82.1, 65.5, 44.0, 22.4, 14.1; IR 
(ATR) . (cm-1): 3340.8 (O-H), 1735.5 (C=O); HRMS (ES): m/z calculated for C7H12O4 
requires 178.1074 for [M+NH4]
+, found 178.1074. 
 











Vanadyl acetyl acetonate (6.89 mg, 0.026 mmol) was added to a solution of aldol 163e (102.9 
mg, 0.256 mmol) in benzene (2.5 mL) followed by addition of tert-butyl hydroperoxide (0.056 
mL, 0.282 mmol) according to General Procedure 5 to afford the crude product as a green oil. 
Purification via column chromatography afforded (3S,4S,5S)-5-hexyl-4-hydroxy-5-
(hydroxymethyl)-3-methyl-dihydrofuran-2(3H)-one, 181e (48.8 mg, 0.212 mmol, 83%) as a 
clear oil. 
 
Rf (7:3 DCM/EtOAc) = 0.62; [#]D
25
 = -31.2 (c = 0.80 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 
3.98 (1H, d, J = 11.9 Hz, CHACHBOH), 3.87 (1H, d, J = 8.3 Hz, CHOH), 3.87 (1H, d, J = 11.9 
Hz, CHACHBOH), 2.86 (1H, dq, J = 8.6, and 6.9 Hz, CHCH3), 1.77-1.54 (2H, m, CCH2), 1.44-
1.18 (8H, m, C4H8), 0.89 (3H, t, J = 6.7 Hz, CH2CH3); 
13C NMR (75 MHz, CDCl3) " 177.9, 
88.2, 81.4, 65.4, 44.9, 36.3, 31.9, 29.9, 23.3, 22.9, 14.5, 14.4;  IR (ATR) . (cm-1): 3325.6 (O-H), 
1751.8 (C=O); HRMS (ESI): m/z calculated for C12H22O4 requires 231.1596 for [M+H]
+, 










Vanadyl acetyl acetonate (17.9 mg, 0.068 mmol) was added to a solution of aldol 163d (233.3 
mg, 0.674 mmol) in benzene (6 mL) followed by addition of tert-butyl hydroperoxide (0.15 mL, 
0.741 mmol) according to General Procedure 5 to afford the crude product as a green oil. 
Purification via column chromatography afforded (3S,4S,5S)-4-hydroxy-5-(hydroxymethyl)-
5-isopropyl-3-methyl-dihydrofuran-2(3H)-one, 181d (93.7 mg, 0.498 mmol, 74%) as a pale 
oil. 
 
" " " 63)7*('"U8"/$7('!0(,*)4"
.UU"
Rf (7:3 DCM/EtOAc) = 0.41; [#]D
25
 = -30.6 (c = 0.43 in CHCl3);  
1H NMR (300 MHz, CDCl3) 
" 4.06 (1H, d, J = 12.2 Hz, CHACHBOH), 3.92 (1H, app. t, J = 8.7 Hz, CHOH), 3.83 (1H, d, J = 
12.2 Hz, CHACHBOH), 2.85-2.69 (2H, m, CHCH3, OH), 2.35 (1H, br. s, OH), 1.86 (1H, septet, 
J = 6.5 Hz, CH(CH3)2), 1.27 (3H, d, J = 7.4 Hz, CHCH3), 0.94 (3H, d, J = 3.5 Hz, CCHCH3), 
0.92 (3H, d, J = 3.3 Hz, CCHCH3); 
13C NMR (75 MHz, CDCl3) " 177.9, 90.6, 79.8, 63.9, 45.9, 
45.6, 34.4, 17.5, 16.9, 14.6; IR (ATR) . (cm-1): 3313.0 (O-H), 1736.6 (C=O); HRMS (ESI): m/z 
calculated for C9H16O4 requires 211.0946 for [M+Na]











Vanadyl acetyl acetonate (9.02 mg, 0.034 mmol) was added to a solution of aldol 146 (138.0 
mg, 0.34 mmol) in benzene (3 mL) followed by addition of tert-butyl hydroperoxide (0.075 mL, 
0.378 mmol) according to General Procedure 5 to afford the crude product as a green oil. 
Purification via column chromatography afforded (3R,4S,5S)-5-hexyl-4-hydroxy-5-
(hydroxymethyl)-3-methyl-dihydrofuran-2(3H)-one, 205 (58.3 mg, 0.253 mmol, 74%) as a 
clear oil. 
 
Rf (7:3 DCM/EtOAc) = 0.53; [#]D
25
 = +4.65 (c = 0.43 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 
4.23 (1H, d, J = 7.0 Hz, CHOH), 3.91 (1H, d, J = 12.0 Hz, CHACHBOH), 3.85 (1H, d, J = 12.0 
Hz, CHACHBOH), 2.86 (1H, m, CHCH3), 1.65-1.47 (2H, m, CH2CH2), 1.36-1.11 (8H, m, C4H8), 
0.81 (3H, t, J = 6.5 Hz, CH2CH3); 
13C NMR (75 MHz, CDCl3) " 179.0, 88.8, 75.5, 64.1, 40.5, 
35.2, 32.0, 30.0, 23.6, 22.9, 14.4, 8.8;  IR (ATR) . (cm-1): 3330.0 (O-H), 1753.0 (C=O); HRMS 
(ESI): m/z calculated for C12H22O4 requires 253.1416 for [M+Na]




















Vanadyl acetyl acetonate (34.5 mg, 0.13 mmol) was added to a solution of aldol 163i (450 mg, 
1.25 mmol) in benzene (6 mL) followed by addition of tert-butyl hydroperoxide (0.28 mL, 1.38 
mmol) according to General Procedure 5 to afford the crude product as a green oil. Purification 
via column chromatography afforded (3S,4S,5S)-4-hydroxy-5-((S)-1-hydroxypropyl)-3,5-
dimethyl-dihydrofuran-2(3H)-one, 181i (174.1 mg, 0.925 mmol, 74%) as a pale oil. 
 
Lit for (ent)-181i [#]D
25
 = +25.4 (c = 0.66 in EtOH). 
235 
Rf (7:3 DCM/EtOAc) = 0.53; [#]D
25
 = -15.0 (c = 0.54 in CHCl3); 
1H NMR (300 MHz, MeOD) " 
3.82 (1H, d, J = 9.0 Hz, CHOH), 3.62 (1H, dd, J = 10.2 and 2.6 Hz, CHOHCH2), 2.74 (1H, dq, 
J = 9.0 and 7.5 Hz, CHCH3), 1.64-1.38 (2H, m, CH2CH3), 1.30 (3H, s, CH3), 1.15 (3H, d, J = 
7.2 Hz, CHCH3), 0.91 (3H, t, J = 7.5 Hz, CH2CH3); 
13C NMR (75 MHz, MeOD) " 179.5, 87.7, 
83.9, 76.9, 44.5, 25.5, 21.6, 14.3, 11.8;  IR (ATR) . (cm-1): 3394.8 (O-H), 1747.5 (C=O); 
HRMS (ES): m/z calculated for C9H16O4 requires 211.0941 for [M+Na]










Vanadyl acetyl acetonate (33.9 mg, 0.128 mmol) was added to a solution of aldol 163j (497.5 
mg, 1.28 mmol) in benzene (6 mL) followed by addition of tert-butyl hydroperoxide (0.28 mL, 
1.41 mmol) according to General Procedure 5 to afford the crude product as a green oil. 
Purification via column chromatography afforded (3S,4S,5R)-4-hydroxy-5-((S)-1-
hydroxyhexyl)-3-methyl-dihydrofuran-2(3H)-one, 181j (232.7 mg, 1.076 mmol, 84%) as a 
pale oil. 
 
Rf (7:3 DCM/EtOAc) = 0.41; [#]D
25
 = +32.8 (c = 0.34 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 
4.07 (1H, br. t, J = 8.8 Hz, CHOH), 3.98 (1H, dd, J = 7.9 and 3.2 Hz, OCH), 3.69 (1H, br. s, 
" " " 63)7*('"U8"/$7('!0(,*)4"
.U\"
CHOHCH2), 2.58 (1H, dq, J = 8.8 and 7.2 Hz, CHCH3), 1.66-1.15 (11H, m, C4H8, CHCH3), 
0.83 (3H, t, J = 7.2 Hz, CH2CH3); 
13C NMR (75 MHz, CDCl3) " 177.78, 85.6, 74.5, 69.5, 44.0, 
34.5, 32.1, 26.0, 23.0, 14.4, 12.7;  IR (ATR) . (cm-1): 3379.9 (O-H), 1736.3 (C=O); HRMS 
(ESI): m/z calculated for C11H20O4 requires 239.1259 for [M+Na]










Vanadyl acetyl acetonate (12.9 mg, 0.049 mmol) was added to a solution of aldol 163h (169.3 
mg, 0.49 mmol) in benzene (3 mL) followed by addition of tert-butyl hydroperoxide (0.118 mL, 
0.58 mmol) according to General Procedure 5 to afford the crude product as a green oil. 
Purification via column chromatography afforded (3S,4S,5S)-4-hydroxy-5-(2-hydroxypropan-
2-yl)-3-methyl-dihydrofuran-2(3H)-one, 181h (66.37 mg, 0.381 mmol, 78%) as a pale oil.  
 
Rf (7:3 DCM/EtOAc) = 0.24; [#]D
25
 = +23.5 (c = 0.17 in CHCl3);  
1H NMR (300 MHz, CDCl3) 
" 4.11 (1H, ddd, J = 8.7, 6.8 and 4.6 Hz, CHOH), 3.88 (1H, d, J  = 7.6 Hz, OCH), 2.61 (1H, dq, 
J  = 8.4 and 6.5 Hz, CHCH3), 2.32 (1H, br. d, J = 4.88 Hz, CHOH), 1.72 (1H, br. s, OH), 1.29-
1.20 (9H, m, CHCH3, C(CH3)2); 
13C NMR (75 MHz, CDCl3) " 176.45, 88.2, 74.9, 71.1, 44.3, 
26.4, 26.2, 12.9;  IR (ATR) . (cm-1): 3398.8 (O-H), 1766.8 (C=O); HRMS (ESI): m/z calculated 
for C8H14O4 requires 197.0789 for [M+Na]












Vanadyl acetyl acetonate (16.2 mg, 0.061 mmol) was added to a solution of aldol 163f (200.5 
mg, 0.605 mmol) in benzene (5 mL) followed by addition of tert-butyl hydroperoxide (0.13 mL, 
0.665 mmol) according to General Procedure 5 to afford the crude product as a green oil. 
Purification via column chromatography afforded (3S,4S,5S)-4-hydroxy-5-((S)-1-
hydroxyethyl)-3-methyldihydrofuran-2(3H)-one, 181fa (46.5 mg, 0.290 mmol, 48%) as a 
" " " 63)7*('"U8"/$7('!0(,*)4"
.UJ"
pale oil. The minor diastereomer was also isolated as a white solid (3S,4S,5R)-4-hydroxy-5-




Rf (7:3 DCM/EtOAc) = 0.17; [#]D
25
 = -35.5 (c = 0.23 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 
4.10 (1H, app. t., J = 8.4 Hz, CHOH), 3.98 (1H, app. pent., J  = 6.2 Hz, CHOHCH3), 3.87 (1H, 
dd, J  = 7.2 and 5.7 Hz, OCH), 2.61 (1H, dq, J  = 8.4 and 6.5 Hz, CHCH3), 2.55 (1H, br. s, OH), 
1.98 (1H, br. s, OH), 1.29 (3H, d, J  = 6.2 Hz, CHOHCH3), 1.27 (3H, d, J  = 7.1 Hz, CHCH3); 
13C NMR (75 MHz, CDCl3) " 176.6, 88.6, 76.1, 68.6, 43.9, 19.9, 12.9;  IR (ATR) . (cm
-1): 
3391.2 (O-H), 1753.4 (C=O); HRMS (ESI): m/z calculated for C7H12O4 requires 183.0633 for 












Rf (7:3 DCM/EtOAc) = 0.21; [#]D
25
 = -36.4 (c = 0.71 in CHCl3);  
1H NMR (300 MHz, CDCl3) 
" 4.31 (1H, dd, J  = 4.4 and 2.9 Hz, CHOH), 4.20 (1H, app. pent., J  = 6.3 Hz, CHOHCH3), 4.1 
(1H, dd, J  = 6.3 and 4.4 Hz, OCH), 2.64 (1H, qd, J  = 7.7 and 3.0 Hz, CHCH3), 1.35 (3H, d, J  
= 6.2 Hz, CHOHCH3), 1.23 (3H, d, J  = 7.7 Hz, CHCH3); 
13C NMR (75 MHz, CDCl3) " 179.1, 
83.1, 75.6, 67.1, 44.9, 20.1, 13.8;  IR (ATR) . (cm-1): 3308.6 (O-H), 1751.8 (C=O); HRMS 
(ESI): m/z calculated for C7H12O4 requires 183.0633 for [M+Na]




N-Propionyl-oxazolidin-2-one resin 222 (500 mg, 0.90 mmol/g, 0.45 mmol) was sealed in an 
IRORI minikan® in an oven-dried round bottomed flask, and dichloromethane (8 mL) added to 
preswell the resin. The reaction flask was then cooled to 0 °C, 9-Borabicyclo[3.3.1]nonyl 
trifluoromethanesulphonate (4.5 mL, 0.5 M in dichloromethane, 2.25 mmol) added slowly and 
the reaction mixture stirred gently for one hour. The solvent was then removed via cannula and 
fresh pre-chilled dichloromethane (10 mL) added to resuspend the resin. N,N-
diisopropylethylamine (0.391 mL, 2.25 mmol) was then added and the reaction stirred for a 
" " " 63)7*('"U8"/$7('!0(,*)4"
.QP"
further hour, before being cooled to -78 °C. 2-Ethylacrolein (0.308 mL, 3.15 mmol) was then 
added dropwise and the stirred reaction mixture allowed to warm to room temperature over a 
period of 12 hours. The reaction was then quenched via addition of phosphate buffer pH 7 (0.1 
M) and the polymer filtered off and washed sequentially with dichloromethane (10 mL), 
dichloromethane/methanol (10 mL) and tetrahydrofuran (10 mL) to afford (syn)-aldol polymer 








 (syn)-Aldol resin 227 was characterised via treatment of a small portion of resin (50 mg) that 
had been preswollen in tetrahydrofuran (2 mL) with a solution of sodium borohydride (6 mg, 
0.15mmol) in water (0.2mL), that was then agitated on an orbital shaker for 4 hours. Polymer 
221 was then filtered off and washed thoroughly with dichlromethane (5 mL) and 
tetrahydrofuran (5 mL), before all organic extracts were combined, dried (magnesium sulphate) 
and evaporated to dryness to afford a clean sample of (2R,3S)-2-methyl-4-methylenehexane-
1,3-diol 228 (16.1 mg, 0.112 mmol, 62%) as a colourless oil.  
 
[#]D
25 -26 (c = 0.8, CHCl3); 
1H NMR (300MHz, CDCl3) % 5.05 (1H, br. s, CHAHBC=C), 4.92 
(1H, br. s, CHAHBC=C), 4.28 (1H, d, J = 3.0 Hz), 3.68 (2H, m), 2.64 (2H, s), 2.08-1.80 (3H, m), 
1.05 (3H, t, J = 7.0 Hz), 0.84 (3H, d, J = 7.0 Hz); 13C NMR (75 MHz, CDCl3) " 152.4, 108.5, 
76.4, 67.0, 37.7, 25.6, 12.6, 9.9; IR (thin film): 3380 (broad OH); MS (CI+, NH3) m/z (%) 162 
(100) [M+NH4]
+, 144 (23) [M+H]+, 52 (23); HRMS (ES+): m/z calculated for C8H16O2 requires 
162.1489 for [M+NH4]




Vanadyl acetyl acetonate (24 mg, 0.09 mmol) was added to (syn)-aldol-resin 227 (200mg, 0.90 
mmol/g, 0.18 mmol) pre-swollen in benzene (8 mL) at room temperature and the reaction 
mixture agitated on an orbital shaker for 30 minutes. tert-Butyl-hydroperoxide (5.0-6.0 M 
solution in decane) (0.098 mL, 5.5 M, 0.54 mmol) was then added and the reaction agitated for 
a further 16 hours at room temperature. The resin was then filtered off and washed thoroughly 
with dichloromethane (5 mL) and CH2Cl2/MeOH (5 mL, 1:1) with all organic extracts being 
combined and evaporated to dryness. The resulting crude product was dissolved in 
" " " 63)7*('"U8"/$7('!0(,*)4"
.Q."
dichloromethane (5 mL) and filtered through a plug of silica, before the solvent was removed in 
vacuo to afford (3S,4S,5S)-!-butyrolactone 181c (17 mg, 0.097 mmol) ([#]D
25
 = -43.7 (c = 0.15, 
CHCl3)) as a crystalline solid in 58% yield over two steps. 
 
Characterisation matched that described for the solution phase synthesis of lactone 181c. 















9-Borabicyclo[3.3.1]nonyl trifluoromethanesulphonate (10.1 mL, 5.1 mmol) was added to a 
solution of (S)-4-benzyl-5,5-dimethyl-3-propionyloxazolidin-2-one, 157 (1.2 g, 4.6 mmol) in 
dichloromethane (30 mL) followed by addition of N,N-diisopropylethylamine (1.0 mL, 6.0 
mmol) and (E)-cinnamaldehyde (0.76 mL, 6.0 mmol) according to General Procedure 2 to 
afford the crude product as a pale yellow oil. Purification via column chromatography afforded 
163g (1.41 g, 3.58 mmol, 78 %) as a colourless oil. 
 
Rf (CH2Cl2) = 0.21;  [#]D
23 = +6.0 (c = 0.89 in CHCl3); mp = 147 – 149 °C (Et2O); 
1H NMR 
(300 MHz, CDCl3) " 7.36-7.13 (10H, m, Ph), 6.59 (1H, dd, J = 16.0 and 1.5 Hz, CH =CHPh), 
6.12 (1H, dd, J = 16.0 Hz and 6.0 Hz, CH=CHPh), 4.54 (1H, m, CHOH), 4.47 (1H, dd, J = 9.0 
and 5.0 Hz, CHN), 3.94 (1H, qd, J = 7.0 and 4.0 Hz, COCH), 3.00 (1H, dd J = 14.0 and 5.0 Hz, 
CHAHBPh), 2.84 (1H, dd, J = 14.0 and 9.0 Hz, CHACHBPh), 2.74 (1H, broad s, OH), 1.32 (3H, 
s, (CH3)C(CH3)), 1.30 (3H, s, (CH3)C(CH3)), 1.13 (3H, d, J = 7.0 Hz, CH3CH); 
13C NMR (75 
MHz, CDCl3) " 177.1, 152.6, 137.7, 134.1, 129.3, 129.2, 129.1, 127.3, 82.7, 73.4, 63.8, 43.3, 
35.9, 32.7, 32.2, 29.6, 29.5, 23.1, 14.5, 12.0; IR (ATR) . (cm-1): 3443.6 (O-H), 1768.0 (C=O), 

























9-Borabicyclo[3.3.1]nonyl trifluoromethanesulphonate (9.46 mL, 4.73 mmol) was added to a 
solution of (S)-4-benzyl-5,5-dimethyl-3-(3-methylbutanoyl)oxazolidin-2-one, 142b (1.24 g, 
4.29 mmol) in dichloromethane (100 mL) followed by addition of N,N-diisopropylethylamine 
(0.97 ml, 5.59 mmol) and methacrolein (0.96 mL, 5.59 mmol) according to General Procedure 2 
to afford the crude product as a pale yellow oil. Purification via column chromatography 
afforded 163m (1.22 g, 3.39 mmol, 79 %) as a colourless oil. 
 
[#]D
25 = -40.0 (c = 1.0, CHCl3); Rf (CH2Cl2) = 0.22; 
1H NMR (300 MHz, CDCl3) " 7.40-7.11 
(5H, m, Ph), 4.96 (1H, app. d, J = 1.0 Hz, CHcisHtrans=C), 4.81 (1H, app. t, J = 1.5 Hz, 
CHcisHtrans=C), 4.53 (1H, dd, J = 9.0 Hz and 4.5 Hz, CHN), 4.46 (1H, dd, J = 10.0 Hz and 3.5 
Hz, CHOH), 4.38 (1H, d, J = 8.5 Hz, CHCH), 3.08 (1H, dd, J = 14.5 Hz and 4.5 Hz, 
CHAHBPh), 2.78 (1H, dd, J =14.5 Hz and 10.0 Hz, CHAHBPh), 2.23 (1H, m, CH(CH3)2) 1.90 
(1H, broad s, OH), 1.71 (3H, s, C=CCH3), 1.23 (6H, app. d, J = 5.5 Hz) (CH3)C(CH3)), 0.97 
(6H, t, J = 7.0 Hz, CH(CH3)2); 
13C NMR (75 MHz, CDCl3) " 174.1, 153.0, 146.2, 137.3, 129.4, 
129.07, 127.2, 113.5, 82.2, 64.1, 51.0, 35.9, 28.6, 28.4, 22.7, 21.2, 19.1, 18.6; IR (thin film / cm-
1) 3499 (broad O-H), 1768 (C=Oox), 1685 (C=O); HRMS (EI+) m/z calculated for C21H29NO4: 


























9-Borabicyclo[3.3.1]nonyl trifluoromethanesulphonate (0.45 mL, 0.912 mmol) was added to a 
solution of (S)-4-benzyl-5,5-dimethyl-3-(2-phenylacetyl)oxazolidin-2-one, 142c (267.9 mg, 
0.83 mmol) in dichloromethane (70 mL) followed by addition of N,N-diisopropylethylamine 
(0.17 ml, 0.99 mmol) and methacrolein (0.083 mL, 0.99 mmol) according to General Procedure 
2 to afford the crude product as a pale yellow oil. Purification via column chromatography 
afforded 163L (244.8 mg, 0.62 mmol, 75 %) as a colourless oil. 
 
[#]D
25 = -89.9 (c = 1.0, CHCl3); Rf (CH2Cl2) = 0.35; 
1H NMR (300 MHz, CDCl3) " 7.42-7.20 
(5H, m, Ph), 7.14-6.98 (5H, m, Ph), 5.27 (1H, d, J = 7.0 Hz, PhCH) 4.92 (1H, m, CHcisHtrans=C), 
4.85 (1H, br. app. pent., J = 1.5 Hz, CHcisHtrans=C), 4.69 (1H, d, J = 8.0 Hz, CHOH), 4.43 (1H, 
dd, J = 9.0 Hz and 4.0 Hz, CHN), 4.40 (1H, m, CHOH), 2.82 (1H, dd J = 14.0 Hz and 4.0 Hz, 
CHAHBPh), 2.63 (1H, dd, J = 14.0 Hz and 9.0 Hz, CHACHBPh), 2.05 (1H, br. s, OH), 1.74 (3H, 
s, CH2=CCH3), 1.27 (3H, s, (CH3)C(CH3)), 1.24 (3H, s, (CH3)C(CH3)); 
13C NMR (75 MHz, 
CDCl3) " 172.9, 152.5, 144.8, 136.9, 134.7, 130.26, 129.4, 129.1, 128.9, 128.4, 127.1, 114.2, 
82.5, 63.7, 53.4, 35.3, 28.7, 22.5, 18.7; IR (ATR) . (cm-1): 3489.6 (O-H), 1768.2 (C=O), 1671.5 
(C=Oox); HRMS (ES): m/z calculated for C24H27NO4 requires 394.2018 for [M+H]
+; found: 












Dibutylboron trifluoromethanesulphonate (2.17 mL, 2.17 mmol) was added to a solution of (S)-
4-benzyl-3-(2-chloroacetyl)oxazolidin-2-one 142d (500 mg, 1.97 mmol) in dichloromethane (60 
mL) followed by addition of N,N-diisopropylethylamine (0.41 mL, 2.34 mmol) and acrolein 
" " " 63)7*('"U8"/$7('!0(,*)4"
.QW"
(0.16 mL, 2.34 mmol) according to General Procedure 3 to afford the crude product as a pale 
yellow oil. Purification via column chromatography afforded 274 (362.2 mg, 1.172 mmol, 54%) 
as a colourless oil. 
 
Rf (CH2Cl2) = 0.20; [#]D
24 = -12 (c = 1.0, CHCl3); 
1H NMR (300 MHz, CDCl3): % 7.47 – 7.05 
(5H, m, Ph), 5.92 (1H, ddd, J = 17.2, 10.5, 5.5 Hz, CHCH2), 5.73 (1H, d, J = 4.5 Hz, CHCl), 
5.46 (1H, dt, J = 17.2, 1.3 Hz, CHCHACHB), 5.34 (1H, dt, J = 10.5, 1.3 Hz, CHCHACHB), 4.81 
– 4.57 (2H, m, CHOH & CHN), 4.37 – 4.19 (2H, m, CH2O), 3.31 (1H, dd, J = 13.5, 3.3 Hz, 
CHACHBPh), 2.84 (1H, dd, J = 13.5, 9.4 Hz, CHACHBPh); 
13C NMR (75.5 MHz, CDCl3): % 
167.95, 153.03, 135.35, 134.91, 129.77, 129.40, 127.90, 119.06, 72.88, 66.88, 59.57, 55.77, 
37.57; IR (ATR) .max (cm
-1): 3497 (broad O-H), 1759 (C=Oox), 1711 (C=O); HRMS (ES+); m/z 
calculated for C15H16ClNO4: requires 310.0846 for [M+H]
+; found: 310.0836; requires 332.0666 











(S)-4-benzyl-3-((2S,3R)-3-hydroxy-2-methylpent-4-enoyl)oxazolidin-2-one 274 (130 mg, 0.0.42 
mmol), zinc dust (110 mg, 1.68 mmol), ammonium chloride (90 mg, 1.68 mmol) and methanol 
(1.82 mL, 14 mL/g) were mixed together and treated according to General Procedure 8. The 
clear oil was purified by column chromatography eluting with dichloromethane, to yield title 
compound, (S)-4-benzyl-3-((S)-3-hydroxypent-4-enoyl)oxazolidin-2-one 275 (65 mg, 0.24 
mmol, 56%) as a colourless oil. 
 
Rf (CH2Cl2) = 0.18; [#]D
25 = -5.0 (c = 0.87, CHCl3); 
1H NMR (300 MHz, CDCl3): % 7.44 – 7.02 
(5H, m, Ph), 5.96 (1H, ddd, J = 17.2, 10.5, 5.4 Hz, CHCH2), 5.37 (1H, dt, J = 17.2, 1.4 Hz, 
CHCHACHB), 5.20 (1H, dt, J = 10.5, 1.4 Hz, CHCHACHB), 4.82 – 4.59 (2H, m, CHOH & 
CHN), 4.29 – 4.15 (2H, m, CH2O), 3.30 (1H, dd, J = 13.4, 3.3 Hz, CHACHBPh), 3.21 (2H, dd, J 
= 11.4, 6.1 Hz, CH2CHOH), 2.81 (1H, dd, J = 13.5, 9.4 Hz, CHACHBPh); 
13C NMR (75.5 MHz, 
CDCl3): % 172.48, 153.75, 139.09, 135.33, 129.76, 129.37, 127.80, 115.87, 69.22, 66.70, 55.43, 
42.64, 38.16; IR (ATR) .max (cm
-1): 3300 (broad O-H), 1776 (C=O), 1698 (C=Oox); HRMS 
(ESI); m/z calculated for C15H17NO4: requires 298.1055 for [M+Na]
+; found: 298.1044. 











Osmium tetroxide (22.4 mg, 0.088 mmol) was added to a solution of aldol 163c (304.5 mg, 0.88 
mmol) in acetone/water (8:1, 3 mL) followed by addition of N-methylmorpholine-N-oxide (60% 
by weight in water, 0.2 mL, 0.97 mmol) according to General Procedure 7 to afford the crude 
product as a black oil. Purification via column chromatography afforded (3S,4S,5R)-5-ethyl-4-
hydroxy-5-(hydroxymethyl)-3-methyl-dihydrofuran-2(3H)-one, 240c (119.5 mg, 0.61 mmol, 
69 %) as a pale oil. 
 
Rf (7:3 DCM/EtOAc) = 0.21; [#]D 
24
  = - 3.4 (c = 0.88 in CHCl3); 
1H NMR (500 MHz, MeOD) 
" 4.24 (1H, d, J = 9.4 Hz, CHOH), 3.74 (1H, d, J = 12.1 Hz, CHAHBOH), 3.52 (1H, d, J = 12.16 
Hz, CHAHBOH), 2.68 (1H, qd, J = 9.4 Hz and 7.1 Hz, CHCO), 1.81 (1H, dq, J = 15.0 Hz and 
7.5 Hz, CHAHBCH3), 1.71 (1H, dq, J = 15.0 Hz and 7.5 Hz, CHAHBCH3), 1.28 (1H, d, J = 7.5 
Hz, CH3), 1.01 (1H, t, J = 7.5 Hz, CH2CH3); 
13C NMR (75 MHz, MeOD) " 179.59, 90.18, 
76.48, 64.74, 44.16, 24.96, 13.86, 8.57; IR (ATR) . (cm-1): 3368 (broad O-H), 1751 (C=O); 
HRMS (ES+): m/z calculated for C8H14O4: requires 175.0970 for [M+H]
+; found: 175.957; 









Osmium tetroxide (14.8 mg, 0.052 mmol) was added to a solution of (S)-4-benzyl-3-((2S,3R)-3-
hydroxy-2-methylpent-4-enoyl)oxazolidin-2-one, 163a (150 mg, 0.52 mmol) in acetone/water 
(8:1, 5 mL) followed by addition of N-methylmorpholine-N-oxide (60% by weight in water, 
0.09 mL, 0.52 mmol) according to General Procedure 7 to afford the crude product as a black 
oil. Purification via column chromatography afforded a diastereomeric mixture of (3S,4S,5S)-4-
hydroxy-5-(hydroxymethyl)-3-methyldihydrofuran-2(3H)-one, 240a1 and (3S,4S,5R)-4-
hydroxy-5-(hydroxymethyl)-3-methyldihydrofuran-2(3H)-one, 240a2 (60.1 mg, 0.41 mmol, 
79%) as a pale oil. The two diastereomers were analysed as a mixture. 









1H NMR (500 MHz, CDCl3): % 4.22 – 4.17 (1H, m, CHCH2OH), 4.17 – 4.11 (1H, m, CHOH), 
3.98 (1H, dd, J = 12.7 and 3.0 Hz, CHACHBOH), 3.83 (1H, dd, J = 12.7 and 3.2 Hz, 
CHACHBOH), 2.68 (1H, dq, J = 8.9 and 7.1, CHCH3), 1.32 (3H, d, J = 7.1 Hz, CH3); 
13C NMR 
(75.5 MHz, CDCl3): % 177.04, 83.59, 74.42, 60.85, 43.95, 12.70; IR (ATR) .max (cm
-1): 3377 
(broad O-H), 2934 (broad O-H), 1763 (C=O); HRMS (ESI); m/z calculated for C6H10O4: 










1H NMR (500 MHz, CDCl3) % 4.55 (1H, dt, J = 6.9 and 3.6 Hz, CHCH2O), 4.35 (1H, d, J = 6.0 
Hz, CHOH), 4.06 (2H, d, J = 3.5 Hz, CHACHBOH), 2.74 (1H, dt, J = 13.6 and 7.5 Hz, CHCH3), 
1.32 (3H, d, J = 7.5 Hz, CH3); 
13C NMR (75.5 MHz, CDCl3) % 178.42, 80.04, 76.08, 61.52, 










Osmium tetroxide (9.1 mg, 0.036 mmol) was added to a solution of aldol 163b (120 mg, 0.36 
mmol) in acetone/water (8:1, 3 mL) followed by addition of N-methylmorpholine-N-oxide (60% 
by weight in water, 0.08 mL, 0.40 mmol) according to General Procedure 7 to afford the crude 
product as a black oil. Purification via column chromatography afforded (3S,4S,5R)-4-
" " " 63)7*('"U8"/$7('!0(,*)4"
.Q\"
hydroxy-5-(hydroxymethyl)-3,5-dimethyl-dihydrofuran-2(3H)-one, 240b (43.2 mg, 0.27 
mmol, 75%) as a white solid. 
 
Rf (7:3 DCM/EtOAc) = 0.19; [#]D
23 = +5.3 (c = 1.78 in MeOH); 1H NMR (500 MHz, MeOD) " 
4.10 (1H, d, J = 9.7 Hz, CHOH), 3.65 (1H, d, J = 12.4 Hz, CHAHBOH), 3.54 (1H, d, J = 12.2 
Hz, CHAHBOH), 2.70 (1H, qd, J = 9.7 Hz and 7.0 Hz, CHCO), 1.28 (1H, d, J = 7.2 Hz, 
CHCH3), 1.28 (3H, s, CCH3); 
13C NMR (75 MHz, MeOD) " 179.0, 88.6, 75.8, 66.5, 43.3, 16.9, 
13.3; IR (ATR) . (cm-1): 3335.7 (broad O-H), 1736.5 (C=O); HRMS (ES+): m/z calculated for 
C7H12O4: requires 161.0814 for [M+H]












Osmium tetroxide (14.7 mg, 0.058 mmol) was added to a solution of aldol 163i (208.8 mg, 0.58 
mmol) in acetone/water (8:1, 3 mL) followed by addition of N-methylmorpholine-N-oxide (60% 
by weight in water, 0.11 mL, 0.64 mmol) according to General Procedure 7 to afford the crude 
product as a black oil. Purification via column chromatography afforded (3S,4S,5R)-4-
hydroxy-5-((R)-1-hydroxypropyl)-3,5-dimethyl-dihydrofuran-2(3H)-one, 240i (89.4 mg, 
0.48 mmol, 82%, >95 % de) as a pale oil.  
 
Rf (7:3 DCM/EtOAc) = 0.22; [#]D
23 = -5.4 (c = 1.3 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 
4.12 (1H, dd, J = 9.8 Hz and 5.4 Hz, CHOH), 3.93 (1H, d, J = 5.39 Hz, OH), 3.57 (1H, d, J = 
8.57 Hz, OH), 3.37 (1H, ddd, J = 10.8 Hz, 8.8 Hz and 2.24 Hz, CHOHCH2), 2.62 (1H, dq, J = 
9.9 Hz and 7.1 Hz, CHCH3) 1.67 (1H, dqd, J = 15.1 Hz, 7.46 Hz and 2.42 Hz, CHAHBCH3) 1.45 
– 1.28 (1H, m, CHAHBCH3), 1.23 (3H, s, CH3CH2), 1.18 (3H, d, J = 7.1 Hz, CHCH3), 0.97 (3H, 
t, J = 7.3 Hz, CH2CH3); 
13C NMR (75 MHz, CDCl3) " 178.02, 89.12, 75.56, 75.24, 41.56, 
24.07, 16.41, 12.84, 11.30; IR (ATR) . (cm-1): 3356.5 (broad O-H), 1748.7 (C=O); HRMS 
(ES+): m/z calculated for C9H16O4: requires 189.1127 for [M+H]
+; found: 189.1120; requires 
211.0946 for [M+Na]+; found: 211.0934. 
 












Osmium tetroxide (12.7 mg, 0.05 mmol) was added to a solution of aldol 163g (198.2 mg, 0.50 
mmol) in acetone/water (8:1, 3 mL) followed by addition of N-methylmorpholine-N-oxide (60% 
by weight in water, 0.1 mL, 0.55 mmol) according to General Procedure 7 to afford the crude 
product as a black oil. Purification via column chromatography afforded (3S,4S,5S)-4-hydroxy-
5-((S)-hydroxy(phenyl)methyl)-3-methyl-dihydrofuran-2(3H)-one, 240g1 (89.9 mg, 0.41 
mmol, 81 %) as a pale oil. 
 
Rf (7:3 DCM/EtOAc) = 0.34; [#]D
23 = +44.0 (c = 1.62 in CHCl3); 
1H NMR (500 MHz, CDCl3) 
" 7.41 – 7.25 (5H, m, ArH), 4.76 (1H, d, J = 5.7, CHPh), 4.22 (1H, dd, J = 9.2 Hz and 7.5 Hz), 
3.95 (1H, dd, J = 9.2 Hz and 7.5 Hz, CHOH), 2.56 (1H, dq, J = 9.2 Hz and 7.2 Hz, CHCO), 
1.19 (3H, d, J = 6.9 Hz, CH3CH); 
13C NMR (75 MHz, CDCl3) " 178.4, 134.5, 129.1, 128.7, 
127.4, 80.1, 74.9, 70.9, 43.1, 14.1; IR (ATR) . (cm-1): 3358.5 (broad O-H), 1753.2 (C=O); 
HRMS (ES+): m/z calculated for C12H14O4: requires 223.0970 for [M+H]
+; found: 223.0964; 









Osmium tetroxide (12.7 mg, 0.05 mmol) was added to a solution of aldol 163f (164.3 mg, 0.50 
mmol) in acetone/water (8:1, 3 mL) followed by addition of N-methylmorpholine-N-oxide (60% 
by weight in water, 0.09 mL, 0.54 mmol) according to General Procedure 7 to afford the crude 
product as a black oil. Purification via column chromatography afforded a diastereotopic 
mixture of diastereomeric mixture of (3S,4S,5R)-4-hydroxy-5-((S)-1-hydroxyethyl)-3-methyl-
dihydrofuran-2(3H)-one, 240f1 and (3S,4S,5S)-4-hydroxy-5-((R)-1-hydroxyethyl)-3-
methyl-dihydrofuran-2(3H)-one, 240f2 (65.6 mg, 0.41 mmol, 83%) as a pale oil. The two 
diastereomers were analysed as a mixture. 










Rf (7:3 DCM/EtOAc) = 0.15; 1H NMR (500 MHz, CDCl3) " 4.11 (1H, dd, J = 8.8 Hz and 7.0 
Hz, CHOH), 4.04 – 3.95 (2H, m, CHOCO and CHOHCH3), 2.68 (1H, dq, J = 9.1 Hz and 7.1 
Hz, CHCO), 1.37 (3H, d, J = 6.5 Hz, CH3CHOH), 1.32 (3H,  d, J = 7.1 Hz, CH3CH); 
13C NMR 
(75 MHz, CDCl3) " 176.8, 86.4, 74.9, 66.6, 44.17, 19.9, 12.8; IR (ATR) . (cm
-1): 3356.6 (broad 
O-H), 1754.5 (C=O); HRMS (ES+): m/z calculated for C7H12O4: requires 183.0628 for 










Rf (7:3 DCM/EtOAc) = 0.15; 1H NMR (500 MHz, CDCl3) " 4.35 - 4.32 (1H, m, CHOH), 4.32 
– 4.27 (2H, m, CHOCO and CHOHCH3), 2.76 (1H, dq, J = 7.7 Hz and 5.3 Hz, CHCO), 1.39 
(3H, d, J = 6.7 Hz, CH3CHOH), 1.32 (3H, d, J = 7.5 Hz, CH3CH); 
13C NMR (75 MHz, CDCl3) 









Osmium tetroxide (13.5 mg, 0.053 mmol) was added to a solution of aldol 163h (184.0 mg, 
0.53 mmol) in acetone/water (8:1, 3 mL) followed by addition of N-methylmorpholine-N-oxide 
(60% by weight in water, 0.10 mL, 0.59 mmol) according to General Procedure 7 to afford the 
crude product as a black oil. Purification via column chromatography afforded (3S,4S,5R)-4-
hydroxy-5-(2-hydroxypropan-2-yl)-3-methyl-dihydrofuran-2(3H)-one, 240h1 (37.8 mg, 
" " " 63)7*('"U8"/$7('!0(,*)4"
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0.22 mmol, 41%) as a pale oil. The minor diastereomer was also isolated as a white solid 
(3S,4S,5S)-4-hydroxy-5-(2-hydroxypropan-2-yl)-3-methyl-dihydrofuran-2(3H)-one, 240h2, 










Rf (7:3 DCM/EtOAc) = 0.32; [#]D
23 = -55.6 (c = 0.99 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 
4.94 (1H, d, J = 4.1 Hz, OH), 4.26 (1H, app. dt, J = 3.9 Hz and 1.5 Hz, C4HOH), 4.09 (1H, d, J 
= 4.1 Hz, CHOCO), 2.96 (1H, br. s, OH),  2.68 (1H, qd, J = 7.8 Hz and 1.5 Hz), 1.38 (3H, s, 
(CH3A)C(CH3B)), 1.36 (3H, s, (CH3A)C(CH3B)), 1.19 (3H, d, J = 7.8 Hz, CH3CH); 
13C NMR (75 
MHz, CDCl3) " 179.52, 84.04, 76.30, 73.03, 46.85, 28.74, 25.01, 13.50; IR (ATR) . (cm
-1): 
3295.1 (broad O-H), 1754.3 (C=O); HRMS (ES+): m/z calculated for C8H14O4: requires 









Rf (7:3 DCM/EtOAc) = 0.24; [#]D
23 = +25.0 (c = 0.53 in CHCl3); 
1H NMR (300 MHz, CDCl3) 
" 4.12 (1H, ddd, J = 9.1 Hz, 7.4 Hz and 4.4 Hz, CHOH), 3.88 (1H, d, J = 7.5 Hz, CHOCO), 
2.61 (1H, dq, J = 9.3 Hz and 7.5 Hz, CHCO), 2.32 (1H, d, J = 4.4 Hz, OH), 1.72 (1H, s, OH), 
1.30 – 1.19 (9H, m, CH3CH and (CH3)2C); 
13C NMR (75 MHz, CDCl3) " 177.2, 88.5, 74.7, 
71.0, 44.4, 26.6, 25.9, 12.9; IR (ATR) . (cm-1): 3398.8 (O-H), 1766.8 (C=O); HRMS (ES+): m/z 
calculated for C8H14O4 requires 197.0789 for [M+Na]
















Osmium tetroxide (14.5 mg, 0.057 mmol) was added to a solution of aldol 163m (206.4 mg, 
0.57 mmol) in acetone/water (8:1, 3 mL) followed by addition of N-methylmorpholine-N-oxide 
(60% by weight in water, 0.11 mL, 0.63 mmol) according to General Procedure 7 to afford the 
crude product as a black oil. Purification via column chromatography afforded (3S,4S,5R)-4-
hydroxy-5-(hydroxymethyl)-3-isopropyl-5-methyl-dihydrofuran-2(3H)-one, 240m1 (46.3 
mg, 0.24 mmol, 43%) as a pale oil. The slightly minor diastereomer was also isolated as a white 
solid (3S,4S,5S)-4-hydroxy-5-(hydroxymethyl)-3-isopropyl-5-methyl-dihydrofuran-2(3H)-











Rf (7:3 DCM/EtOAc) = 0.33; [#]D
23 = +39.1 (c = 0.69 in CHCl3); 
1H NMR (300 MHz, CDCl3) 
" 4.05 (1H, app. br. d, J = 7.5 Hz, CHOH), 3.87 (1H, d, J = 12.6 Hz, CHAHBOH), 3.75 Hz (1H, 
d, J = 12.6 Hz, CHAHBOH), 2.67 (1H, dd, J = 8.3 Hz and 4.9 Hz, CHCO), 2.19 (1H, d sept., J =  
6.9 Hz and 4.9 Hz, CH(CH3)2), 1.29 (3H, s, CH3), 1.03 (3H, d, J = 6.8 (CH3
A)CH(CH3
B)), 0.94 
(3H, d, J = 6.8 (CH3
A)CH(CH3
B)); 13C NMR (75 MHz, CDCl3) " 175.6, 85.9, 69.6, 65.9, 52.1, 
27.2, 20.1, 19.3, 17.3; IR (ATR) . (cm-1): 3333.6 (broad O-H), 1736.7 (C=O); ); HRMS (ES+): 
m/z calculated for C9H16O4: requires 189.1127 for [M+H]
+; found: 189.1124: requires 

















Rf (7:3 DCM/EtOAc) = 0.42; [#]D
23 = -17.0 (c = 0.53 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 
4.05 (1H, app. br. d, J = 7.5 Hz, CHOH), 3.87 (1H, d, J = 12.6 Hz, CHAHBOH), 3.75 Hz (1H, d, 
J = 12.6 Hz, CHAHBOH), 2.67 (1H, dd, J = 8.3 Hz and 4.9 Hz, CHCO), 2.19 (1H, d.sept., J =  
6.9 Hz and 4.9 Hz, CH(CH3)2), 1.29 (3H, s, CH3), 1.03 (3H, d, J = 6.8 (CH3
A)CH(CH3
B)), 0.94 
(3H, d, J = 6.8 (CH3
A)CH(CH3
B)); 13C NMR (75 MHz, CDCl3) " 176.3, 85.8, 66.8, 56.1, 28.1, 
22.6, 20.1, 19.1; IR (ATR) . (cm-1): 3308.0 (broad O-H), 1744.9 (C=O); HRMS (ES): m/z 
calculated for C9H16O4: requires 189.1127 for [M+H]
+; found: 189.1115: requires 211.0946 for 












Osmium tetroxide (6.3 mg, 0.025 mmol) was added to a solution of aldol 163l (94 mg, 0.25 
mmol) in acetone/water (8:1, 3 mL) followed by addition of N-methylmorpholine-N-oxide (60% 
by weight in water, 0.05 mL, 0.26 mmol) according to General Procedure 7 to afford the crude 
product as a black oil. Purification via column chromatography afforded (3S,4S,5R)-4-
hydroxy-5-(hydroxymethyl)-5-methyl-3-phenyl-dihydrofuran-2(3H)-one, 240l (42 mg, 0.19 
mmol, 75%) as a pale oil. 
 
Rf (7:3 DCM/EtOAc) = 0.34; [#]D
25 = -9.1 (c = 0.83 in MeOH); 1H NMR (300 MHz, CDCl3) " 
7.29 – 7.23 (3H, m, PhH), 7.18 – 7.13 (2H, m, PhH), 4.62 (1H, d, J = 10.5 Hz, CHOH), 3.80 
(1H, d, J = 10.5 Hz, CHCO), 3.70 (1H, d, J = 12.6 Hz, CHAHBOH), 3.58 (1H, d, J = 12.6 Hz, 
CHAHBOH), 1.32 (3H, s, CH3); 
13C NMR (75 MHz, CDCl3) " 174.33, 135.10, 129.42, 128.95, 
128.42, 86.51,75.28, 65.47, 53.75, 16.87; IR (ATR) . (cm-1):  3308.3 (broad O-H), 1745.7 
(C=O); HRMS (ES): m/z calculated for C12H14O4: requires 223.0970 for [M+H]
+; found: 
223.0961: requires 245.0790 for [M+Na]+; found: 245.0767. 












Osmium tetroxide (13.7 mg, 0.054 mmol) was added to a solution of aldol 163k (175.2 mg, 
0.54 mmol) in acetone/water (8:1, 3 mL) followed by addition of N-methylmorpholine-N-oxide 
(60% by weight in water, 0.1 mL, 0.59 mmol) according to General Procedure 7 to afford the 
crude product as a black oil. Purification via column chromatography afforded (3S,4R,5R)-3-
chloro-4-hydroxy-5-(hydroxymethyl)-5-methyl-dihydrofuran-2(3H)-one, 240k (74.1 mg, 
0.41 mmol, 76%) as a pale oil. 
 
Rf (7:3 DCM/EtOAc) = 0.13; [#]D
23 = +12.7 (c = 0.85 in MeOH); 1H NMR (500 MHz, MeOD) 
" 4.82 (1H, d, J = 9.6 Hz, CHCl), 4.50 (1H, d, J = 9.6 Hz, CHOH), 3.66 (1H, d, J = 13.5 Hz, 
CHAHBOH), 3.55 (1H, d, J = 13.5 Hz, CHAHBOH), 1.33 (3H, s, CH3); 
13C NMR (75 MHz, 
MeOD) " 174.5, 91.6, 72.9, 68.0, 59.0, 18.1; IR (ATR) . (cm-1): 3331.0 (broad O-H), 1755.1 








HO OH  
 
Osmium tetroxide (7.5 mg, 0.024 mmol) was added to a solution of aldol 275 (165 mg, 0.24 
mmol) in acetone/water (0.07 mL, 0.24 mmol) followed by addition of N-methylmorpholine-N-
oxide (60% by weight in water, 0.1 mL, 0.59 mmol) according to General Procedure 7 to afford 
the crude product as a black oil. Purification via column chromatography afforded a mixture of 
diastereomers (S)-4-benzyl-3-((S)-3-hydroxypent-4-enoyl)oxazolidin-2-one, 272a and 
(4S,5R)-4-hydroxy-5-(hydroxymethyl)dihydrofuran-2(3H)-one, 272b (14.5 mg,  0.11 mmol, 
47%) as a pale oil. 
 
1H NMR (300 MHz, MeOD): % 4.47 (1H, dt, J = 6.7, 2.3 Hz, CHOH), 4.43 – 4.37 (1H, m, 
CHCH2OH), 3.81 (1H, dd, J = 12.4, 3.3 Hz, CHACHBOH), 3.73 (1H, dd, J = 12.4, 3.6 Hz, 
" " " 63)7*('"U8"/$7('!0(,*)4"
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CHACHBOH), 2.94 (1H, dt, J = 17.6, 6.2 Hz, CHACHBC=O), 2.51 – 2.32 (1H, m, 
CHACHBC=O); 
13C NMR (75.5 MHz, MeOD): % 179.5, 91.1, 70.6, 63.4, 40.1; IR (ATR) .max 
(cm-1): 3329 (broad O-H), 2941 (broad O-H), 1793 (C=O); HRMS (ESI); m/z calculated for 
C5H8NO4: requires 155.0320 for [M+Na]






HO OH  
 
1H NMR (300 MHz, MeOD): % 4.62 – 4.50 (1H, m, CHOH & CHCH2OH), 3.91 (1H, dd, J = 
5.4, 1.6 Hz, CHACHBOH), 2.94 (2H, dt, J = 17.6, 6.2 Hz, CHACHBC=O), 2.52 – 2.32 (1H, m, 
CHACHBC=O); 
13C NMR (75.5 MHz, MeOD): % 179.4, 87.4, 69.9, 62.1, 40.9; IR (ATR) .max 
(cm-1): 3329 (broad O-H), 2941 (broad O-H), 1793 (C=O); HRMS (ESI); m/z calculated for 
C5H8NO4: requires 155.0320 for [M+Na]















9-Borabicyclo[3.3.1]nonyl trifluoromethanesulphonate (6.40 mL, 3.20 mmol) was added to a 
solution of (S)-4-benzyl-3-(2-chloroacetyl)-5,5-dimethyloxazolidin-2-one, 142d (750.0 mg, 
2.67 mmol) in dichloromethane (70 mL) followed by addition of N,N-diisopropylethylamine 
(0.58 ml, 3.335 mmol) and methacrolein (0.28 mL, 3.335 mmol) according to General 
Procedure 3 to afford the crude product as a pale yellow oil. Purification via column 
chromatography afforded 163p (610.5 mg, 1.73 mmol, 65 %) as a colourless oil. 
 
Rf = 0.21 (DCM); [#]D
24 = -20 (c = 1.20 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 7.30-7.10 
(5H, m, Ph), 5.80 (1H, ddd, J = 15.5 Hz, 6.5 Hz and 1Hz, CH=CHCH3), 5.66 (1H, d, J = 5.5 Hz, 
CHCl), 5.47 (1H, dqd, J = 15.5 Hz, 6.5Hz and 1Hz, CH=CHCH3), 4.51– 4.40 (2H, m, CHOH 
and CHN), 3.09 (1H, dd, J = 14.5Hz and 4.0 Hz, CHAHBPh), 2.85 (1H, dd, J = 14.5 Hz and 9.5 
Hz, CHAHBPh) 2.61 (1H, br d, J = 4.0 Hz, OH), 1.65 (3H, d, J = 6.5 Hz, CH=CHCH3), 1.34 
(3H, s, C(CH3)), 1.29 (3H, s, C(CH3)); 
13C NMR (75 MHz, CDCl3) " 168.5, 152.3, 136.7, 131.8, 
129.5, 129.2, 128.1, 127.4, 83.4, 73.4, 64.4, 59.6, 35.3, 28.8, 22.6, 18.2; IR (ATR) . (cm-1): 
3451 (broad O-H) 1772 (C=O), 1652 (C=Oox); HRMS (ES): m/z calculated for C18H22ClNO4: 





















According to General Procedure 8, Zinc dust (234 mg, 3.60 mmol) was added in one portion to 
a stirred mixture of aldol 163p (314 mg, 0.89 mmol), solid NH4Cl (191 mg, 3.60 mmol) and 
methanol (20 mL). The crude reaction product was purified by chromatography (CH2Cl2) to 
afford (S)-4-benzyl-3-((2S,3R)-3-hydroxy-3-((1S,2S)-2-methylcyclopropyl)-2-
phenylpropanoyl)-5,5-dimethyloxazolidin-2-one, 296 (210 mg, 0.66 mmol) as a colourless oil 
in 74% yield.   
 
[#]D
23 = -51.5 (c = 1.23, CHCl3); 
1H NMR (300 MHz, CDCl3): % = 7.28-7.11 (5H, m, ArH), 
5.68 (1H, dqd, J = 15.5, 6.5, 1Hz, CH=CHCH3), 5.47 (1H, ddq, J = 15.5, 6.5, 1Hz, 
CH=CHCH3), 4.50–4.39 (2H, m, CHOH and CHN), 3.1-3.0 (3H, m, CH2CHOH and 
CHAHBPh), 2.8 (1H, dd, J = 14.5, 6.5 Hz, CHAHBPh), 1.63 (3H, dt, J = 6.5 Hz, CH=CHCH3), 
1.32 (3H, s, C(CH3)), 1.30 (3H, s, C(CH3)); 
13C NMR (75 MHz, CDCl3): % = 172.8, 153.0, 
137.2, 132.1, 129.4, 129.2, 127.8, 127.3, 82.9, 69.1, 63.8, 53.8, 43.3, 35.9, 28.8, 18.1; IR (KBr / 
cm-1) 3502 (broad OH) 1777 (C=O), 1695 (C=Oox); HRMS (ES+): m/z calculated for 
C18H23NO4 requires [M+Na]












According to General Procedure 9, (S)-4-benzyl-3-((2S,3R,E)-3-hydroxy-2-methylhex-4-enoyl)-
5,5-dimethyloxazolidin-2-one 163f (200 mg, 0.658 mmol) in dichloromethane (10 mL) was 
treated with diethylzinc (3.29 mL, 3.289 mmol, 1.0 M in hexane) and diiodomethane (0.26 mL, 
3.289 mmol) to afford (S)-4-benzyl-3-((2S,3R)-3-hydroxy-2-methyl-3-((1S,2S)-2-
63)7*('"U8"/$7('!0(,*)4"
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methylcyclopropyl)propanoyl))-5,5-dimethyloxazolidin-2-one, 295f as a white solid in 
quantitative yield.  
 
1H NMR (300 MHz, CDCl3) % 7.33-7.20 (5H, m, Ph), 4.53 (1H, dd, J = 9.2, 4.3 Hz, CHOH), 
3.99 (1H, dq, J = 14.0, 3.7 Hz, COCH), 3.20 (1H, dd, J = 8.4, 3.6 Hz, CHN), 3.08 (1H, dd, J = 
14.3, 4.3 Hz, CHAHBPh), 2.90 (1H, dd, J = 14.3, 9.2 Hz, CHAHBPh), 2.46 (1H, s, OH), 1.38 
(3H, s, (CH3)C(CH3)), 1.37 (3H, s, (CH3)C(CH3)), 1.25 (3H, d, J = 7.0 Hz, CHCH2CHCH3), 
1.03 (3H, d, J = 6.0 Hz, CH3CH), 0.77-0.63 (2H, m, CHCH2CH), 0.55-0.49 (1H, m, 
CHCH2CHCH3), 0.35-0.29 (1H, m, CHCH2CHCH3); 
13C NMR (75 MHz, CDCl3) % = 11.0, 
11.8, 18.4, 22.3, 23.2, 28.6, 35.6, 43.0, 63.6, 76.2, 77.4, 82.4, 127.0, 128.8, 129.2, 136.9, 152.6, 
176.9; IR (ATR) . (cm-1) = 3485.31 (O-H), 1775.98 (C=Oox), 1685.41 (C=O); HRMS (ES): m/z 
calculated for C20H27NO4: requires 368.1837 for [M+Na]













According to General Procedure 9, (S)-4-benzyl-3-((2S,3R,E)-3-hydroxy-2-methyl-5-
phenylpent-4-enoyl)-5,5-dimethyloxazolidin-2-one 163g (355 mg, 0.901 mmol) in 
dichloromethane (10 mL) was treated with diethylzinc (4.535 mL, 4.54 mmol, 1.0 M in hexane) 
and diiodomethane (0.36 mL, 4.535 mmol) to afford (S)-4-benzyl-3-((2S,3R)-3-hydroxy-2-
methyl-3-((1S,2S)-2-phenylcyclopropyl)propanoyl)-5,5-dimethyloxazolidin-2-one, 295g as a 
white solid in quantitative yield.  
 
1H NMR (300 MHz, CDCl3) % 7.33-7.04 (10H, m, Ph and CH2Ph), 4.44 (1H, dd, J = 9.2, 4.3 
Hz, CHN), 4.04 (1H, qd, J = 7.0, 4.4 Hz, COCH), 3.47 (1H, m, CHOH), 3.08 (1H, dd, J = 14.3, 
4.2 Hz, CHCHAHBPh), 2.87 (1H, dd, J = 14.3, 9.3 Hz, CHCHAHBPh), 1.91 (1H, m, 
CHCH2CHPh), 1.35 (3H, s, (CH3)C(CH3)), 1.25 (3H, d, J = 7.0 Hz, (CH3CH), 1.16 (3H, s, 
(CH3)C(CH3)), 1.12-1.05 (1H, m, CHCH2CHPh), 1.03-0.83 (2H, m, CHCH2CHPh); 
13C NMR 
(75 MHz, CDCl3): % 176.7, 152.5, 142.3, 136.9, 129.2, 128.8, 128.5, 127.0, 125.9, 125.8, 82.3, 
75.5, 63.5, 43.5, 35.5, 28.3, 26.6, 22.4, 21.3, 14.0, 12.4; IR (ATR) & (cm-1) = 3488.90 (O-H), 
1769.80 (C=Oox), 1692.60 (C=O); HRMS (ES): m/z calculated for C25H29NO4: requires 













According to General Procedure 9, (S)-4-benzyl-3-((2S,3R)-3-hydroxy-2,5-dimethylhex-4-
enoyl)-5,5-dimethyloxazolidin-2-one, 163h (430 mg, 1.25 mmol) in dichloromethane (10 mL) 
was treated with diethylzinc (6.23 mL, 6.23 mmol, 1.0 M in hexane) and diiodomethane (0.5 
mL, 6.23 mmol) to afford (S)-4-benzyl-3-((2S,3R)-3-((S)-2,2-dimethylcyclopropyl)-3-
hydroxy-2-methylpropanoyl)-5,5-dimethyloxazolidin-2-one, 295h as a white solid in 
quantitative yield.  
 
[#]D
24 = +12.0 (c = 1.00, CHCl3); 
1H NMR (300 MHz, CDCl3) " 7.27-7.10 (5H, m, Ph) 4.48 
(1H, dd, J = 9.2 Hz and 4.5 Hz, CHN), 3.91 (1H, qd, J = 7.0 Hz and 3.4 Hz, COCH), 3.47 (1H, 
dd, J = 9.5 Hz and 3.5 Hz, CHOH), 3.03 (1H, dd, J = 14.0 Hz and 4.5 Hz, CHAHBPh), 2.83 (1H, 
dd, J = 14.0 and 9.2 Hz, CHACHBPh), 2.69 (1H, broad s, OH), 1.32 (3H, s, (CH3)C(CH3)), 1.31 
(3H, s, (CH3)C(CH3)), 1.18 (3H, d, J = 7.0 Hz, CH3CH), 1.01 (3H, s, (CH3)C(CH3)-
cyclopropane), 0.98 (3H, s, (CH3)C(CH3)-cyclopropane), 0.77 (1H, app. td, J = 8.3 Hz and 5.6 
Hz, CHCH2C), 0.51 (1H, dd, J = 8.3 Hz and 4.2 Hz, CHCHAHBC), 0.25 (1H, app. t, J = 5 Hz, 
CHAHBC); 
13C NMR (75 MHz, CDCl3) " 177.8, 152.5, 137.1, 129.5, 129.0, 127.3, 82.5, 73.5, 
64.2, 43.3, 35.8, 28.8, 28.1, 27.5, 23.1, 22.0, 19.5, 18.6, 11.4; IR (ATR) . (cm-1): 3483.7 (O-H), 
1776.9 (C=O), 1686.4 (C=Oox); HRMS (ES): m/z calculated for C21H29NO4: requires 382.1994 
























According to General Procedure 9, (S)-4-benzyl-3-((2S,3R,Z)-3-hydroxy-2-methyldec-4-enoyl)-
5,5-dimethyloxazolidin-2-one, 163j (363 mg, 0.938 mmol) in dichloromethane (10 mL) was 
treated with diethylzinc (4.68 mL, 4.68 mmol, 1.0 M in hexane) and diiodomethane (0.37 mL, 
4.68 mmol) to afford (S)-4-benzyl-3-((2S,3R)-3-hydroxy-2-methyl-3-((1S,2R)-2-




24 = -19.0 (c = 1.0, CHCl3); 
1H NMR (300 MHz, CDCl3) " 7.30-7.15 (5H, m, Ph), 4.50 (1H, 
dd, J = 9.3 Hz and 4.3 Hz, CHN), 3.95 (1H, qd, J = 7.0 and 3.0 Hz, COCH), 3.55 (1H, app. dt, J 
= 9.2 Hz and 3.0 Hz, CHOH), 3.09 (1H, dd, J = 14.5 and 4.3 Hz, CHAHBPh), 2.91 (1H, dd, J = 
14.5 and 9.3 Hz, CHACHBPh), 2.65 (1H, d, J = 2.1 Hz, OH), 1.65-1.20 (8H, obs. m, (CH2)4), 
1.40 (3H, s, (CH3)C(CH3)), 1.37 (3H, s, (CH3)C(CH3)), 1.29 (3H, d, J = 7.0 Hz, CH3CH), 1.07-
0.93 (2H, m, CHCH2CH), 0.88 (3H, t, J = 7.0 Hz, CH2CH3), 0.86-0.76 (1H, m, CHCH2CH); 
13C 
NMR (75 MHz, CDCl3) " 177.9, 152.7, 137.1, 129.5, 129.1, 127.3, 82.6, 72.4, 63.9, 43.3, 35.8, 
32.1, 30.2, 29.3, 28.8, 23.1, 22.6, 19.4, 16.7, 14.5, 11.6, 10.2; IR (ATR) . (cm-1): 3510.7 (O-H), 
1774.4 (C=O), 1694.4 (C=Oox); HRMS (ES): m/z calculated for C24H35NO4: requires 424.2464 













According to General Procedure 9, (S)-4-benzyl-3-((2S,3R,E)-3-hydroxy-2-phenylhex-4-enoyl)-
5,5-dimethyloxazolidin-2-one, 163o (915 mg, 2.33 mmol) in dichloromethane (10 mL) was 
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treated with diethylzinc (11.6 mL, 11.6 mmol, 1.0 M in hexane) and diiodomethane (0.935 mL, 
11.6 mmol) to afford (S)-4-benzyl-3-((2S,3R)-3-hydroxy-3-((1S,2S)-2-methylcyclopropyl)-2-
phenylpropanoyl)-5,5-dimethyloxazolidin-2-one, 295o as a white solid in quantitative yield. 
 
[#]D
24 = -6.0 (c = 1.00, CHCl3); 
1H NMR (300 MHz, CDCl3) " 7.49 – 7.10 (10H, m, Ph), 5.17 
(1H, br. d, J = 5.2 Hz, CHPh), 4.56 (1H, dd, J = 9.7 Hz and 3.0 Hz, CHN), 3.59 (1H, dd, J = 7.4 
Hz and 5.2 Hz, CHOH), 2.98 (1H, dd, J = 14.9 Hz and 3.7 Hz, CHAHBPh), 2.69 (1H, dd, J = 
14.9 Hz and 10.4 Hz, CHAHBPh), 1.36 (3H,s, (CH3)C(CH3)), 1.29 (3H, s, (CH3)C(CH3)), 1.01 
(3H, d, J = 5.9, CHCH3), 0.80 – 0.64 (1H, m, CHCH2CHMe), 0.63 – 0.45 (2H, m, 
CHCH2CHMe), 0.34 – 0.19 (1H, m, CHCH2CHMe); 
13C NMR (75 MHz, CDCl3) " 174.1, 
152.2, 137.1, 134.5, 130.5, 129.4, 129.1, 128.9, 128.1, 127.2, 82.4, 76.7, 63.9, 55.1, 35.1, 29.1, 
24.1, 22.7, 18.7, 12.0, 11.8; IR (ATR) . (cm-1): 3511.9 (O-H), 1771.6 (C=O), 1690.3 (C=Oox); 
HRMS (ES): m/z calculated for C25H29NO4: requires 430.1994 for [M+H]













According to General Procedure 9, (S)-4-benzyl-3-((2S,3R,E)-2-chloro-3-hydroxyhex-4-enoyl)-
5,5-dimethyloxazolidin-2-one, 163p (599 mg, 1.70 mmol) in dichloromethane (10 mL) was 
treated with diethylzinc (8.5 mL, 8.5 mmol, 1.0 M in hexane) and diiodomethane (0.682 mL, 
8.5 mmol) to afford (S)-4-benzyl-3-((2S,3R)-3-hydroxy-3-((1S,2S)-2-methylcyclopropyl)-2-
phenylpropanoyl)-5,5-dimethyloxazolidin-2-one, 295p as a white solid in quantitative yield.  
 
[#]D
24 = -18.0 (c = 1.00, CHCl3); 
1H NMR (300 MHz, CDCl3) " 7.30 – 7.11 (5H, m, Ph), 5.72 
(1H, d, J = 4.1 Hz, CHCl), 4.45 (1H, dd, J = 9.5 Hz and 3.5 Hz, CHN), 3.39 (1H, dd, J = 7.9 Hz 
and 4.1 Hz, CHOH), 3.15 (1H, dd, J = 14.5 Hz and 3.5 Hz, CHAHBPh), 2.84 (1H, dd, J = 14.5 
Hz and 9.8 Hz, CHAHBPh), 1.33 (3H, s, (CH3)C(CH3)), 1.29 (3H, s, (CH3)C(CH3)), 0.97 (3H, d, 
J = 5.7, CHCH3), 0.86 – 0.68 (2H, m, CHCH2CHMe), 0.62 – 0.53 (1H, m, CHCH2CHMe), 0.37 
– 0.27 (1H, m, CHCH2CHMe); 
13C NMR (75 MHz, CDCl3) " 168.69, 152.3, 136.8, 129.4, 
129.2, 127.4, 83.5, 75.5, 64.6, 60.7, 35.1, 28.9, 23.1, 22.7, 18.6, 12.18, 11.34; IR (ATR) . (cm-
1): 3509.8 (O-H), 1774.9 (C=O), 1711.8 (C=Oox); HRMS (ES): m/z calculated for C19H24ClNO4: 
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According to General Procedure 9, (S)-4-benzyl-3-((2S,3R,E)-3-hydroxy-2-isopropylhex-4-
enoyl)-5,5-dimethyloxazolidin-2-one, 163q (810 mg, 2.28 mmol) in dichloromethane (10 mL) 
was treated with diethylzinc (11.4 mL, 11.4 mmol, 1.0 M in hexane) and diiodomethane (0.92 
mL, 11.4 mmol) to afford (S)-4-benzyl-3-((S)-2-((R)-hydroxy((1S,2S)-2-methylcyclopropyl)-




24 = -8.0 (c = 1.0, CHCl3); 
1H NMR (300 MHz, CDCl3) " 7.47 – 7.15 (5H, m, Ph), 4.63 (1H, 
dd, J = 10.4 Hz and 3.2 Hz, CHN), 4.24 (1H, dd, J = 8.5 Hz and 6.4 Hz, CH(CH3)2), 3.67 
(1H,dd, J = 8.9 Hz and 6.4 Hz, CHOH), 3.24 (1H, dd, J = 14.3 Hz and 3.2 Hz, CHAHBPh), 2.87 
(1H, dd, J = 14.5 Hz and 10.0 Hz, CHAHBPh), 2.29 (1H, m, CH(CH3)2), 1.36 (3H, s, 
(CH3)C(CH3)), 1.34 (3H, s, (CH3)C(CH3)), 1.06 (3H, d, J = 6.1 Hz, CHCH3), 1.03 (3H, d, J = 
6.8 Hz, (CH3
A)C(CH3
B)), 0.95 (3H, d, J = 6.8 Hz, (CH3
A)C(CH3
B)), 0.85 – 0.67 (2H, m, 
CHCH2CHMe), 0.60 – 0.39 (1H, m, CHCH2CHMe), 0.37 – 0.23 (1H, m, CHCH2CHMe); 
13C 
NMR (75 MHz, CDCl3) " 174.9, 153.7, 137.4, 129.4, 129.1, 127.2, 82.2, 75.8, 64.3, 54.5, 35.8, 
28.9, 28.7, 23.5, 22.8, 21.3, 21.0, 18.8, 14.7, 13.1, 10.7; IR (ATR) . (cm-1): 3511.1 (broad O-
H), 1771.7 (C=O), 1689.4 (C=Oox); HRMS (ES): m/z calculated for C22H31NO4: requires 
















According to General Procedure 10, (S)-4-benzyl-3-((2S,3R)-3-hydroxy-2-methyl-3-((1S,2S)-2-
methylcyclopropyl)-propanoyl)-5,5-dimethyloxazolidin-2-one 295f (152 mg, 0.440 mmol) in 
dichloromethane (8.8 mL) was treated with sodium methoxide (0.88 mL, 0.440 mmol, 0.5 M in 
methanol). The crude product was purified using flash chromatography. Pure fractions were 
evaporated to afford (2S,3R)-methyl 3-hydroxy-2-methyl-3-((1S,2S)-2-
methylcyclopropyl)propanoate, 309f (42 mg, 55%) as a colourless liquid.  
 
Rf  = 0.24 (1:4, EtOAc:Hexane); [#]D
24 = -8.0 (c = 1.0, CHCl3); 
1H NMR (300 MHz, CDCl3) % 
3.71 (3H, s, OCH3), 3.13-3.08 (1H, m, CHOH), 2.70 (1H, dq, J = 14.2 Hz and 5.2 Hz, COCH), 
2.19 (1H, s, OH), 1.26 (3H, d, J = 7.1 Hz, CH3CH), 1.01 (3H, d, J = 5.7 Hz, CHCH2CHCH3)), 
0.71-0.58 (2H, m, CH(CH2)CHCH3), 0.54-0.49 (1H, m, CH(CH2)CHCH3), 0.34-0.28 (1H, m, 
CH(CH2)CHCH3); 
13C NMR (75 MHz, CDCl3) % 175.8, 76.8, 52.0, 45.6, 23.9, 18.3, 12.3, 11.5, 
11.3; IR (ATR) & (cm-1) = 3444.07 (O-H), 1718.01 (C=O); HRMS (ES+): m/z calculated for 
C9H16O3: requires 195.0997 for [M+Na]








According to General Procedure 10, (S)-4-benzyl-3-((2S,3R)-3-hydroxy-2-methyl-3-((1S,2S)-2-
phenylcyclopropyl)-propanoyl)-5,5-dimethyloxazolidin-2-one 295g (168 mg, 0.412 mmol) in 
dichloromethane (8.2 mL) was treated with sodium methoxide (0.82 mL, 0.412 mmol). The 
crude product was purified using flash chromatography. The pure fractions were concentrated 
under reduced pressure to afford (2S,3R)-methyl 3-hydroxy-2-methyl-3-((1S,2S)-2-
phenylcyclopropyl)propanoate, 309g (86 mg, 89%) as a colourless liquid.  
 
Rf = 0.49 (3:7, EtOAc:Hexane); 
1H NMR (300 MHz, CDCl3) " 7.20-7.14 (2H, m, Ph), 7.10-7.04 
(1H, m, Ph), 6.98-6.95 (2H, m, Ph), 3.53 (3H, s, OCH3), 3.35 (1H, dd, J = 8.0Hz and 4.7 Hz, 
CHOH), 2.68 (1H, dq, J = 14.2 and 4.7 Hz, COCH), 2.43 (1H, s, OH), 1.79-1.72 (1H, m, 
CH(CH2)CHPh), 1.30-1.23 (1H, m, CH(CH2)CHPh), 1.20 (3H, d, J = 7.2 Hz, CH3CH), 1.03-
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0.97 (1H, m, CH(CHAHB)CHCH3), 0.93-0.87 (1H, m, CH(CHAHB)CHCH3); 
13C NMR (75 
MHz, CDCl3) " 175.9, 142.1, 128.5, 125.9, 125.8, 75.8, 51.8, 45.3, 26.4, 21.2, 13.9, 12.1; IR 
(ATR) & (cm-1) = 3439.46 (O-H), 1730.03 (C=O); HRMS: m/z calculated for C14H18O3: requires 








According to General Procedure 10, (S)-4-benzyl-3-((2S,3R)-3-((S)-2,2-dimethylcyclopropyl)-
3-hydroxy-2-methylpropanoyl)-5,5-dimethyloxazolidin-2-one 295h (272 mg, 0.75 mmol) in 
dichloromethane (7 mL) was treated with sodium methoxide (2.3 mL, 1.15 mmol). The crude 
product was purified using flash chromatography. The pure fractions were concentrated under 
reduced pressure to afford (2S,3R)-methyl 3-((S)-2,2-dimethylcyclopropyl)-3-hydroxy-2-
methylpropanoate, 309h (99.0 mg, 71 %) as a colourless oil. 
 
Rf (3:1, Petrol:EtOAc) = 0.5; [#]D
23 = -11 (c = 1.0, CHCl3); 
1H NMR (300 MHz, CDCl3) " 3.72 
(3H, s, OCH3), 3.50 (1H, dd, J = 9.4 Hz and 4.1 Hz CHOH), 2.64 (1H, dq, J = 7.1 Hz and 3.9 
Hz, COCH), 1.27 (3H, d, J = 7.5 Hz, CH3CH), 1.07 (3H, s, CH3), 1.03 (3H, s, CH3), 0.83-0.74 
(1H, m, CH(CHAHB)C), 0.57 (1H, dd, J = 8.4 Hz and 4.3 Hz, CH(CHAHB)C), 0.33 (1H, app t, J 
= 5.1 Hz, CH(CH2)C); 
13C NMR (75 MHz, CDCl3) " 176.3, 73.5, 52.2, 45.7, 28,6, 27.5, 21.0, 
18.8, 17.1, 11.5; IR (ATR) . (cm-1): 3451.9 (O-H), 1721.4 (C=O); HRMS (ES): m/z calculated 
for C10H18O3: requires 209.1153 for [M+Na]








According to General Procedure 10, (S)-4-benzyl-3-((2S,3R)-3-hydroxy-2-methyl-3-((1S,2R)-2-
pentylcyclopropyl)propanoyl)-5,5-dimethyloxazolidin-2-one, 295j (340.1 mg, 0.848 mmol) in 
dichloromethane (7 mL) was treated with sodium methoxide (2.54 mL, 1.27 mmol). The crude 
product was purified using flash chromatography. The pure fractions were concentrated under 
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reduced pressure to afford (2S,3R)-methyl 3-hydroxy-2-methyl-3-((1S,2R)-2-
pentylcyclopropyl)propanoate, 309j (157.0 mg, 81%) as a colourless liquid 
 
Rf (3:1, Petrol:EtOAc); [#]D
23 = +8.0 (c =0.88, CHCl3); 
1H NMR (300 MHz, CDCl3) " 3.71 
(3H, s, OCH3), 3.58 (1H, dd, J = 9.3 Hz and 3.2 Hz CHOH), 2.66 (1H, dq, J = 7.3 Hz and 3.2 
Hz, COCH), 1.63-1.46 (2H, m, CH2-alkyl), 1.46-1.16 (9H, m, (CH2)3 and CH3CH) 0.93 (2H, m, 
CH(CHAHB)CH), 0.88 (3H, t, J = 7.0 Hz, CH2CH3), 0.80 (1H, m, CH(CHAHB)CH); 
13C NMR 
(75 MHz, CDCl3) " 176.6, 72.6, 52.2, 45.3, 32.1, 30.2, 29.2, 23.0, 19.8, 16.9, 14.4, 10.8, 10.2; 
IR (ATR) . (cm-1): 3335.1 (O-H), 1715.1 (C=O); HRMS (ES): m/z calculated for C13H24O3: 









According to General Procedure 10, (S)-4-benzyl-3-((S)-2-((R)-hydroxy((1S,2S)-2-
methylcyclopropyl)methyl)-3-methylbutanoyl)-5,5-dimethyloxazolidin-2-one 295q (900 mg, 
2.5 mmol) in dichloromethane (10 mL) was treated with sodium methoxide (5.5 mL, 2.75 
mmol). The crude product was purified using flash chromatography. The pure fractions were 
concentrated under reduced pressure to afford (S)-methyl 2-((R)-hydroxy((1S,2S)-2-
methylcyclopropyl)methyl)-3-methylbutanoate, 309q (375 mg, 75%) as a colourless liquid 
 
Rf (3:1, Petrol:EtOAc) =  0.6; [#]D
24 = -13.0 (c = 0.78, CHCl3); 
1H NMR (300 MHz, CDCl3) " 
3.70 (3H, s, OCH3), 3.18 (1H, app. t, J = 8.2 Hz, CHOH), 2.53 (1H, dd, J = 7.9 Hz and 6.1 Hz, 
COCH), 2.21 (1H, m, CH(CH3)2), 1.00 (3H, app. s, CHCH3), 0.98 (3H, d, J = 2.77 Hz, CH3CH), 
0.97 (3H, d, J = 2.7 Hz, CH3CH), 0.80-0.63 (2H, m, CH(CH2)CHCH3), 0.55-0.41 (1H, m, 
CH(CH2)CHCH3), 0.33-0.21 (1H, m, CH(CH2)CHCH3);
 13C NMR (75 MHz, CDCl3) " 174.1, 
75.2, 58.6, 51.4, 27.5, 25.5, 21.8, 19.2, 18.6, 12.8, 11.1; IR (ATR) . (cm-1): 3451.0 (broad O-














According to General Procedure 10, (S)-4-benzyl-3-((S,E)-3-hydroxyhex-4-enoyl)-5,5-
dimethyloxazolidin-2-one, 296 (242 mg, 0.76 mmol) in dichloromethane (10 mL) was treated 
with sodium methoxide (0.5 M in methanol, 1.54 mL, 0.77 mmol). The crude product was 
purified using flash chromatography. The pure fractions were concentrated under reduced 
pressure to afford (S)-methyl 3-hydroxy-3-((1S,2S)-2-methylcyclopropyl)propanoate, 297 
(78 mg, 0.54 mmol, 71%) as a colourless oil. 
 
[#]D
22 = -22.2 (c = 0.72 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 5.70 (1H, dqd, J = 15.0 Hz, 
6.0 Hz and 1.0 Hz, CH=CHCH3), 5.43 (1H, ddq, J = 15.0 Hz, 6.0 Hz and 1.0 Hz, CH=CHCH3), 
4.42 (1H, app. q, J = 6.5 Hz, CHOH), 3.62 (3H, s, OCH3), 2.78 (1H, br. s, CHOH), 2.47 (2H, m, 
CH2), 1.63 (3H, t, J = 6.5 Hz, CH=CHCH3); 
13C NMR (75 MHz, CDCl3) " 173.1, 132.2, 127.9, 
69.3, 52.1, 41.8, 18.0; IR (KBr / cm-1) 3431 (broad O-H), 1734 (C=O); HRMS (ES+): m/z 
calculated for C7H12O3 requires 167.0684 for [M+Na]







According to General Procedure 9, diethylzinc (1.9 mL) and diiodomethane (510 mg, 1.9 
mmol) were added to (S)-methyl 3-hydroxy-3-((1S,2S)-2-methylcyclopropyl)propanoate, 297 
(56 mg, 0.39 mmol) in dichloromethane (5 mL) to afford the crude reaction product that was 
purified by column chromatography to afford the (S)-methyl 3-hydroxy-3-((1S,2S)-2-
methylcyclopropyl)propanoate, 298 (258 mg, 0.65 mmol) as a yellow oil in 95% yield.  
 
[#]D
25 = +6.0 (c = 0.60 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 3.65 (3H, s, OCH3), 3.25 (1H, 
m, CHOH), 2.56 (1H, m, CHAHB), 2.54 (1H, d, m, CHAHB), 0.96 (3H, d, J = 5.5 Hz, CH3), 0.57 
(2H, m, CH-cyclopropyl), 0.49 (1H, m, cyclopropyl-CHAHB), 0.25 (1H, m, cyclopropyl-
CHACHB); 
13C NMR (75 MHz, CDCl3) " 171.9, 71.2, 50.7, 40.5, 24.6, 17.2, 10.5, 9.6; IR (KBr / 
cm-1) 3435 (broad O-H), 1739 (C=O); HRMS (ES+): m/z calculated for C8H14O3 requires 












Mercury trifluoroacetate (371 mg, 0.87 mmol) was added in one portion to a stirring solution of 
(2S,3R)-methyl 3-hydroxy-2-methyl-3-((1S,2S)-2-methylcyclopropyl)propanoate, 309f (60 mg, 
0.35 mmol) in dichloromethane (5 mL). The reaction was stirred at ambient temperature for 24 
hours, before being quenched with brine (5 mL) and stirred for one hour. The solution was 
extracted with dichloromethane, washed with saturated sodium hydrogen carbonate, dried over 
MgSO4 and concentrated to afford crude product, which was purified over a column of silica gel 
eluting with DCM/EtOAc (9:1). The pure fractions were concentrated under reduced pressure to 
afford (((2S,3R,4S,5S)-4-hydroxy-2,5-dimethyl-6-oxotetrahydro-2H-pyran-3-yl)methyl)-
mercury(II) chloride, 313f (107.6 mg, 0.27 mmol, 78%) as a colourless oil 
 
Rf (10:1 DCM/EtOAc) = 0.12; 1H NMR (500 MHz, CDCl3) " 4.06 (1H, dq, J = 9.9 Hz and 6.3 
Hz, OCHCH3), 3.39 (1H, br. d, J = 5.6 Hz, OH), 3.30 (1H, app. dt, J = 10.1 Hz and 5.1 Hz, 
CHOH), 2.48 (1H, dq, J = 9.8 Hz and 7.1 Hz, CHCH3), 2.09 – 1.98 (2H, m, CHCHOH and 
CHAHBHg), 1.48 (3H, d, J = 6.3 Hz, CH3CO), 1.43 (3H, d, J = 7.1 Hz, CH3CH), 1.38 (1H, app. 
t, J = 9.9 Hz, CHAHBHg); 
13C NMR (75 MHz, CDCl3) " 173.2, 80.1, 74.8, 47.1, 45.2, 27.1, 
20.6, 14.3; 199Hg NMR (89 MHz, CDCl3) " -933.9 ppm; IR (ATR) . (cm
-1): 3335.4 (broad O-
H), 1682.1 (C=O); HRMS (ES+): m/z calculated for C8H13ClHgO3: requires 395.0338 for 










Mercury trifluoroacetate (64 mg, 0.273 mmol) was added in one portion to a stirring solution of 
(2S,3R)-methyl-3-hydroxy-2-methyl-3-((1S,2S)-2-phenylcyclopropyl)-propanoate 309g (290 
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mg, 0.683 mmol) in dichloromethane (5 mL). The reaction was stirred at ambient temperature 
for 24 hours, before being quenched with brine (5 mL) and stirred for one hour. The solution 
was extracted with dichloromethane, washed with saturated sodium hydrogen carbonate, dried 
over MgSO4 and concentrated to afford crude product (((2R,3R,4S,5S)-4-hydroxy-5-methyl-6-
oxo-2-phenyltetrahydro-2H-pyran-3-yl)methyl)mercury(II) chloride, 313g. The product 
was not purified due to its potential toxicity.  
 
1H NMR (300 MHz, CDCl3) " 7.42-7.38 (3H, m, Ph), 7.32-7.28 (2H, m, Ph), 4.76 (1H, d, J = 
10.5 Hz, OCHPh), 3.45-3.39 (1H, m, CHOH), 3.19 (1H, d, J = 4.5 Hz, OH), 2.62 (1H, m, 
COCHCH3), 2.35 (1H, m, CHCH2HgCl), 1.49-1.43 (5H, m, CHCH3 and CHCH2HgCl); 
13C 










Mercury trifluoroacetate (585 mg, 1.37 mmol) was added in one portion to a stirring solution of 
(S)-methyl-2-((R)-hydroxy((1S,2S)-2-methylcyclopropyl)methyl)-3-methylbutanoate, 309h (110 
mg, 0.55 mmol) in dichloromethane (5 mL). The reaction was stirred at ambient temperature for 
24 hours, before being quenched with brine (5 mL) and stirred for one hour. The solution was 
extracted with dichloromethane, washed with saturated sodium hydrogen carbonate, dried over 
MgSO4 and concentrated to afford crude product, which was purified over a column of silica gel 
eluting with DCM/EtOAc (9:1). The pure fractions were concentrated under reduced pressure to 
afford (((2S,3R,4S,5S)-4-hydroxy-5-isopropyl-2-methyl-6-oxotetrahydro-2H-pyran-3-
yl)methyl)mercury(II) chloride, 313h (193.0 mg, 0.46 mmol, 83%) as a colourless oil 
 
Rf (10:1 DCM/EtOAc) = 0.2; 1H NMR (500 MHz, CDCl3) " 4.00 (1H, dq, J = 9.9 Hz and 6.3 
Hz, OCHCH3), 3.44 (1H, app. dt, J = 10.2 Hz and 6.6 Hz, CHOH), 3.25 (1H, br. d, J = 6.3 Hz, 
OH), 2.55 (1H, dd, J = 6.9 Hz and 3.9 Hz, CHCOO), 2.41 – 2.31 (2H, m, CH(CH3)2), 2.05 (1H, 
dd, J = 12.0 Hz and 3.9 Hz, CHAHBHg), 1.95 (1H, dq, J = 10.5 Hz and 3.9 Hz, CHCH2Hg), 
1.44 (3H, d, J = 6.0 Hz, CH3CH), 1.35 (1H, t, J = 11.7 Hz, CHAHBHg), 1.27 (1H, d, J = 6.9 Hz, 
(CH3
A)C(CH3
B)), 1.08 (1H, d, J = 6.9 Hz, (CH3
A)C(CH3
B)); 13C NMR (75 MHz, CDCl3) " 
172.7, 78.6, 72.1, 57.3, 47.1, 30.6, 27.1, 20.8, 20.1, 19.9; 199Hg NMR (89 MHz, CDCl3) " -
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937.7 ppm; IR (ATR) . (cm-1): 3334.9 (broad O-H), 1681.8 (C=O); HRMS (ES+): m/z 
calculated for C10H17ClHgO3: requires 423.0650 for [M+H]










Mercury trifluoroacetate (692 mg, 1.625 mmol) was added in one portion to a stirring solution 
of (2S,3R)-methyl 3-hydroxy-2-methyl-3-((1S,2R)-2-pentylcyclopropyl)propanoate, 309j (149.0 
mg, 0.65 mmol) in dichloromethane (5 mL). The reaction was stirred at ambient temperature for 
24 hours, before being quenched with brine (5 mL) and stirred for one hour. The solution was 
extracted with dichloromethane, washed with saturated sodium hydrogen carbonate, dried over 
MgSO4 and concentrated to afford a mixture of lactone products, which were purified over a 
column of silica gel eluting with DCM/EtOAc (9:1). The pure fractions were concentrated 
under reduced pressure to afford (((2R,3R,4S,5S)-4-hydroxy-5-methyl-6-oxo-2-
pentyltetrahydro-2H-pyran-3-yl)methyl)mercury(II) chloride, 313j (160.5 mg, 0.36 mmol, 
55%) as a colourless oil and (((2R,3R)-5-methyl-6-oxo-2-pentyl-3,6-dihydro-2H-pyran-3-
yl)methyl)mercury(II) chloride, 323 (92.5 mg, 0.214 mmol, 33%) as a white solid. 
 
Rf (10:1 DCM/EtOAc) = 0.36; 1H NMR (300 MHz, CDCl3) " 4.49 (1H, dq, 1H, J = 8.0 Hz and 
4.0 Hz, CHO), 3.44 (1H, dd, J = 9.3 Hz and 5.6 Hz, CHOH), 2.65 (1H, dq, J = 13.3 Hz and 6.8 
Hz), 2.42 – 2.33 (1H, m, CHCH2Hg), 1.97 (1H, dd, J = 11.6 Hz and 3.6 Hz, CHAHBHg), 1.69 
(1H, app. t, 11.6 Hz, CHAHBHg), 1.70 – 1.46 (2H m, CH2CHO), 1.36 (3H, d, J = 6.8 Hz, 
CH3CH), 1.36 – 1.27 (6H, m, (CH2)3),  0.91 (3H, t, J = 6.4, CH3CH2); 
13C NMR (75 MHz, 
CDCl3) " 175.1, 79.8, 45.1, 43.3, 31.9, 31.4, 29.1, 26.0, 22.9, 14.4, 13.7; 
199Hg NMR (89 MHz, 
CDCl3) " -958.1 ppm; IR (ATR) . (cm

















Rf (DCM) = 0.4; 1H NMR (300 MHz, CDCl3) " 6.77 (1H, dq, J = 6.27 Hz and 1.39 Hz), 4.45 
(1H, ddd, J = 8.9 Hz, 5.1 Hz and 3.5 Hz, CHO), 2.73 (1H, m, CHCH2Hg), 2.02 (1H, dd, J =11.6 
Hz and 4.7 Hz, CHAHBHg), 1.92 (3H, s, CH3C=C), 1.82 (1H, dd, J = 11.6 Hz and 8.9 Hz, 
CHAHBHg); 1.62 – 1.48 (2H, m, CHOCH2), 1.43 – 1.2 (6H, m, (CH2)3), 0.90 (3H, t, J = 6.8 Hz, 
CH3CH2); 
199Hg NMR (89 MHz, CDCl3) " -937.6 ppm; IR (ATR) . (cm
-1): 1697.9 (C=O); 










Mercury trifluoroacetate (607.0 mg, 1.42 mmol) was added in one portion to a stirring solution 
of (S)-methyl-2-((R)-hydroxy((1S,2S)-2-methylcyclopropyl)methyl)-3-methylbutanoate, 309h 
(106 mg, 0.57 mmol) in dichloromethane (5 mL). The reaction was stirred at ambient 
temperature for 24 hours, before being quenched with brine (5 mL) and stirred for one hour. 
The solution was extracted with dichloromethane, washed with saturated sodium hydrogen 
carbonate, dried over MgSO4 and concentrated to afford crude product, which was purified over 
a column of silica gel eluting with DCM/EtOAc (9:1). The pure fractions were concentrated 
under reduced pressure to afford (R)-((2,2,5-trimethyl-6-oxo-3,6-dihydro-2H-pyran-3-
yl)methyl)mercury(II) chloride, 324 (195.0 mg, 0.47 mmol, 83%) as a colourless oil 
 
Rf (DCM) = 0.15; 1H NMR (300 MHz, CDCl3) " 6.52 (1H, br. d, J = 5.1 Hz), 2.14 (1H, dd, J = 
11.3 Hz and 3.9 Hz, CHAHBHg), 1.94 (3H, s, CH3C=C), 1.91 (1H, dd, J = 12.5 Hz and 10.2 Hz, 
CHAHBHg), 1.49 (3H, s, (CH3)C(CH3)), 1.44 (3H, s, (CH3)C(CH3)); 
13C NMR (75 MHz, 




(C=O); HRMS (ES): m/z calculated for C9H13HgClO2: requires 391.0389 for [M+H]
+; found: 









Sodium borohydride (1 mL, 0.5M in NaOH(aq)) was added dropwise to a stirring solution of 
(((2S,3R,4S,5S)-4-hydroxy-2,5-dimethyl-6-oxotetrahydro-2H-pyran-3-yl)methyl)-mercury(II) 
chloride, 313f (30.0 mg, 0.075 mmol) in methanol (1 mL) and aqueous sodium hydroxide 
(2.5M, 0.8 mL). After 5 minutes the reaction was washed with 2.0 M HCl and 5% sodium 
hydrogen carbonate, the resulting organics were dried over magnesium sulphate and 
concentrated under reduced pressure to yield (3S,4R,5R,6S)-4-hydroxy-3,5,6-
trimethyltetrahydro-2H-pyran-2-one, 326 in quantitative yield. 
 
[#]D
25 = -27.1 (c = 0.48 in CHCl3); 
1H NMR (300 MHz, CDCl3) 4.01 (1H, dq, J = 10.5 Hz and 
7.1 Hz, CHOCH3), 3.31 (1H, app. t, J = 9.9 Hz, CHOH), 2.41 (1H, dq, J = 10.49 Hz and 7.06 
Hz, CHCO), 1.71-1.60 (1H, m, CHCHOH), 1.42 (3H, d, J = 7.0 Hz, CHCH3), 1.41 (3H, d, J = 
6.1 Hz, CHCH3), 1.11 (3H, d, J = 6.3 Hz, CHCH3), 
13C NMR (75 MHz, CDCl3) " 173.5, 79.0, 
75.6, 44.9, 43.4, 20.2, 14.2, 13.6; IR (ATR) . (cm-1): 3423.6 (broad O-H), 1711.8 (C=O); 
HRMS (ES): m/z calculated for C8H14O3: requires 159.1021 for [M+H]
+; found: 159.1026; 









Sodium borohydride (0.63 mL, 0.325 mmol, 0.5M in NaOH(aq)) was added dropwise to a 
stirring solution of (((2S,3R,4S,5S)-4-hydroxy-5-isopropyl-2-methyl-6-oxotetrahydro-2H-pyran-
3-yl)methyl)-mercury(II) chloride, 313h (70.0 mg, 0.17 mmol) in methanol (0.42 mL) and 
aqueous sodium hydroxide (2.5M, 0.8 mL). After 5 minutes the reaction was washed with 2.0 
M HCL and 5% sodium hydrogen carbonate, the resulting organics were dried over magnesium 
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sulphate and concentrated under reduced pressure to yield ((3S,4R,5R,6S)-4-hydroxy-3-
isopropyl-5,6-dimethyltetrahydro-2H-pyran-2-one, 327 in quantitative yield. 
 
[#]D
25 = -30.1 (c = 0.76 in CHCl3); 
1H NMR (300 MHz, CDCl3) " 3.96 (1H, dq, J = 9.6 Hz and 
5.7 Hz, CHOCH3), 3.49 (1H, dd, J = 9.6 Hz and 7.4 Hz, CHOH), 2.47 (1H, dd, J = 7.9 Hz and 
3.9 Hz, CHCO), 2.44-2.33 (1H, m, CH(CH3)2), 1.66-1.54 (1H, m, CHCHOH), 1.38 (3H, d, J = 
6.2, CH3CHCO), 1.12 (3H, d, J = 6.8 Hz, (CH3)CH(CH3)), 1.09 (3H, d, J = 6.8 Hz, 
(CH3)CH(CH3)), 1.07 (3H, d, J = 7.4 Hz, CHCH3); 
13C NMR (75 MHz, CDCl3) " 172.8, 77.8, 
72.38, 56.6, 43.2, 30.1, 20.8, 20.0, 19.9, 13.6; IR (ATR) . (cm-1): 3434.4 (broad O-H), 1706.1 
(C=O); HRMS (ES): m/z calculated for C10H18O3: requires 187.1335 for [M+H]
+; found: 
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Table 1.  Crystal data and structure refinement for (S,S,S)-lactone 163c. 
                                                        
 Identification code c:\x-ray\kappa\k05rg1\maxus\k05rg1 
 Empirical formula C8 H14 O4 
 Formula weight 174.19 
 Temperature 150(2) K 
 Wavelength 0.71073 Å 
 Crystal system Monoclinic 
 Space group P21 
 Unit cell dimensions a = 5.4370(2)Å # = 90o 
       b = 14.1610(6)Å $ = 101.723(2)o 
       c = 5.9280(2)Å ! = 90o 
 Volume 446.90(3) Å3 
 Z 2 
 Density (calculated) 1.294 Mg/m3 
 Absorption coefficient 0.103 mm-1 
 F(000) 188 
 Crystal size 0.18 x 0.18 x 0.03 mm 
 Theta range for data collection 5.46 to 27.47o 
 Index ranges -6<=h<=7; -18<=k<=18; -7<=l<=7 
 Reflections collected 8674 
 Independent reflections 2025 [R(int) = 0.0559] 
 Reflections observed (>2,) 1779 
 Data Completeness 0.989 
 Absorption correction None 
 Refinement method Full-matrix least-squares on F2 
 Data / restraints / parameters 2025 / 1 / 116 
 Goodness-of-fit on F2 1.149 
 Final R indices [I>2,(I)] R1 = 0.0554   wR2 = 0.0926 
 R indices (all data) R1 = 0.0679  wR2 = 0.0959 
 Absolute structure parameter 0.3(13) 
 Largest diff. peak and hole 0.191 and -0.154 eÅ-3 
 
Notes: absolute configuration assigned on basis of known stereochemistry at 
one chiral centre. Lattice dominated by hydrogen bonded sheets in ac plane. 
 
 
Hydrogen bonds with  H..A < r(A) + 2.000 Angstroms  and  <DHA > 110 
deg. 
 
 D-H           d(D-H)   d(H..A)   <DHA    d(D..A)   A 
 
 O3-H3          0.840    1.897   169.72    2.728    O4 [ x, y, z+1 ] 
 O4-H4A         0.840    1.924   167.70    2.750    O2 [ x-1, y, z ] 












Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters 
(Å2 x 103) for 1.U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
                                                             
                                                             
  Atom   x   y   z  U(eq) 
                                  
O(1) 8345(3) 8800(1) 9406(2) 31(1) 
O(2) 9941(3) 7395(1) 8907(3) 37(1) 
O(3) 3756(3) 8476(2) 12861(2) 41(1) 
O(4) 3461(3) 8491(1) 7400(2) 39(1) 
C(1) 6453(4) 9224(2) 10561(4) 32(1) 
C(2) 8566(4) 7873(2) 9808(3) 31(1) 
C(3) 6985(4) 7555(2) 11478(4) 33(1) 
C(4) 6210(4) 8485(2) 12435(3) 31(1) 
C(5) 8376(5) 6859(2) 13253(4) 45(1) 
C(6) 4074(4) 9335(2) 8710(4) 35(1) 
C(7) 7494(5) 10172(2) 11493(4) 40(1) 
C(8) 5845(5) 10676(2) 12916(5) 47(1) 






                       
 
 
   
 Table 3.   Bond lengths [Å] and angles [o] for 1. 
  
O(1)-C(2) 1.335(3) O(1)-C(1) 1.474(2) 
O(2)-C(2) 1.210(3) O(3)-C(4) 1.407(2) 
O(4)-C(6) 1.427(3) C(1)-C(7) 1.517(3) 
C(1)-C(6) 1.525(3) C(1)-C(4) 1.550(3) 
C(2)-C(3) 1.506(3) C(3)-C(5) 1.526(3) 
C(3)-C(4) 1.527(3) C(7)-C(8) 1.527(3) 
                                        
C(2)-O(1)-C(1) 111.29(17) O(1)-C(1)-C(7) 106.57(17) 
O(1)-C(1)-C(6) 106.11(16) C(7)-C(1)-C(6) 111.7(2) 
O(1)-C(1)-C(4) 103.15(18) C(7)-C(1)-C(4) 114.57(19) 
C(6)-C(1)-C(4) 113.71(19) O(2)-C(2)-O(1) 120.8(2) 
O(2)-C(2)-C(3) 127.5(2) O(1)-C(2)-C(3) 111.6(2) 
C(2)-C(3)-C(5) 112.2(2) C(2)-C(3)-C(4) 102.95(18) 
C(5)-C(3)-C(4) 115.90(18) O(3)-C(4)-C(3) 113.69(19) 
O(3)-C(4)-C(1) 110.93(18) C(3)-C(4)-C(1) 104.21(16) 
O(4)-C(6)-C(1) 112.0(2) C(1)-C(7)-C(8) 113.45(19) 




  Table 4.   Anisotropic displacement parameters (Å2 x 103) for 1. The anisotropic 
displacement 
   factor exponent takes the form: -2 gpi2 [ h2 a*2 U11 + ... + 2 h k a* b* U 
                                                                                 
  Atom  U11  U22  U33  U23  U13  U12 
                                               
O(1) 28(1) 40(1) 28(1) 0(1) 12(1) -5(1) 
O(2) 38(1) 44(1) 31(1) -7(1) 11(1) -3(1) 
O(3) 34(1) 71(1) 19(1) -2(1) 9(1) -13(1) 
O(4) 33(1) 65(1) 20(1) -2(1) 9(1) -9(1) 
C(1) 31(1) 43(1) 24(1) 0(1) 12(1) -1(1) 
C(2) 28(1) 41(2) 22(1) -4(1) 3(1) -8(1) 
C(3) 33(1) 42(2) 22(1) -2(1) 5(1) -12(1) 
C(4) 31(1) 44(1) 19(1) -2(1) 5(1) -7(1) 
C(5) 59(2) 43(2) 31(1) 5(1) 5(1) -5(1) 
C(6) 34(1) 47(2) 26(1) 5(1) 13(1) -3(1) 
C(7) 38(1) 44(2) 42(1) -3(1) 14(1) -8(1) 
C(8) 57(2) 49(2) 39(1) -6(1) 17(1) -6(1) 
 
   
 
 
 Table 5.   Hydrogen coordinates ( x 104) and isotropic displacement 
   parameters (Å2 x 103) for 1. 
                                     
  Atom   x   y   z  U(eq) 
                                  
H(3) 3822 8436 14286 60(8) 
H(4A) 2238 8224 7801 41(7) 
H(3A) 5445 7238 10591 39 
H(4) 7423 8644 13891 38 
H(5A) 9903 7157 14124 67 
H(5B) 8828 6297 12464 67 
H(5C) 7289 6676 14311 67 
H(6A) 2658 9506 9449 41 
H(6B) 4312 9856 7662 41 
H(7A) 7681 10581 10186 48 
H(7B) 9185 10075 12464 48 
H(8A) 5700 10286 14248 71 
H(8B) 4172 10782 11963 71 
H(8C) 6606 11285 13450 71 
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